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The nucleocapsid protein (N) is a structural protein of the Severe Acute Respiratory 
Syndrome Coronavirus (SARS-CoV) which interacts with the single-stranded 
genomic RNA to form the helical nucleocapsid core. Nucleocapsid proteins fused to 
polyhistidine, glutathione S-transferase (GST) or maltose-binding protein (MBP) 
were expressed in Escherichia coli (E. coif) and purified. It was demonstrated that the 
majority of the purified tagged proteins formed small "soluble aggregates" and unable 
to yield preparations of high purities. Modifications to the purification strategies 
allowed us to purify successfully the tag-cleaved N proteins in a soluble, dispersed 
moiety to near homogeneity under native conditions. 
The "aggregated" tagged N proteins, but not the dispersed and tag-cleaved ones, were 
found to be associated with RNA of E. coli and the associations were very tight as 
demonstrated by their resistance to RNase A digestions. The dispersed, tags removed 
proteins were shown to bind both in vitro transcribed SARS-CoV genomic RNA 
fragments of about 1 kb in length and the total RNA of Vero E6 cells by gel mobility 
shift assays (EMSA). The ability to bind to the total RNA of Vero E6 cells indicated 
that the interaction between N protein and RNA is not selective. Moreover, the N 
protein/ RNA complexes formed in EMSA were unable to protect the RNA from • 
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Abstract 
RNase A digestions. This is in contrast to the RNA protective effect conferred by the 
N protein aggregates and the native N proteins found in the virions. 
A fragment comprising amino acid residues 214 to 422 of the N protein was designed 
according to the results of the limited trypsinolysis experiments. The fragments fusion 
to MBP tags were expressed in E. coli and purified as well. The purified proteins were 
not aggregated and contained no nucleic acids in their native forms. 
In addition, using the purified tag-cleaved N proteins, the SARS-CoV nucleocapsid 
protein was found susceptible to sumoylation by an in vitro sumoylation assay. 
However, the exact sumoylation site remains to be elucidated. Nevertheless, this proof 














R N A結合的能力’這個現象在電泳遷移率改變的實驗中得以證明°由於那些高 
- 純度而且分散的核毅蛋白可以跟所有的大腸桿菌RNA及一段大約1 kb在體外轉 
錄的SARS-CoV基因組RNA片段結合’因此這種結合不是專一的’這和病毒複 
製時的包般作用有所不同。而且，那些高純度而且分散的核毅蛋白在體外跟RNA 







大腸桿菌的R N A結合。 
除此之外’我們亦對純化之核般蛋白作後轉譯修飾的研究，並發現S A R S - C o V 
核殼蛋白是可以被S U M O化°雖然在數基酸序列上確切的S U M O化位置仍有待 
研究，但這個發現啟發出很多核般蛋白對細胞作用的可能性。 
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1.1 Epidemiology of the Severe Acute Respiratory Syndrome 
In 16 November 2002, the first known case of the novel life-threatening disease, the 
Severe Acute Respiratory Syndrome (SARS), formally named by the World Health 
Organization (WHO) later in April 2003, emerged in Guangdong province, China. 
Official report of the disease reached WHO on 11 February 2003. Before actions can 
be posed to contain SARS, rapid transmission caused serious outbreak in Mainland 
China, Hong Kong, Taiwan, Singapore and Canada. Until 5 July 2003, the last 
reported probable case, there are in total 8422 cumulative cases, with 916 deaths, 
from 29 countries over the world. The global case-fatality-ratio (CFR) is 11%, but can 
be as high as 52% in patients over 60-year-old in Hong Kong (Consensus report on 
the epidemiology of SARS, WHO). 
The aetiological agent of the disease was isolated and identified in April 2003 as a 
previously unknown coronavirus (Figure 1.1.1) named SARS coronavirus 
(SARS-CoV) (Peiris et al, 2003; Ksiazek et al, 2003; Drosten et al., 2003). 
Patients in the early stage of onset generally have clinical symptoms of persistent 
fever, chills/ rigor, myalgia, dry cough, headache and dizziness. Progression of the 
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disease may cause recurrence of fever, oxygen desaturation and severe pneumonia. 
Serious cases are characterized by the use of necessitating ventilatory support. 
Laboratory evidences like the detection of antibodies against SARS-CoV, detection of 
SARS-CoV RNA by reverse transcriptase-polymerase chain reaction (RT-PCR) and 
isolation of SARS-CoV from the patients' specimens were used to supplement 
diagnosis (Peiris et al, 2003; Hui and Sung, 2003). 
•i 
Figure 1.1.1 Electron micrograph of lung biopsy sample f rom patient with SARS (A) and 
of SARS-CoV infected cells (B) (Adopted from Peiris et ai, 2003). 
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1.2 The SARS Coronavirus 
Taxonomy and phylogenetic analysis Coronaviruses have big, nonsegmented, 
positive sense, single stranded RNA genomes. They are grouped together with 
Torovirus to form the family Coronaviridae, which share with Arterivirus and 
Roniviridae certain important features to be united under the order Nidovirales, 
designated by the nested-set subgenomic mRNA. 
Most of the coronaviruses caused respiratory and enteric diseases in birds and 
mammals. Up to date, there are three known human infectious coronaviruses. They 
are the SARS-CoV and the human coronaviruses (HCoV), HCoV-229E and 
HCoV-OC43，which are responsible for the common cold (Lai and Cavanagh, 1997). 
The phylogenetic relationships of the SARS-CoV are under controversy. Previously, 
coronaviruses are divided into three groups. Group 1 are mammalian coronaviruses, 
while group 2 infects both birds and mammals. Group 3, which contain only the 
infectious bronchitis virus (IBV), is currently confined only to birds. Initially, it was 
suggested that the SARS-CoV has to be classified into group 2. However, more and 
more analyses point out that the virus should be, more likely, somewhat between 
group 1 and 2 or sometimes group 1 and 3 depending on the genome or proteins under 
investigation. The sequence divergence between SARS-CoV and other known 
coronaviruses indicates a long period of independent evolution (Moya et al., 2004). 
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Concerning origin of the virus, recent studies had isolated SARS-CoV from 
Himalayan palm civet {Paguma larvata, strain SZ16), which has 99.8% homology to 
the human SARS-CoV. Moreover, a 29-nucleotide (nt) deletion was found in the 
human SARS-CoV 246 nt before the start of N gene. This stretch of 29 nucleotides, 
found only in one sequenced human SARS-CoV genome GZOl, will merge open 
reading frame (orf) 10 and 11 into one and encodes a putative protein of 122 amino 
acids (Guan et al., 2003). 
Viral structure The SARS-CoV exhibits a typical viral structure of the 
Coronavirus genus — being crown-like in morphology (Latin corona means crown) 
(Figure 1.2.1). A SARS-CoV virion has an outer membranous envelope that is 
composed of the membrane glycoproteins (M), the envelope proteins (E) and the 
spike glycoproteins (S), and an inner nucleocapsid core that contain nucleocapsid 
proteins (N) binding to the piece of single-stranded RNA genome in a helical structure 
(Holmes and Enjuanes, 2003) (Figure 1.2.2). Sera from SARS patients have found to 
be immunogenic against a SARS-specific novel protein, XI, and therefore it was 
suggested to be a structural protein of the SARS-CoV as well (Zeng et al., 2004; Yu et 
a/., 2004; Ito etal, 2005). 
4 ‘ 
Chapter I 
. f “ ‘ . J i • • Figure 1.2.1 Negative-stain electron microscopy 
shows a methylamine tungstate stain-coronavims 
particle with club-shaped surface projections 
‘ ‘ W surrounding the particle, a finding typical of 
. c o r o n a v i r u s e s (Adopted from Ksiazek et al, 2003). 
Figure \2.2 A model of the coronavirus structure 
f showing the organization of the spike (S), membrane 
(M), and envelope (E) proteins. The RNA is protected 
by a helical capsid of N protein (Adopted from 
Holmes et ai, 2003). 
Genome organization The SARS-CoV genome is generally around 29,751 
nucleotides in size (Rota et al., 2003; Marra et ai, 2003), containing 14 predicted orfs. 
On its 5'-proximal position is a cap and a leader sequence, followed by the orf lab. 
The orf lab occupies over two-third of the genome encoding the polyprotein replicase 
ppla and pplab. One of the hallmarks of Nidovirales is the division of orf 1 into a and 
b parts as frameshift is needed for the translation of the second part. Presence of a 
'slippage' site just before the stop codon of orf la facilitates the -1 frameshift 
translation of orf lb (Ziebuhr et al., 2000). After translation, the polypeptide is then 
autocatalytically cleaved into non-structural proteins (nsps) by the main proteinases 
(3C-like proteinase, 3CLpro) and accessory proteinases (papain-like proteinase, PLP) 
domains present in the orf 1 a itself (Prentice et aL, 2004; Harcourt et al., 2004; Gao et 
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al, 2003). Other than the two proteinases, some of the nsps also encode functional 
proteins like the RNA-dependent RNA polymerase (RDRP), NTPase/ helicase (Hel), 
exonuc lease (ExoN), poly(u)-specific endonuclease (XendoU) and 
2'-0-methyltransferase (2,-0-MT) (Prentice et al., 2004). This would result in 16 
polypeptides according to the predicted cleavage sites of the two proteinases (Thiel et 
al., 2003). Part of these nsps will then associate together to form the replication 
complex for genome replication and transcription (Prentice et al., 2004). 
Follow closely to the 3' end of orf 1 is the S protein, and then other structural proteins: 
E, M and N proteins. They are located at the orf 2, 5，6 and 12 correspondingly (Rota 
et al,, 2003; Marra et al.’ 2003). In between these, there are some predicted orfs that 
may encode non-structural proteins of unknown functions. Amongst them, the protein 
encoded from orf 3 (known as protein 3a, XI or U274) and orf 8 (known as protein 7a, 
X4 or U122) have been detected in SARS-CoV infected Vero E6 cells and thus are 
better characterized (Yu et al., 2004; Chen et al, 2005; Fielding et al, 2004). Unlike 
group II coronaviruses, SARS-CoV does not express the hemagglutinin esterase (HE). 
Hemagglutinin esterase is a protein present in the coronavirus envelope that is known 
to bind to host cell receptor. It possesses acetylesterase activity and is thus given its 
name. 
Finally, the 3' end of the SARS-CoV genome is a poly(A) tail and adjacent to it, in the 
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3’ untranslated region (UTR), is the s2m motif, a rigorously conserved RNA element 
within the astrovirus (Jonassen et al, 1998). It is about 45 bases in length and was 
found to confer a characteristic stem-loop structure (Robertson et al., 2005). 
Moreover, a bugled stem-loop and overlapping pseudoknot structure that is believed 
to be essential for viral replication was also found in the 3’ UTR of the genome near 
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1.3 Cell Biology of Coronavirus Infection and Replication and the Role of 
Nucleocapsid Protein 
Viral entry Viral infection starts with the specific interaction between coronavirus 
spike proteins and receptors on host cell surface. The spike protein accounts for the 
infection virulence. In MHV, carcinoembryonic antigen-cell adhesion molecule 1 
(CEACAMl) has been studied extensively as the spike target receptor. By far, two 
putative SARS-CoV receptors have been identified experimentally. 
Angiotensin-converting enzyme 2 (ACE2) was identified in African green monkey 
kidney cell line Vero E6 by immunoprecipitation (Li et al, 2003), while CD209L 
(L-SIGN) is originally identified in human lung. It was expressed in Chinese hamster 
ovarian (CHO) cells by transduction so that the cells can bind to purified spike protein 
(Jeffers et al, 2004). Vero E6 cells expressing CD209L seemed to be less susceptible 
to SARS-CoV infection than ACE2. 
The coronavirus spike glycoprotein belongs to the class I fusion protein. Its fusion 
core resembles that of influenza virus, human immunodeficiency virus (HIV), Ebola 
and paramyxovirus. According to the studies in those similar viral transmembrane 
glycoprotein and the crystal structures of MHV and SARS-CoV spike protein fusion 
core, it was suggested that upon binding, certain conditions, like change of pH or 
interaction with receptors, the spike protein will be activated and an extensive 
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rearrangement and refolding of the molecule occur, which results in the extrusion of 
the fusion peptide and insertion into the cellular membrane (Simmons et al., 2004; 
Yang et al., 2004b). This is then followed by a confoimational change of the spike 
protein and juxtaposition of the target and viral membrane anchors. Thus the two 
membranes are brought together and fused. The viral RNA genome is then released 
into the cytoplasm of the infected cell (Xu et al, 2004a; Xu et al” 2004b; Skehel and 
Wiley, 1998). 
Genome replication, transcription and translation Coronavirus replication took 
place in the cytoplasm utilizing the host cell ribosomes and translation machinery. It 
should be noted that, for every piece of viral RNA, only the first orf will be translated. 
The other orfs can only be translated from the subgenomic mRNA (sgRNA) generated 
afterwards in the cytoplasm. Thus after viral uncoating, the first macromolecular 
synthetic event is the translation of orf 1 from the incoming viral genomic RNA. 
Since, the polyproteins la and lab contain proteinase structure, the cis- or 
/r騰-proteolytic activities of the 3CLpro and PLP cleave the ppl into a number of 
nsps. As soon as the nsps were produced, RNA replication can start by the binding of 
RDRP to the genomic RNA and the formation of the replication complex. 
Constituents of the replication complex are still being elucidated. Despite RDRP, N 
protein and a number of proteins processed from orf 1 have been suggested to be part 
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of the complex (Prentice et al； 2004; Egloff et al, 2004; Denison et aL, 1999). The 
replicase activity results in two populations of RNAs. One is the viral genomic RNA 
and the other is the subgenomic mRNA (sgRNA). RNA replication is the synthesis of 
the entire viral RNA genome, while synthesizing the sgRNAs, with lengths that 
depend on the orfs it started with, and is regarded as transcription (Figure 1.3.1). The 
subgenomic mRNAs are actually nested sets of RNA having 3' co-termini, which we 
refer as the 'body' and includes varies number of orfs of the 3, end of the genome, and 
common 5, leader sequence, that are derived from the 5，end of the genome. The core 
sequence (CS), 5'-CGAAC-3；, of the leader sequence is identical to that of the 
transcription regulatory sequence (TRS) which is present at the beginning of each orf. 
(Figure 1.3.2 a) Contribute to the detection of a set of replicative intermediates (RIs, 
the negative sense sgRNA) (Sawicki et aL, 2001), recent publications suggested the 
joining of the two non-contiguous fragments presumably occurred during 
minus-strand synthesis. Extension of the negative sense sgRNA ((-)sgRNA) starts 
from the 3，most of the genome till it reaches the TRS. The mRNA body will then 
translocate to the 5' end of the genomic RNA and CS of the TRS in the body can base 
pair with the CS in the leader sequence such that the (-)sgRNA finished with the 
leader sequence at the 3，end (Figure 1.3.2 b). These RIs act as the mirror images for 
.1 
the positive strand synthesis. However, the detailed mechanism of this discontinuous 
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Figure 1.3.1 Schematic diagram showing the replication, transcription and translation 
mechanism of nidoviruses (Adopted from Snijder and Meulenberg, 1998). 
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Figure 1.3.2 (A) Overview of the nested set structures of the genomic RNA ( R N A l ) as 
well as the largest (RNA2) and smallest (RNA7) sgRNAs. The locations of leader and 
anti-leader sequence (gray boxes), (+) TRS (black boxes) and (-) TRS (white boxes) are indicated. 
(B) Transcription model illustrating the proposed mechanism of discontinuous transcription 
during t he minus-strand synthesis. The 'body ' of the (-)sgRNA starts from the 3，end of the 
‘ genomic RNA till a TRS. The 'body ' then jumps to the 5’ end of the genomic RNA where a 
consensus TRS can be found. The (-)sgRNA elongates such that a leader sequence is incorporated. 
The subgenomic m R N A is then synthesized from the (-)sgRNA template (Adopted from Snijder 
and Meulenberg, 1998). 
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transcription remains to be elucidated. For each corresponding sgRNA, a structural 
protein or non-structural protein like XI or X4 is translated and is subjected to 
post-translational modification in some cases. 
Viral packaging The actual mechanism of coronaviruses assembly has not been 
demonstrated experimentally. Therefore current understandings are mainly derived 
from the protein localization, protein-protein and protein-RNA interaction as well as 
experiments involving defective-interfering (DI) RNAs. Majority of he studies focus 
on MHV. 
The first step of viral packaging involves the formation of the ribonucleoprotein 
(RNP). A packaging signal (PS) is usually present at the 3，end of orf 1 of each 
coronavirus genome. This may explain why only the genomic RNAs but not the 
sgRNAs are encapsidated. According to the multi-alignment and RNA secondary 
structure prediction, the putative packaging signal of SARS-CoV (NC_004718) was 
mapped to 19893-19946 nt, located within the orf lb (Qin et al, 2003). The N protein 
can specifically recognize and bind to the PS. Their association elite the encapsidation 
process, in which N proteins form a polymer and bind to the RNA in a helical 
conformation. It has been suggested that SARS-CoV genomic RNA replication is 
coupled to encapsidation in coronavirus because no free genomic RNA can be found 
in infected cells (Perlman et al, 1986). 
13 . 
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In parallel to encapsidation, newly synthesized SARS-CoV S and M protein acquire 
their N-linked oligosaccharides at the endoplasmic reticulum (ER). From observations 
in their subcellular localizations, it was suggested that they obtain "core glycans" at 
the ER first, and are then transported to Golgi apparatus for further modification 
(Helenius and Aebi, 2001). SARS-CoV E protein has a short half-life and is not 
subjected to glycosylation. According to Nal et al. (2005), S protein distributed along 
the secretory pathway and they assemble into trimers at ER while E mainly localized 
at the ER in perinuclear patches. 
Previous study showed that coronaviruses assemble primarily at the intermediate 
compartment between the ER and the Golgi apparatus and the presence of only M and 
E proteins are sufficient for the formation of virus-like particles (VLPs) in MHV but 
not M proteins alone (Bos et al., 1996; Vennema et al., 1996). E protein was found to 
account for a minor proportion in the virion. Some researchers hypothesized that after 
glycosylation, M protein was transported back to the ER-Golgi intermediate 
compartments where E and M proteins drive the budding process and incorporate the 
mature spike proteins and RNP as it buds into the swollen lumen of the Golgi 
complex. Subsequently, virus particles are transported to the plasma membrane in 
smooth vesicles and then they are pinch off by exocytosis (Nal et al., 2005; Ng et al, 
2003a; Ng et al., 2003b; Lai and Cavanagh, 1997). However, the formation of VLPs 
14 
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in SARS-CoV seems to be independent of E and the presence of M and N protein are 
the minimum requirement for virus formation. Addition of S assists viral budding 
(Huang et al., 2004). Thus further investigation is needed to understand specific 




1.4 Current Advances in the SARS-CoV Nucleocapsid Protein 
The SARS-CoV N protein is expressed from the orf 12 of the viral genome at the 3’ 
most position. The gene is 1269 nt in length, which is translated into a protein of 422 
amino acid residues. The protein shares only 20-30% homology with the N protein of 
other coronavirus (Rota et al, 2003; Marra et al, 2003). It is highly basic and 
contains no cysteine residue. Thus the protein possesses no disulfide linkage. N 
protein has high content of serine (8.3%), which is a potential target for 
phosphorylation. Most of the coronavirus N proteins (such as MHV, IBV, BCV, PEDV) 
were described to be phosphorylated in previous studies and this modification was 
suggested in relation to the potency of infection (Stohlman and Lai, 1979; Lomniczi 
and Morser, 1981; King and Brian, 1982; Utiger et al, 1995; Mohandas and Dales, 
1991; Wilson et al” 1990). However, phosphorylation in the SARS-CoV N protein 
cannot be detected (Krokhin et al, 2003; Ying et al., 2004) until publications of 
several recent reports that employ metabolic labeling for detection (Zakahrtchouk et 
al” 2005; Tang et al., 2005). Instead, the first methionine of the protein was found 
depleted, other methionines were oxidized and the second serine acetylated by mass 
spectrometric analysis (Krokhin et al, 2003; Ying et al” 2004). And the recombinant 
N protein can be cleaved by caspase-3 but not caspase-6 (Ying et al., 2004). Moreover, 
it was shown SARS-CoV N protein is subjected to sumoylation in overexpression of 
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both SARS-CoV N protein and SUMO-1 in HeLa cells (Li et al, 2005). The 
sumoylation site was mapped to the lysine residue located at amino acid residue 62. 
This modification poses certain alteration on the protein localization, oligomerization 
and the host cell division. 
Similar to other coronavirus N proteins, the SARS-CoV N protein also contains two 
nuclear localization signals (NLSs), one at 257-260 aa, a 4-residue NLS, while the 
other at 373-389 aa, a 7-residue NLS. With these signals, the protein has the 
probability to be transported into the nucleus as observed in many other coronaviruses, 
like MHV, IBV and the transmissible gastroenteritis virus (TGEV) (Wurm et al., 2001; 
Hiscox et al, 2001). In a recent publication, different fragments of the SARS-CoV N 
protein were found to produce different cellular localization (Timani et al., 2005). The 
N-terminal of N protein was localized to the nucleus, similar to the observation 
described by Li et al. (2005), while the C-terminal was localized to the cytoplasm and 
the nucleolus. Concerning the full length protein, especially the GFP fusion ones, the 
protein were distributed in the cytoplasm and perinuclear patches instead (Timani et 
al., 2005). Besides NLS, the SARS-N protein also contains a stretch of 
serine/arginine-rich (SSRSSSRSRGNSRNSTPGSSRY residues (SR region) at 
174-194 aa. Several functions have been speculated for this special region as serine 
residues are prone to phosphorylation while arginine is a popular site of RNA binding. 
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However these have not been proven thus far. 
To understand the structure-function relationship of N, much effort has been put to 
identify functional domains of the protein, especially those domains that interact with 
the RNA, M protein as well as the N protein itself. The N protein is known to from a 
complex with the viral RNA as in the MHV and IBV (Molenkamp and Spaan.，1997; 
Zhou and Collisson, 2000). Two regions on the RNA have been identified: PS and the 
leader sequences (Molenkamp and Spaan, 1997; Stohlman et al., 1988; Nelson et al, 
2000). Also, non-specific RNA like the endogenous RNAs in the expression cells 
were found to be capable to bind to N protein as well (Master, 1992; Yu et al., 2005). 
There were suggestions that it is the M protein but not N that triggers the selective 
binding of PS (Narayanan et aL, 2000). The RNA binding site has been predicted to 
be the SR region due to the positively charged arginine residues. However, the NMR 
structure of the N-terminal domain determined suggested another binding motif 
(sheet-and-hairpin junction) which does not involve the SR region (Huang et al.’ 
2004). 
In addition to the RNA, it is also well documented that N protein can interact with the 
membrane protein (Narayanan et aL, 2000; Lai and Cavanagh, 1997; Kuo and Masters, 
2002; Escors et al., 2001). This interaction was thought to be critical as this made the 
link between the viral envelope and the RNP core and this helps incorporating the 
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genomic RNA during viral budding. For the SARS-CoV, the interaction has been 
proven by He et al. (2004) in vivo by the mammalian two-hybrid and amino acids 
168-208 were found to be responsible for this interaction. Furthermore, the C-terminal 
138 aa was mapped to be the site of self-interacting domain (Yu et al., 2005; Surjit et 
al, 2004a). The majority of the nucleocapsid protein purified actually exist in a dimer 
form at low concentration and become trimeric, tetrameric and pentameric under high 
concentrations (Tang et al., 2005). The dimer formation seems to be the first step of 
encapsidation and further association of dimers triggers the formation of higher order 
structure like tetramers, and finally assembly of the nucleocapsid core (Figure 1.4.1). 
SUMO SR region NLS NLS 
K SSRSSSRSRGNSR KKPR KKXXXXXXXXXXQRQKK 
1 62 174-194 257-260 373-389 422 
N' 國 C, 
< > < 5. 
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""Figure,1.4.1 The map of the key features of the SARS-CoV N protein showing the 
SUMO-1 conjugation site (SUMO), the serine/arginine rich region (SR region), the two predicted 
nuclear localization signals (NLS), the RNA binding domain, the horn A l binding region, the M 
protein binding domain and the self-association domain. 
N protein is a multifunctional protein in a virus life cycle. There are reports 
suggesting that it is one of the components of the replication complex according to 
‘ localization studies and coimmunoprecipitation assays (Bost et aL, 2001; Denison et 
al, 1999; ven der Meer et al., 1999). Due to its ability to bind to both the PS and 
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leader sequences, investigators believed that the protein may play a key role in 
mediating the switches between transcription, translation and encapsidation, even 
though Narayanan et al. had demonstrated packaging of RNA transcripts into VLPs 
occurs in the absence of the N protein. Due to the above mentioned crucial putative 
function, both viral and cellular proteins interacting with the N protein are interesting 
targets to prove these speculations. The ribonucleoprotein Al was found to interact 
with the MHV N protein in vitro and in vivo (Wang and Zhang, 1999) and this 
interaction has also been proven viable for the SARS-CoV N protein (Luo et al., 
2005)，whose binding site was ..found overlapping the M protein interacting domain 
(Figure 1.4.1). Nucleolar antigens like fibrillarin and nucleolin was found to be the 
IBV N protein interacting partners (Chen et al, 2002). This further confirms the 
nuclear localization of the IBV N protein and proposed an inhibitory role of the 
protein on cell proliferation as well as cytokinesis. Moreover, the MHV N protein is 
able to induce the transcription of a prothrombinase, the fibrinogen-like protein 2 
{fgl2), through the transcription factor, hepatic nuclear factor-4a (HNF4a). This plays 
a pivotal role in the pathogenesis of virus induced hepatocellular necrosis (Ning et al, 
2003; Ning et al., 1999). For the SARS-CoV N protein, it was reported to induce 
apoptosis in the stressed COS-1 monkey kidney cells through the p38 MAPK pathway 
that results in actin reorganization (Surjit et aL, 2004b). 
20 . 
Chapter I 
Besides focusing on the protein's functions, structure of the N-terminal domain 
(45-18laa) of the protein has also been solved by NMR spectroscopy. It is found that 
the protein has a distinct RNA-binding topology. The protein consists of a 
five-stranded P sheet and between strand 2 and 3 is a flexible, positively charged (3 
hairpin. It has also been shown that single-stranded RNA can bind to the junction 
between the hairpin and the p sheet (Huang et al.，2004). In another group, circular 
dichroism (CD) was employed in supplementary experiments to reveal the full length 
protein structure. There is no significant signature of a-helix. The majority of the 
proteins are turns and coils that intercepted with some p strands (Tang et al, 2005; 
Wang et al., 2004). This result is coherent with the secondary structure prediction 
from PHD (Figure 1.4.2). 
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Figure 1.4.2 Secondary structure prediction of the SARS-CoV nucleocapsid protein from PHD 
(Rost and Sander, 1994) [http://npsa-pbil.ibcp.fr]. About 73% is random coil ( ); 14% is extended 
strand (eE); 13% is helix (hH). Numbers indicate the position of amino acid residues. 
Since the outbreak of SARS, researchers had been eager to develop effective 
treatments and preventive measures. Plenty of investigations had shown N protein is 
abundantly expressed during infection and is able to elite prominent immunological 
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response throughout the course of infection (Liu et al,, 2004). N antigen had been 
used in western blotting, ELISA and immunofluorescence test for the detection of 
anti-N antibodies (Woo et al., 2004; Leung et al, 2004). Serodiagnosis making used 
of the nucleocapsid protein was highly sensitive and specific (Woo et al., 2004; Leung 
et aL, 2004). Also, anti-N antibodies (IgM, IgG and IgA) can be found in patients' 
sera during the acute phase of infection (within 14 days after infection). Thus, the 
SARS-CoV N protein antibodies had been a promising target for diagnosis, 
sometimes even at an early stage of infection (Tan et al, 2004; Huang et al., 2004b; 
Chan et al” 2005; Shi et al., 2004). 
The strong potency to elite immune response makes N protein at the same time an 
attractive target for vaccination. Plenty of research studies, including N protein 
administration, DNA vaccines or recombinant vaccinia virus utilizing N as antigen, 
had demonstrated a prominent induction of N protein-specific antibody as well as 
cell-mediated immune response on the experimental animals like mice, monkeys and 
hamsters (Gao et al., 2003; Buchholz et al, 2004; Zakhartchouk et al., 2005; Zhu et 
al., 2004; Jin et al, 2005; Zhao et al, 2005a; Wang et al, 2005; Pei et al, 2005). 
However, very few studies verified the antiviral effect of the humoral and 
cell-mediated response against SARS-CoV infection. The protective effect had only 
been shown by Gao et al. (2003) at a cell line level. Buchholz et al. (2004) even 
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demonstrated the recombinant BHPIV3-N was incapable of inducing detectable 
SARS-CoV-neutralizing antibodies in immunized hamsters and cannot provide any 
protection to the animal upon SARS-CoV challenge. Since anti-N antibodies are 
non-neutralizing, the antibody may just confer its protection in some other ways as 
observed in MHV (Nakanaga et al., 1986). On the contrary, immunization targeting 
spike can elite strong neutralizing antibody production that has been proven in both 
cell lines and animals to be protective on SARS-CoV challenge (Buchholz et al., 2004; 
Yang et al” 2004a; Faber et al., 2005). But it is not without drawback that sometimes 
vaccination may accompany severe inflammatory response like hepatitis and 
delayed-type hypersensitivity (DTH) (Weingartl et al, 2004; Zhao et al, 2004). 
To be prepared for the recurrence of SARS, despite drugs like lopinavir/ritonavir, 
ribavirin, glycyrrhizin and human interferons (Chu et al.’ 2004; So et al., 2003; Cinatl 
et al, 2003a; Cinatl et al, 2003b; Haagmans et al, 2004), small interfering RNAs 
(siRNAs) is also a potential therapeutic strategy. siRNA targeting the N protein has 
been confirmed on its silencing effect (Zhao et al” 2005b). But further investigation is 
needed to analyze its effect on viral replication. It is hope that RNA interference 
\ (RNAi) can be developed into a safe and effective treatment of the disease to release 
-
human beings from the threat (Soutschek et al,, 2004). 
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1.5 The Sumoylation System 
A number of post-translational modifications (PTM) have been proven or speculated 
for the SARS-CoV nucleocapsid protein. PTM can directly affect the function or fate 
of a protein as it may cause alteration of the protein structure, influence the 
protein-protein interaction or as a tag that directs further modification or changes of 
protein sub-cellular localization. Among, sumoylation is a strong suspected 
modification to the N protein because of the high probability score of putative 
sumoylation sites (See section 2.3.7.1). In contrast to many other PTM, sumoylation 
cannot be easily detected by directly isolating N proteins in vivo followed by mass 
spectrometric analysis. Therefore, assays have to perform to see if a protein can be 
sumoylated. 
SUMO stands for the Small Ubiquitin-like Modifiers. As it was named, SUMO are 
modifiers tKat carry structural similarities with ubiquitins. Yet, in contrast to 
ubiquitylation, sumoylation does not tag protein for degradation, but for the 
modification of the protein functions, activities, stabilities and sub-cellular 
\ localizations. These alterations of the SUMO substrates may ultimately lead to the 
� regulations of cellular processes like signal transduction, nuclear transport, cell 




Up till now, sumoylation was found only in the eukaryotic kingdoms, but it is highly 
conserved from yeast to human. In mammalian cells, the majority of the SUMO-1 are 
in conjugated form while SUMO-2 and SUMO-3 are in free forms, which are 
subjected to conjugation rapidly upon cellular stress. Analogous to ubiquitylation, the 
tag, i.e, SUMO in sumoylation, is covalently attached to the substrate through its 
carboxyl-terminal glycine to the s-amino group of a lysine residue in the target protein. 
This single conjugation involves four successive enzymatic reactions namely 
maturation, activation, conjugation and ligation (Figure 1.5). 
The newly synthesized SUMO polypeptide after translation is a pre-protein that 
required maturation through cleavage by the SUMO protease to expose the 
carboxyl-terminal glycine. Then, activation involves the ATP-dependent formation of 
a thioester linkage between the SUMO carboxyl-terminal glycine and a cysteine 
residue of the El activating enzyme. El is a heterodimer composed of Aosl and Uba2, 
which are the structural homology to the amino- and carboxyl-terminal of the 
ubiquitin El counterpart respectively. Next, the "activated" SUMO is passed from El 
^ to E2 conjugating enzyme, Ubc9 by again forming a thioester bond with the cysteine 
residue at the active site (Cys93). Finally, the SUMO was ligated to the substrate 
lysine residue located at the consensus sequence of sumoylation site,平KXE (中：a 
hydrophobic residue; K: lysine; X: any amino acid residue; E: glutamate), through the ‘ 
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E3 ligase. The SUMO tag is removed from the substrate through de-sumoylation by 
the isopeptidase activity of SUMO protease (Seeler and Dejean, 2003). 
In the sumoylation pathway, all the reactions involve the same El and E2 enzymes. 
There are several SUMO proteases that each of them is responsible for the reaction 
which take place at specific subcellular localizations, whereas there are lots of E3 
ligases. Each of them is specific to only a few number of substrates. Also, Ubc9, the 
E2 enzyme, alone can recognize the sumoylation site and interact with the substrate 
without the E3 ligase and in vitro experiments have shown that El and E2 are 
sufficient to catalyze the modification for a number of substrates (Desterro et al., 1997; 
Desterro et al,, 1998; Okuma et ai, 1999). Therefore, the key function of E3 ligase 
lies at the regulation of the SUMO modification but not substrate identification. 
Thus far, about 150 sumoylation substrates in human had been reported and possible 
ones are still being explored. Concerning viral nucleocapsid protein, there are only 
four viral N proteins that had been identified with SUMO modification (Kaukinen et 
a l , 2003; Meada et al, 2003; Lee et a!•，2003; Li et al” 2005). Three of them are the 
hantaviruses, the Tula, Seoul and Hantaan hantaviruses N proteins, while the other 
one is the SARS-CoV N protein. The SUMO modification to the SARS-CoV N 
protein has been demonstrated by Li et al (2005) in vivo by overexpression of both 
the N protein and the SUMO-1 protein in HeLa cells. Sumoylated N proteins were • 
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detected b y the increase in molecular weight of the N proteins as detected by western 
blotting. The sumoylat ion site was also mapped to K62. Further s tudy for an in vitro 
evidence of the sumoylat ion of the S A R S - C o V N protein can strengthen the f indings 
in the in vivo assays. 
Maturation Activation: El Conjugation: E2 Ligation: E3 
— 4 A T p T I 
\ AMP + PPj � j 
Figure 1.5 Diagrammatic elaboration of the SUMO pathway. Maturation and 
de-modification is catalyzed by a SUMO protease, Ulp, a carboxyl-terminal hydrolase. Activation 
is catalyzed by the El activating enzyme, Aosl-Uba2. E2 conjugation enzyme is Ubc9. Three 
examples are listed here for the E3 ligase: Siz/PIAS, RanBP2 and Pc2. They are responsible for 
the ligation of SUMO to different target proteins. Pc2: Polycomb protein 2; Siz/ PIAS: Sap and 
Miz/ protein inhibitors of activated STAT; RanBP2: Ran-binding protein 2; SUMO: small 




1.6 Objectives of the Present Study 
As mentioned above, the SARS-CoV N protein plays a crucial role in RNA binding 
and encapsidation. It also presents a novel model of RNA-binding proteins. Therefore, 
to elucidate a crucial PTM, sumoylation that may pose certain effect on the protein 
activities and know more about how the protein behaves in the presence of RNA as 
well as how this correlate with the protein structural properties would be interesting 
fields for investigations. 
Therefore, in the present study, purify the protein to homogeneity is the primary aim. 
This can aid the structural determination of the protein. The purified proteins were 
then used to characterize the SARS-CoV nucleocapsid protein in two fold: its 
susceptibility to sumoylation and its RNA-binding ability. 
\ . . 
、..“ ’ . .  
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Chapter II 
Purification of SARS-CoV N Protein/ Fragment and 
Sumoylation of the N protein 
2.1 INTRODUCTION 
A variety of functions, for example, control of virus replication (Bost et aL, 2001; 
Denison et al, 1999; ven der Meer et al” 1999) and packaging by binding to the 
leader sequences and packaging signals (Molenkamp and Spaan, 1997; Stohlman et 
al., 1988; Nelson et al., 2000)，as well as interacting with a number of host proteins 
and viral proteins (Luo et al, 2005; He et al, 2004; Chen et al” 2002; Wang and 
Zhang, 1999), has been speculated for the nucleocapsid proteins of coronaviruses. All 
these functions are in close relationship with its strong RNA and protein interacting 
ability. A way to understand thoroughly how these functions can be exerted by this 46 
kDa protein is to solve the protein structure. Therefore it was a primary aim of the 
project to purify the protein to homogeneity so as to make further structural 
determination possible. Before the publication of several articles describing the 
strategies of purifying the N protein, a number of approaches has been attempted in 
order to purify the protein to a purity of above 95%. A more stable truncated fragment 
was also designed in a hope to generate a protein of a conformation that is less prone ‘ 
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to degradation as this may aid crystallization for which prolonged storage is needed. 
Establishment of a successful purification strategy is absolutely beneficial towards 
future analysis and characterization of the protein. 
Since the natural host of the SARS-CoV is homo sapiens and civet cats, 
post-translational modifications (PTMs) play important roles in altering the proteins' 
functions, activities, fates and localizations after completion of their synthesis in these 
higher organisms. Unlike phosphorylation, oxidation, acetylation and glycosylation, 
isolation of the N protein in vivo and then applying directly to mass spectrometry 
cannot easily identify the presence of SUMO modification. Instead, specifically 
designed assays were needed to reveal the modification. Therefore, an in vitro 
sumoylation assay was performed in the present study to analyze if the protein can be 
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2.2 METHODOLOGY 
Materials 
Vectors for expression of N proteins in E. coli 
pAC28m (modified) 
pAC28m originates from pAC28, which is also a modified vector as described in 
BioTechniques 31:322-328 (Aug 2001). Plasmids pET28a (Novagen) and pACYC177 
(New England Biolabs) were digested with Fsp\ and CM. The DNA fragments of 
1723 bp from pACYC177 containing the pi5A origin and 3457 bp from pET28a were 
purified, ligated and verified by sequencing. The modified vector generated was 
designated pAC28, which has its structure similar to pET28a except that the original 
pBR322 origin was replaced by the pi 5A origin from pACYC177. 
Further modification was made to pAC28 to generate pAC28m, in which the linker 
region between the six polyhistidine (Hise) tag and the Ndel restriction site that 
contains the thrombin cutting site was removed. The vector carries an N-terminal 
\ His6-tag/ T7-tag configuration plus an optional. C-teraiinal His6-tag sequence. 
Transcription was driven by the strong phage T7 promoter upon induction from 
isopropyl p-D-thiogalactoside (IPTG). The vector is selected against kanamycin. 
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pGEX-6P-l (Amersham Biosciences) 
The vector allowed translational fusion of the glutathione S-transferase (GST) to the 
N-terminus of the cloned target protein and the GST-tag can be removed by 
subsequent digestion of the fusion protein by PreScission™ protease which 
recognizes the amino acid sequence LEVLFQGP situated between the tag and the 
target protein. Transcription is controlled by the "lac" promoter (Piac) and basal 
expression is minimized by the binding of the Lac repressor (encoded by the lacf 
gene) to the lac operator immediately downstream of Piac. The vector is under 
selection by ampicillin. 
pMAL-c2E (New England Biolahs) 
The vector allowed translational fusion of the Escherichia coli {E. coli) maltose 
binding protein (MBP, encoded by the malE gene) to the N-terminus of the cloned 
target protein and the MBP-tag can be removed by subsequent digestion of the fusion 
protein by enterokinase which recognizes the amino acid sequence DDDDK situated 
\ between the tag and the target protein. Transcription is controlled by the "lac" 
—• promoter (Piac) and basal expression is minimized by the binding of the Lac repressor 
(encoded by the lacf gene) to the lac operator immediately downstream of Piac. The 
Vector is under selection by ampicillin. ‘ 
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pMAL-c2P (modified) 
The vector is similar to pMAL-c2E except that the enterokinase cutting recognition 
site is replaced by that of PreScission™ protease (LEVLFQGP). Detailed 
modification strategies are described in section 2.2.1. 
E. coli cell strains 
DH5a(GIBC0) 
F"(p80/acZAM15 A(lacZYA-arg¥)\J\69 recAl endAl hsdR\l{A, mk+)phoA supE44 
thi-l gyrA96 relAl X' 
DH5a is a commonly used E. coli strain for molecular cloning. The lacZAMlS 
marker provides a-complementation of the P-galactosidase gene, allowing blue / 
white screening of colonies. The cells also support replication of M13mp vectors but 
do not support plaque formation. Mutation of recAl ensures insert stability and endAl 
mutation produce higher plasmid yield. 
B834 (DE3) (Novagen) • 
F" ompT hsdSB (rs" HIB') gal dcm met (DE3) 
B834 is the parental strain for BL21. The strain is deficient in the ompT and Ion 
proteases, which may interfere with isolation of intact recombinant proteins. It is 
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auxotrophic for methionine and allows high specific-activity labeling of target 
proteins with ^^S-methionine and selenomethionine. The designation (DE3) indicates 
that the strain is a lysogen of bacteriophage 入DE3, and therefore carries a 
chromosomal copy of the T7 RNA polymerase gene under control of the lacUVS 
promoter. 
B834+ 
The strain is derived from B834 with similar properties as BL21 (DE3) pLysS, and 
thus requires chloramphenicol for selection during propagation. 
C41 (DE3) 
C41 has a genotype similar to BL21 (DE3). It is a mutated host strain derived from 
BL21 (DE3) by selection of bacterial colonies that can tolerate over-expression of the 
membrane protein OGCP, oxoglutarate-malate transport protein. Therefore, the strain 
is able to survive under medium toxicities that arise from the over-expression of 
\ membrane proteins and produces the protein as inclusion bodies at an elevated level 
without toxic effect (Miroux and Walker, 1996). 
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BL21 (DE3) pLysS (Novagen) 
F" ompT hsdSB (rs" HIB") gal dcm (DE3) pLysS (Cm^) 
The BL21 strains are deficient in the ompT and Ion proteases, which may interfere 
with the isolation of intact recombinant proteins. The designation (DE3) indicates that 
the strain is a lysogen of bacteriophage X.DE3, and therefore carries a chromosomal 
copy of the T7 RNA polymerase gene under the control of the lacUVS promoter. 
pLysS designates host strains that carry plasmids encoding the T7 lysozyme, which is 
a natural inhibitor of T7 RNA polymerase. Thus, the strain can produce a small 
amount of T7 lysozyme to suppress basal expression of T7 RNA polymerase prior to 
induction and hence stabilize recombinants encoding target proteins that affect cell 
growth and viability. The plasmids encoding the T7 lysozyme provide resistance 
against chloramphenicol (Studier and Moffatt, 1986). 
Mediums 
LB medium 
20 g LB broth (USB) was dissolved in IL ddHiO and the medium was sterilized by 
autoclave. 
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LBA, LBC, LBK and LBAC media 
Antibiotics were added to the LB medium just prior to use from stock to a final 
concentration of 0.1 mg/ml, 0.017 mg/ml and 0.015 mg/ml for ampicillin, 
chloramphenicol and kanamycin respectively. 
LB, LBA, LBC, LBK and LBAC agar plates 
17.5 g LB agar (USB) was dissolved in 500 ml ddHzO and made sterile by autoclave. 
The medium was allowed to cool down to 55°C and antibiotics were added, if needed， 
from the stock to a final concentration of 0.1 mg/ml, 0.017 mg/ml and 0.015 mg/ml 
for ampicillin, chloramphenicol and kanamycin respectively. The agar was poured 
into Petri dishes and allowed to solidify by cooling. 
buffers and solutions 
lOX Tris-glycine electrophoresis buffer 
30.2 g Tris base, 188 g glycine and 100 ml 10% SDS (w/v) was added to distilled 
Water and brought up the volume to 1 L. IX working buffer was prepared by dilution 
with distilled water. 
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6X SDS gel loading dye 
30 ml IM Tris-Cl (pH 6.8)，12 g SDS, 0.6 g bromophenol blue and 60 ml glycerol 
was mixed and the volume was brought up to 100 ml with ddHzO to give a clear blue 
solution. Just before use, 100 \i\ IM DTT stock was freshly added to 900 |il solution 
prepared as described above. 
Ampicillin (100 mg/ml stock) 
The stock was made by dissolving Ig of chloramphenicol (Sigma) in 10 ml 
autoclaved ddHiO or absolute ethanol. The solution was sterilized by filtration and 
stored at -20°C for use. 
Chloramphenicol (34 mg/ml stock) 
The stock was made by dissolving 340mg of chloramphenicol (Sigma) in 10 ml 
absolute ethanol. The solution was sterilized by filtration and stored at -20�C for use. 
Kanamycin (30 mg/ml stock) , 
The stock was made by .dissolving 300mg of kanamycin (Sigma) in 10 ml autoclaved 
ddHaO. The solution was sterilized by filtration and stored at -20°C for use. 
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RFI 
The solution was prepared by dissolving 12 g RbCl, 9.9 g MnCl2'4H20 and 1.5 g 
CaCl2-2H20 in 700 ml deionized water. 30 ml IM KOAc and 150ml glycerol was also 
added. The pH was adjusted to 5.8 by acetate acid. Finally, the solution was brought 
up to 1 L by deionized water and sterilized by filtration. 
RFII 
The solution was prepared by dissolving 1.2 g RbCl and 11 g CaCl2.2H20 in 700 ml 
deionized water. 150ml glycerol was also added. pH was adjusted to 6.8 by NaOH. 
Finally, the solution was brought up to 1 L by deionized water and sterilized by 
filtration. 
Materials for agarose gel electrophoresis, coomassie blue staining and destaining 
solution see section 3.2. 
Preparation of SDS-PAGE gel see appendix V. 
\ ‘ 
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Methods 
2.2.1 Construction of the pMAL-c2P Vector 
pMAL-c2E vector purchased from New England BioLabs Inc. (NEB) was modified to 
replace the enterokinase cutting site with the PreScission™ protease (PP) cutting site 
without altering the multiple cloning sites (MCS). The PreScission™ protease cutting 
site originates from the vector pGEX-6P-l (Amersham Biosciences). The vector 
constructed was designated pMAL-c2P and can express protein fusion to the maltose 
binding protein (MBP). The MBP-tag can be cleaved by the PreScission™ protease 
through the cutting site 'Leu Glu Val Leu Phe Gin Gly Pro' (CTG GAA GTT CTG 
TTC CAG GGG CCC). 
In pMAL-c2E, as shown in figure 2.2.1.1, there is a unique Ndel cutting site situated 
at the start of malE gene (encodes the MBP). Thus a forward primer containing the »� 
^del site and 16 bp downstream of the vector sequence was designed: 
GC clamp Start cod on 
5'-'TAG GGC'CAT ATG AAA ACT GAA GAA GGT -3, 
, I I 
A/del site 
\ 
While the reverse primer contains an EcoRI site which is present at the MCS of 
P M A L - C 2 E (see figure 2.2.1.1), the P r e S c i s s i o n ™ protease cutting site and 21 bp 
Upstream of the enterokinase cutting site in pMAL-c2E and is represented as follow: 
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GC clamp PreScission"™ protease recognition site 
5'-'TAG GGC 'GAA TTC GGG CCC CTG GAA CAG AAC TTC CAG €CC 
I I— “…. 
EcoRI site 
GAG GTT GTT ATT GTT ATT -3' 
Utilizing this pair of primers, a DNA fragment containing the melE gene followed by 
the PreScission™ protease cutting site can be amplified. Ligation of the restricted 
DNA fragment and pMAL-c2E using typical cloning method as described in section 
2.2.2 can yield the pMAL-c2P vector. Figure 2.2.1.2 illustrates the vector construction 
strategy. 
M s c I 
B t g l 
, EcoOl09t.PpuMI \ EC001091.PPUMI 
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B s p E I \ \ \ 
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Figure 2.2.1.1 
Restriction map of the pMAL-c2E indicating the restriction sites of Ndel and 
丑coRI (boxed). The region between these two sites was replaced by the DNA fragment amplified 
with PreScission™ 
protease recognition site. 
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^ PreSdssion Protease 
W \ ^ Ndel (1526) recognition site 
f p 斷 C 2 E j f fF \ 
\ R � I ^ _ I malE 
\ ^ " ^ ^ y l ： ^ "^a/E PGR amplification 




i Restriction digestion I 
by A/del and EcoRI + 
\ . Ndel (1526) PreSdssion Protease 
m X^ ^  recognition site 
T p M A L - c 2 E \ 
\ J malE »r 
\ ^EcoRI (2704) 
W s 
^ r ‘ 
I Ligation 
A ^ Ndd (1526) 
T p M A L - c 2 E I 
Amp^  • \ \ 
\ "-EcoRI (2707) 
W s 
Figure 2.2.1 Systemic diagram illustrating the strategy of construction of pMAL-c2P (Not 
drawn in proportion). F: Forward primer; R: Reverse primer; ori: origin; lac: lac repressor gene; 
Amp: ampicillin resistance gene; malE. gene encoding the maltose binding protein; MCS. 
multiple cloning site. 
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2.2.2 Sub-Cloning of the N Protein into Different Vectors 
Different expression system had been used to aid purification of the N protein with 
different tags as summarized in table 2.2.2.1. The N protein gene was sub-cloned or 
PCR amplified from the N protein-pcDNA4 plasmid (kindly provided by Ms. Pat 
Cheung P.Y.) which originated from the SARS-CoV genome CUHK-Wl sequenced 
previously in our laboratory. 
Expression 
Vector Tag Brand/ modification 
system 
1. ori pl5A from pACYC177 (NEB) 
replaced the ori in pET28a (Novagen) 
pAC28m His6 2. Thrombin cutting site was deleted to 
minimize the linker region 
. {BioTechniques 31:322-328 (Aug 2001)) 
—— Bacterial —— 
pGEX-6P-l GST Amersham Biosciences 
pMAL，c2E New England Biolabs 
Enterokinase cutting site of pMAL-c2E MBP 呂 
pMAL-c2P replaced by that of PreScission"^ protease 
(see section 2.2.1) 
Table 2.2.2.1 A summary of the expression vectors used in the cloning of N protein. His6 
\ designates the presence of six histidine residues as a tag in the polypeptide. All the vectors 
produce N-terminal tag fusion proteins. 
// 
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2.2.2.1 Design of primers for the cloning of N protein 
To clone the N protein into the four vectors listed before, two forward and a reverse 
primers were designed to suit different restriction sites in the MCS of the expression 
vectors. 
Ndel site was chosen for the cloning of N protein into pAC28m because in between 
the Ndel site and the MCS is a T7 tag (see appendix II). Using the site can make the N 
protein express right after the six histidine residues without any linker region. Thus, in 
the cloning of the N protein gene into the pcDNA4/HisMax© vector (by Ms. Pat 
Cheung), the forward primer was designed with its 3 end complementary to the 5 
end of the N protein and an Ndel site was placed just beyond and overlapping the 
ATG start codon of the N gene. A GC clamp was added at the 5 end of the primer. 
Forward primer TA = 66°C 
GC clamp Start codon 
5'-'GCC' CAT ATS TCT GAT AAT GGA CCC CAA TC -3' 
I …I 
Nde\ site 
Accordingly, the N protein gene was sub-cloned into the pAC28m vectors by 
restriction digesting the N protein-pcDNA4 plasmid with Ndel and EcoRl, which are 
‘ ii 
inserted during amplification of the gene and is present in the MCS of pcDNA4 
vector. 
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Another pair of primers was designed for the directional cloning of N protein into the 
vector pMAL-c2E. BamHI was chosen as the forward restriction site. 
Forward primer TA = 66°C 
GC clamp Start codon 
S ' - ' ^ G G A TCC ATG TCT GAT AAT GGA CCC CAA TC -3' 
I 1 
BamHl site 
The reverse primer was designed with the 3 end complementary to the 3 end of the N 
protein. Since a stop codon TAA was present at the end of N gene originally, no 
additional stop codon was added and a Sail site and a GC clamp follow right after that 
at the 5 end of the primer. 
Reverse primer TA = 66°C 
GC clamp Stop codon 
S ' - ' ^ G T C GAC TTA TGC CTG AGT TGA ATC AGC A -3' 
I I 
Sa/I site 
After N protein Was cloned into pMAL-c2E, the gene was again restriction digested 
by Barnm and Sail, and then sub-cloned into the vectors pGEX-6P-l and pMAL-c2P. 
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2.2.2.2 DNA amplification using Polymerase Chain Reaction (PGR) 
A standard PGR reaction mix was set with the following composition: 
；Pl^PQnepte J；' ‘ 乂 / : � : ; 厂 ： Volume ： Final concentration 
J OX cDNA PCR reaction buffer * 2.5 i^l ]X 
dNTPs mix (2 mM each nucleotide) 2.5 pA 200 each nucleotide 
_Forward primer (10 )aM) I j d 0.4 ^iM 
_Reverse primer (10 piM) I j i l 0.4 ^iM 
_PNA template (50 ng /n l ) I j i l 2 ng/ i^l 
_50X Advantage cDNA polymerase mix 0.25 0.5X 
Autoclaved ddHzO 16.75 \x\ -
J o t a l 25 }il -
* lOX cDNA PCR reaction buffer: 400 mM Tricine-KOH (pH 9.2)，150 mM KOAc, 
35 mM Mg(0Ac)2, 37.5 )j,g/ ml bovine serum albumin 
The PCR buffer and the polymerase mix is obtained from the Advantage® cDNA 
PCR Kit and & Polymerase Mix (CLONTECH) (Cat. No. PT1580-1). The PCR was 
proceeded in thermocycler (Eppendorf) equipped with a heat lid (105°C). A 'hot start' 
temperature profile was set as following: 
_ 2 m i n , 
� ^ f � ^ IVS A. \ ！ V，《、叙h » ^ vA, Jl&fil 
Step 2 Denaturation 95 36 sec 
Step 3 … � 。 ： 哪 : � L : 5 4 , C � 36 sec 
Step 4 Extension 68 1 min 30 sec 
Mep 2 to 4 was repeated for 30 more cycles ^ ” 
Step 5 Final extension 68 10 min 
Amplification of the N protein was checked by running the PCR product in 1% 
agarose gel electrophoresis in TAE buffer under 120 V for 20 min. The DNA product 
Was revealed under UV trans-illumination after ethidium bromide staining. 
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2.2.2.3 DNA extraction from agarose gels 
QIAquick Gel Extraction Kit purchased from QIAGEN was used to extract DNA 
from agarose gels. 
DNA fragments were excised out from the agarose gel with a scalpel. For gel slice 
smaller than 350 mg，1 ml of Buffer QG was added to dissolve the gel by incubation 
at 50�C. Otherwise the gel slice was cut into smaller pieces (<350 mg). After the gel 
piece was dissolved completely in the solution, the mixture with optimal pH (yellow 
in color or sometimes green when mixed with the DNA loading dye) was applied to 
the QIAquick column and centrifiiged for 1 min at maximum speed (14,000rpm) in a 
bench top centrifuge so that the DNA fragment can bind to the column. Flow-through 
was discarded. 750 |J1 Buffer PE was added to the column and centrifuged for 1 min 
again to wash. Flow-through was discarded and the QIAquick column was 
centrifuged for 1 'min further to remove residual ethanol. 30 |al autoclaved ddHzO 
pre-warmed at 70°C was added to the centre of the column membrane and allowed to 
stand for 1 min. Finally, DNA was eluted by centrifugation for 2 min. 
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2.2.2.4 Restriction digestion of purified PCR product and vectors 
The amplified N protein DNA was subjected to two different restriction digestion 
according to the primers used for amplification. For the sub-cloning of N protein into 
pAC28m, the following reaction profile was used: 
Compgyeiit ^^  1 ' pAC28m . . N protein 
J OX One-Phor-All PLUS buffer * 1.5 i^l 3^1 
m i (lOU/ III) UU 1 1x1 
EcoRl (lOU/ [x\) Uf l 1 
Vector 5 |xl -
j^CR products - 15 i^l 
_Autoclaved ddHiO 1.5 [i\ -
Jo t a l ., 10 III 20 III 
For the cloning of N protein into pGEX-6P-l, pMAL-c2E and pMAL-c2P, the 
following reaction profile was used: 
J V … ； '杀广’•<：： pGEX-6P-l/ pMAL-C2E/ “ ~ 
Component “ N protein 
丄：^ ‘； .. ^ 一 pMAL-c2P . 
丄OX One-Phor-All PLUS buffer * ^ 4^1 
j a m H I (lOU/ ^il) I j d 1 |il 
^ n (lOU/ |Lil) ‘ I j i l 1 i^l 
^ -
丄CR product - 14 pi 
^Autoclaved ddHzO ^ -
JTotal volume \0 \x\ 20 [i\ 
* lOX One-Phor-All PLUS buffer: lOOmM Tris-acetate (pH 7.5)，lOOmM magnesium 
acetate, 500mM potassium actetate. . 
,The One-Phor-All PLUS buffer and the enzymes were purchased from Amersham 
Biosciences. The reaction mixtures were incubated at 37°C for 3 hours. The 
completion of digestion was checked by agarose gel electrophoresis and DNA was 
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extracted and purified as described in section 2.2.2.3. 
2.2.2.5 Ligation of N protein into expression vectors 
The T4 DNA ligase together with the lOX ligation buffer was supplied by New 
England Biolabs Inc. The purified cohesive inserts from restriction digestion were 
ligated into the restricted vectors at 3:1 to 6:1 (insert : vector) molar ratio. The 
reactions were performed at 16°C overnight. The following table shows the 
composition of the reaction mixture: 
_^mponent$ ；： '-. ‘ C ‘ • Ligation reaction Negative control 
丄OX T4 DNA ligation buffer * ^ I j d 
Jnsert 14 \i\ -
_Vec^ 3jd 
J 4 D N A ligase I j d 0.5 pi 
j^utoclaved ddHzO - 5.5 i^l 
JTotal volume 20 I M 
* lOX T4 DNA ligation buffer: SOOiriM Tris-HCl, lOOmM MgCb, lOOmM DTT， 
lOmM ATP, 250 fig/ml bovine serum albumin (pH 7.5) 
2.2.2.6 Preparation of competent cells 
The RF I and RF II buffers were prepared prior to the preparation of competent cells. 
Frozen glycerol stock of DH5a stored at -80°C was streaked onto a LB agar plate. 
The streaked plate was incubated at 37�C for 16 hours for the bacteria to grow. A 
• • 
single colony was picked and inoculated into 5ml LB medium and cultured at 3TC 
for 16 hours with shaking at 250 rpm. After that, the starter culture was inoculated . 
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into 250 ml LB medium. The culture was allowed to grow at 37®C with shaking at 250 
rpm until OD at 600 nm reached 0.3-0.5. The bacterial cells were harvested by 
centrifugation at 2500 rpm for 10 min at 4°C. The supernatant was discarded. The 
pellet was resuspended in 83 ml RF I buffer and chilled on ice for 15 min. The 
suspension was centrifuged again at 2500 rpm for 10 min at 4®C. The supernatant was 
discarded. The pellet was resuspended in 20 ml RF II buffer and further incubated on 
ice for 15 min. The competent cells were then snap frozen in liquid nitrogen in 200 \x\ 
aliquots and stored at -80°C until use. 
2.2.2.7 Transformation of plasmids into competent Escherichia coli 
200 |Lil aliquots of E. coli strain DH5a competent cells were thawed on ice for 10 min. 
The ligation products or negative control was added into the each tube of competent 
cells and mixed gently. The mixtures were then incubated on ice for 20 min followed 
by heat shock at 42°C for 1 min 30 sec. After that, the mixture was placed on ice for 2 
to 3 min. 1 ml LB medium was added to each tube and the bacteria was allowed to 
recover at 37°C with shaking at 250 rpm for 45 min. Next, the bacterial cells were 
spun down. Most of the medium was removed and the transformed cells were 
resuspended in about 200 medium. The bacterial suspensions were spread onto LB 
agar plate supplemented with appropriate antibiotics (Agar plates with 0.1 mg/ ml . 
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ampicillin for cloning into pAC28m vector and 0.015 mg/ ml kanamycin for cloning 
into pGEX-6P-l, pMAL-c2E and pMAL-c2P vectors). Finally, the plates were 
incubated at 37�C overnight (16 to 18 hours). 
2.2.2.8 Preparation of plasmid DNA 
2.2.2.8.1 Mini-preparation of plasmid DNA 
A single bacterial colony was inoculated from the agar plate into 3 ml LB medium 
supplemented with appropriate antibiotics. The culture was grown for 16 to 18 hours 
at 3TC with shaking at 250 rpm. The bacterial cells were harvested by centrifugation 
at 14000 rpm for 10 min. The plasmid DNA was isolated using the Marligen 
Biosciences CONCERf™ Rapid Plasmid Minipreps kit. 
The cell pellet obtained was resuspended in 250 jil chilled G1 buffer (50mM Tris-HCl 
(pH 8.0), lOmM EDTA) containing RNase A. 250 G2 cell lysis solution (200mM 
NaOH, 1% SDS (w/v)) was further added and then mixed gently by inversion. The 
mixture was incubated at room temperature for 5 min. After that, 350 |J.1 M3 
neutralizing buffer (contains acetate and guanidine hydrochloride) was added and 
mixed by inversion for five times. The mixture was centrifuged immediately at 14000 
rpm at room temperature for 10 min. The supernatant obtained was loaded into the 
spin cartridge and centrifuged at 14000 rpm for 1 min. The flow-through was 
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discarded. The cartridge was washed by adding to it 700 G4 wash buffer (contains 
NaCl, EDTA, Tris-HCl (pH 8.0) and ethanol) and then spun at 14000 rpm for 1 min 
again. The flow-through was discarded. Residual ethanol was removed by further 
spinning at 14000 rpm for 1 min. Finally, 60 to 75 pre-warmed autoclaved ddHiO 
was added to the centre of the cartridge membrane and incubated at room temperature 
for 1 min. Finally, plasmids were eluted into clean sterile eppendorfs by spinning at 
14000 rpm for 2 min. 
The presence of insert was checked by restriction digestion, PCR amplification of the 
N gene and sequencing. 
2.2.2.8.2 Midi-preparation of plasmid DNA 
A scale up preparation of plasmid was performed using the QIAGEN^"^ HiSpeed 
Plasmid Midi Kit. A single colony was picked from a freshly streaked plate and 
inoculated into 5 ml LB medium supplemented with appropriate selective antibiotics. 
The starter culture was grown overnight at 37�C with shaking (250 rpm). The culture 
was then inoculated into 250 ml LB medium with appropriate antibiotics and grown 
-overnight again at 37°C with 250 rpm shaking. The bacterial cells were harvested by 
centrifugation at 6000 rpm for 15 min at 4°C. The cell pellet was resuspended 
completely in 6 ml chilled PI buffer (50mM Tris-Cl (pH 8.0), lOmM EDTA, 100 
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|ag/ml RNase A). 6 ml P2 buffer (200mM NaOH, 1% SDS (w/v)) was added and 
mixed gently by inversion for 5 times. The mixture was kept at room temperature for 
5 min. 6 ml of P3 (3.0M potassium acetate, pH 5.5) buffer was further added and 
mixed gently by inversion for 5 times. The lysate was poured into the QIAfilter 
cartridge and stood at room temperature for 10 min. After incubation, the lysate was 
filtered through the QIAfilter cartridge and the flow-through was drained into QBT 
buffer (750mM NaCl，50mM MOPS (pH 7)，15% isopropanol (v/v), 0.15% Triton® 
X-100 (v/v)) equilibrated HiSpeed Midi Tip. The lyaste was allowed to enter the resin 
by gravity. The HiSpeed Midi Tip was washed with 20 ml QC buffer (IM NaCl, 
50mM MOPS (pH 7)，15% isopropanol (v/v)). Then DNA was eluted in 5 ml QF 
buffer (1.25M NaCl, 50mM Tris-Cl (pH 8.5), 15% isopropanol (v/v)). DNA was 
precipitated by adding 3.5 ml isopropanol to the eluted DNA solution. It was mixed 
and incubated at room temperature for 1 hour to overnight. Next, the eluate/ 
isopropanol mixture was injected through the QIAprecipitator with a constant speed. 
The flow-through was injected through the QIAprecipitator once again. The 
QIAprecipitator was washed with 2 ml chilled 70% ethanol and then made dry by 
injecting air rapidly for at least five times. Finally, plasmid DNA was eluted in 300 i^l 
autoclaved ddH20 pre-warmed at 70°C. The yield of the DNA was checked by 
spectrophotometric measurement at 260 run. The plasmid was stored at -20�C for use. • 
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2.2.3 Expression of Tagged and Untagged N Proteins 
2.2.3.1 Preparation ofE. coli competent cells for protein expression 
Several E. coli strains had been tried out for protein expression to optimize a 
condition that can produce the highest proportion of soluble N protein. These included 
the B834, B834+，BL21(LysS) and C41(DE3) strains. The procedures were the same 
as that described in section 2.2.2.5 for the preparation of DH5a except 17 \x%l ml 
chloramphenicol was added to the LB agar plates as well as the LB medium during 
the propagation of B834+，BL21(LysS) and C41(DE3) strains. 
2.2.3.2 Expression of N proteins 
N protein-pAC28m, N protein-pMAL-c2P or N protein-pGEX-6P-l was transformed 
into desired E. coli strain following the procedures described in section 2.2.2.7. 
Except B834 cells, all bacterial cells were spread onto LB plates supplemented with 
Mg/ ml chloramphenicol in addition to the antibiotic resistance conferred by the 
expression plasmids. Successfully transformed clones were inoculated into LB 
medium with the same constituent of antibiotics as in the agar plated. The bacterial 
cells were cultured at 3TC overnight with shaking at 250 rpm. 
The overnight cultures were step-cultured into flasks with LBA or LBK medium , 
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(devoid of chloramphenicol) at a concentration of 1 to 5 % culture. Cells were grown 
at 3TC with shaking at 250 rpm until OD600 reached 0.5. If proteins were to be 
expressed at 25�C or below, cells were pre-incubated at the desirable temperature for a 
while to cool down the medium. A final concentration of 0.1 mM IPTG was added to 
induce protein expression. Cultures were further incubated at the expression 
temperature for 3 hours, 6 hours or overnight with shaking at 250 rpm. Cells with N 
protein expressed were harvested by centrifugation at 8000 rpm at 4°C for 5 minutes. 
Cell pellet was kept at -80�C or -20°C for future analysis. 
2.2.3.3 Solubility tests on the fusion proteins expressed 
To test the solubility of the fusion proteins, about 80 ml bacterial culture was grown 
and the expression was induced as described in the last section. At each time point, 3 
hours, 6 hours and overnight, 25 ml culture was collected and the cell pellet was 
collected by centrifugation. The pellet was then resuspended in 25 ml lysis buffer (10 
mM Tris, 300 mM NaCl) and of which, 1 ml was taken out to represent the total cell 
lysate. The remaining culture was sonicated in lysis buffer. 1 ml of the lysed bacterial 
�ee l l s was ftirther taken and centrifuged at 14000 rpm at 4°C for 20 min to separate the 
soluble fraction and insoluble cell debris and inclusion bodies. The pellet obtained 
Was resuspended in 1 ml lysis buffer. The samples were run in SDS-PAGE. . 
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2.2.4 Purification of N Proteins 
Chromatosraphic methods 
2.2.4.1 Affinity chromatography 
2.2.4.1.1 Ni-NTA affinity chromatography 
The Ni-NTA agarose (Cat no.: 30210) from QIAGEN was used for the purification of 
His6-tagged N proteins. The six histidine residues serve as a metal binding domain 
with affinity towards nickel. All the buffers, including the one containing the sample, 
were prepared devoid of DTT and EDTA and pH 8.0 was used throughout the process 
as this may reduce non-specific binding. The resin was equilibrated with the same 
buffer of the samples to be loaded for at least 5 bed volumes. Then sample loading 
proceeded either by incubating the resin with the sample at 4°C for 1 hour to 
overnight or by pumping the ice-cold sample through the resin gently at a flow rate of 
1 ml/ min at room temperature. The sample-loaded resin was washed with the 
equilibration buffer until no protein was washed out and then non-specifically bound 
proteins were further washed away by washing buffer containing 20mM imidazole. 
於 The His6-tagged N protein was then eluted in the washing buffer with 150mM 
imidazole at a rate of 1 to 2 ml/ min. 
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2.2.4.1.2 Glutathione affinity chromatography 
The Glutathione Sepharose™ 4 Fast Flow (Cat. No.: 17-5132-01) from Amersham 
Biosciences was used for the purification of GST-tagged N proteins. The resin was 
equilibrated with the same buffer as the samples to be loaded for at least 5 bed 
volumes. Then sample loading proceeded either by incubating the resin with the 
sample at 4°C for 1 hour to overnight or by pumping the ice-cold sample through the 
resin gently at a flow rate of 1 ml/ min at room temperature. The sample-loaded resin 
was washed with the equilibration buffer until no protein was washed out. The 
GST-tagged N protein was then eluted in the washing buffer with 10 to 20mM 
reduced L-glutathione (Sigma) at a rate of 1 to 2 ml/ min. 
2.2.4.1.3 Amylose affinity chromatography 
The amylose/ agarose bead affinity matrix (Cat. No.: E8021S) from New England 
fiiolabs was used for the purification of MBP-tagged N proteins. The resin was firstly 
equilibrated with the same buffer of the samples to be loaded for at least 5 bed 
I ‘ ’ 
Volumes. Then sample loading proceeded either by incubating the resin with the 
sample at 4°C for 1 hour to overnight or by pumping the ice-cold sample through the 
resin gently at a flow rate of 1 ml/ min at room temperature. The sample-loaded resin 
術as washed with the equilibration buffer until no protein was washed out. The . 
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MBP-tagged N protein was then eluted in the washing buffer with 20mM maltose at a 
rate of 1 to 2 ml/ min. 
2.2.4.2 Ion exchange chromatography 
2.2.4.2.1 Cation exchange chromatography 
Equilibration buffer: lOmM MES，50mM NaCl, 0.2mM PMSF, 0.2mM 
benzamidine, 0.5mM EDTA and 2mM DTT, pH 6.5 
Washing buffer: Same as equilibration buffer 
Elution buffer: lOmM MES, 1 M NaCl, 0.2mM PMSF, 0.2mM 
benzamidine, 0.5mM EDTA and 2mM DTT, pH 6.5 
Strong functional group sulfopropyl present in the SP Sepharose^'^ Fast Flow (Cat. 
no.: 17-0729-01) from Amersham Biosciences was used for cation exchange 
chromatography.• Self-prep column of 5 to 20 ml resin bed volume depending on the 
sample size was equilibrated with 5 bed volume of buffer. Ice-cold sample was loaded 
at a rate of 1 ml/ min at room temperature. The resin was then washed with washing 
buffer until no protein was further washed out. The protein bound was eluted from the 
. J^ esin at 4°C by setting a linear gradient with elution buffer against the washing buffer 
of at least 10 bed volumes. 
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2.2.4.2.2 Anion exchange chromatography 
Equilibration buffer: lOmM Tris，50mM NaCl, 0.2mM PMSF, 0.2mM 
benzamidine, 0.5mM EDTA and 2mM DTT，pH 7.5 
Washing buffer: Same as equilibration buffer 
Elution buffer: lOmM Tris, 1 M NaCl, 0.2mM PMSF, 0.2mM 
benzamidine, 0.5mM EDTA and 2mM DTT, pH 7.5 
Strong functional group quaternary ammonium present in the Q Sepharose^^ Fast 
Flow (Cat. no.: 17-0510-01) from Amersham Biosciences was used for anion 
exchange chromatography. Self-prep column of 5 to 20 ml resin bed volume 
depending on the sample size was equilibrated with 5 bed volume of buffer. Ice-cold 
sample was loaded at a rate of 1 ml/ min at room temperature. The resin was then 
Washed with washing buffer until no protein was further washed out. The protein 
bound was eluted from the resin at 4°C by setting a linear gradient with elution buffer 
against the washing buffer of at least 10 bed volumes. 
^•2.4.3 Heparin affinity chromatography 
• Pre-prep 5 ml HiTrap Heparin HP column (Cat. no.: 17-0407-01) from Amersham 
Biosciences was used for the affinity chromatography of nucleotide binding protein. 
The adsorption and desorption of proteins towards the heparin resin depend on both • 
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affinity interaction and ionic strength. Thus protein can be eluted under changes in salt 
concentrations. The column was firstly equilibrated with buffer of lOmM Tris, 
250mM NaCl, 0.2mM PMSF, 0.2mM benzamidine, 0.5mM EDTA and 2mM DTT, pH 
7.5 for 5 bed volumes. Sample in the same buffer was loaded onto the resin with flow 
rate of about 1 ml/ min. Unbound proteins were washed away with the buffer. Next, 
bound proteins with different binding affinities were eluted in a stepwise approach. 
Same buffers but with different salt concentrations (500mM, 600mM, 700mM, 
SOOmM, 900mM and IM) were used in serial for elution until no more proteins can be 
washed out. Syringe or Pump P-1 (Amersham Biosciences) was used to load buffers 
and sample. The whole process was carried out at room temperature. 
2.2.4.4 Size exclusion chromatography 
Pre-prep SuperdexTM 200 16/60 GL column (Cat. no.: 17-5175-01) from Amersham 
Biosciences was used for size exclusion chromatography. AKTAprime^^ plus served 
as the pumping system. The column was firstly washed with 1 bed volume distilled 
Water (120ml) and then equilibrated with buffer of lOmM Tris, 500mM NaCl, 0.2mM 
PMSF, 0.2mM benzamidine, 0.5mM EDTA and 2mM DTT, pH 7.5 for 1 bed volume. 
Concentrated sample of 1.5ml was injected and proteins were eluted at 1 to 2 ml/ min 
according to their size by further running 1 bed volume of buffer. The whole process 
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was carried out at 4°C and all the water, buffer and sample had been passed through 
0.22|Lim filters prior to loading. 
Purification stratesies 
2.2.4.5 Purification of His6-tagged N proteins 
N protein expressed bacterial cells were lysed in buffer containing lOmM Tris, 
500mM NaCl, 0.2mM PMSF, 0.2mM benzamidine，pH 7.5 by sonication on ice. 
Soluble fraction was obtained by spinning down the cell debris and inclusion bodies at 
20,000 rpm at 4°C for 45 min. The supernatant was filtered by 0.45^im filters and 
passed through a Ni-NTA column. A final concentration of 0.5mM EDTA and 2mM 
DTT was added to eluted fractions to prevent protein degradation. Fractions 
containing the majority of His6-N protein were collected and concentrated to 1.5 ml 
and then passed through the gel filtration column. 
2.2.4.6 Purification of MBP-tagged N proteins 
Procedures for obtaining soluble cell lysate fraction were same as that in section 
”2.2.4.5 except 0.5mM EDTA and 2mM DTT was added to the lysis buffer. 
Supernatant was filtered by 0.45}xm filters and passed through the amylose column. 
Fractions containing MBP-N protein were collected and concentrated to 1.5 ml and 
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then passed through the gel filtration column. 
2.2.4.7 Purification of GST-tagged N proteins 
Procedures for obtaining soluble cell lysate fraction was same as that in section 
2.2.4.6 except 150mM NaCl was used instead of 500mM in the lysis buffer. The 
supernatant was filtered by 0.45 fim filters and passed through the glutathione column. 
Fractions containing GST-N protein were collected and concentrated to 1.5 ml and 
then passed through the gel filtration column. 
2.2.4.8 Purification of untagged N proteins 
MBP-N protein expressed bacterial cells were lysed in buffer containing lOmM MES, 
300mM NaCl, pH 6.5 by sonication on ice. The soluble fraction was obtained by 
spinning down cell debris and inclusion bodies at 20,000 rpm at 4 � C for 45 min. 
Supernatant was diluted 6 fold by lOmM MES, pH 6.5 to give a final concentration of 
lOmM MES/ 50mM NaCl and was then filtered by 0.22|im filters and pass through a 
SP sepharose column (cation exchange chromatography). The flow-through was 
collected. IM Tris, pH 7.5 stock was added to the flow-through to give a final 
concentration of lOmM Tris. The pH was also adjusted to 7.5 by titrating slowly with 
lOmM Tris, pH 8.5 buffer. The flow-through was then passed through the second ‘ 
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column, the Q sepharose (anion exchange chromatography). The MBP-N protein was 
eluted at about 510mM NaCl. Fractions containing the MBP-N protein were collected 
and diluted by lOmM Tris, pH 7.5 buffer to a salt concentration of 250mM. The 
MBP-N protein sample was then passed through the third column, the heparin column. 
The MBP-N protein was eluted at 700mM NaCl. Fractions containing MBP-N protein 
was collected. 200|al PreScission protease (10 mg/ ml) was added to the solution. 
Proteolytic cleavage was carried out at 4°C for 4.5 hours with gentle shaking. After 
that, the solution was diluted to 250mM NaCl again and injected into the forth and 
fifth column, the GST HiTrap and heparin HiTrap column, together at a flow rate of 
about 0.4 ml/ min. The GST HiTrap column was then detached and the heparin 
column was washed. Untagged N protein was eluted in 600mM NaCl concentration. 
Finally, the fraction containing the untagged N protein was collected and concentrated 
to 1.5 ml and then passed through the gel filtration column. Protease inhibitors, 
0.2mM PMSF and 0.2mM benzamidine, 0.5mM EDTA and 2mM DTT was added in 
all the buffers to prevent protein degradation. Protein samples and buffers, when 
possible, were kept at 4°C or on ice in most of the time. Figure 2.2.4.8.1 illustrated the 
.P^ification scheme of untagged N protein. 
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Total cell lysate 
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I 邑 • 
J L A Superdex 200 
• Size exclusion 
Chromatography 
S Sepharose ^ 
： < 、 1 
dm \ 
Collect f l ^ t h rough Eluted at 600mM NaCI 
Adjusted tne sample to Concentrated saii)ple|to 1.5 ml 
10mM Tris, SOmM NaCI, pH7.5 | 
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i ^ 1 
I Glutathione HiTrap f 
Q Sepharose I + J 
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Eluted at 闷m M NaCI 
Adjusted tne sample to 丨 I 
10mM Tris, 256mM NaCI, pH 7.5 Eluted sit 700mM NaCI 
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— \ U U Incubat0 at 4°C 4.5 hrs 
• A d ] u ^ d the sample to 
10mM Tris, 250mM NaCI, pH 7.5 
Heparin HiTrap ^ J 
J i^gure 2.2.4.8.1 The procedures for purification of untagged N protein expressed 
with MBP-fusion system in E. coli and cleavage of the MBP-tagged protein. 
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2.2.5 Trypsin Digestion Assay for the Design of Stable Fragment 
Trypsin digestion was carried out to determine a region in the N protein that is less 
prone to proteolytic degradation. Peptides resistant to cleavage suggested that they 
can exist in a rather rigid conformation and hence cleavage sites are less accessible to 
protease. Therefore, partial purified His6-N proteins were subjected to digestion with 
increasing concentrations of trypsin by setting up the following reactions: 
- Ke “ • 平 ’ 2 , 1 , 3 I 4 I 5 ~ 
His6-N protein 
5 ul 
(1.2 \ig/ ^1) 
lOX buffer 
- 2 LLL 
(IM Tris, pH 8.5) 
20 mM CaCh ^ 
0.1 M DTT 1 [il 
Trypsin (50 ng/ i^l) 0 \i\ Ijd ^ ^ 7 \i\ 
ddHiO 10 III 9 til 8^1 5 III 3 ^ 1 — 
Total 20 til 
After incubated at room temperature for 20 minutes, the reactions were run in 15% 
SDS-PAGE. Bands present in reaction 2，3，4 and 5 showing relatively limited 
digestion were recognized and excised. Through mass spectrometric analysis, the 
corresponding region in N protein included in the fragment was identified. Together 
with the secondary structure of N protein predicted by the PHD secondary structure 
prediction method (Rost and Sander, 1993) at the Network Protein Analysis 
(http://npsa-pbil.ibcp.fr\ a comparatively stable fragment of N protein which may 
form a single structural unit was designed. ‘ 
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2.2.6 Partial purification of the N protein amino acid residue 214-422 
fragment 
The MBP-tagged N protein fragment containing the residues 214-422 was only 
partially purified by ion exchange chromatography, heparin affinity chromatography 
and size exclusion chromatography. 
Bacterial cells expressing the MBP-N (214-422) fragment were lysed in buffer 
containing lOmM MES, 300mM NaCl, pH 6.5 by sonication on ice. The soluble 
fraction was obtained by spinning down cell debris and inclusion bodies at 20,000 
rpm at 4°C for 45 min. The supernatant was diluted 6 fold by lOmM MES, pH 6.5 to 
give a final concentration of lOmM MES/ 50mM NaCl and was then filtered by 
0.45|Lim filters and pass through a SP sepharose column (cation exchange 
chromatography). The MBP-N (214-422) was eluted at about 330 mM NaCl. 
PreScission protease was added to fractions containing MBP-N (214-422) and then 
dialyzed against 4 L buffer of 10 mM Tris, 250 mM NaCl, pH 7.5 at 4°C overnight. 
The sample was then incubated with glutathione resin at 4°C for 1 hour and then the 
resin was spun down at 4000 rpm at 4°C for 3 min. The supernatant was applied to a 
-heparin column which utilized a gradient elution with an increasing salt concentration 
(250 mM to 2 M) for 10 bed volumes, instead of stepwise serial elution as described 
previously. The N (214-422) fragment was eluted at 864 mM NaCl. Finally, the eluent . 
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was concentrated to 1.5 ml and passed through the gel filtration column at a flow rate 
of 1-2 ml/ min. Protease inhibitors, 0.2mM PMSF and 0.2mM benzamidine, 0.5mM 
EDTA and 2mM DTT was added in all the buffers to prevent protein degradation. 
Protein samples and buffers, when possible, were kept at 4°C or on ice in most of the 
time. 
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2.2.7 Sumoylation of the SARS-CoV N Protein 
The susceptibility of the SARS-CoV N protein to sumoylation was tested by the in 
vitro assay, in which, presence of only the activation enzyme (El) and conjugation 
enzyme (E2) is able to conjugate SUMO to the substrate with an appropriate 
sumoylation site. 
2.2.7.1 In vitro sumoylation assay 
The El was cloned into a pGEX vector, which is a generous gift from Prof. Ron Hay, 
University of St. Andrews, Scotland. E2 conjugation enzyme and SUMO-1 were 
cloned into the pET28m vector. The E l , E2 and SUMO-1 were then purified by Mr. 
Xu Zheng. In the present study, only the conjugation of SUMO-1 was studied and the 
untagged N protein purified according to section 2.2.4.8 was used as the substrate. 
Reaction mixtures were set as follow and incubated at 30°C for three hours. 
� 。 广 . r 1 ~ T T " 
Reaction r i ! i f • � ‘‘ xr 务.厂 V. i ：笼 ；p � � N ^ ^ o f l a n o n reaction ： . Negative control 
J r i s (500 mM)，pH 7.5 2^1 ^ 
j g P (IQOmM) 2 pi " 2\x\ 
J l^Clz (50 mM) . 2f i l ^ 
(450 mM) 2^1 2\ i \ 
^ T ( l O m M ) I j d 1 111 
,Olycerol 1 jil \ j j 1 
跑 0.1 ^g/ ^1) u a LH! 
j ? ( 3 ^ g / }xl) " . ‘ l M 
. S ^ O - 1 (15 \igl 0.15 i^l 0.15 III 
J jp ro te in (0.8 jig/III) . 5 i^l , 
^ t i l l e d water 2.85 i^l 7.85 |al 
J I ^ 20 20^1 ‘ ‘ 
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A duplicate of reaction 1 was set with the addition of loading buffer and incubated on 
ice instead of to inhibit the reaction. The three reaction mixtures were then run 
in 15% SDS-PAGE for band shift analysis. Reaction 1 was scaled up and run in 10% 
SDS-PAGE for a clearer analysis of the shifted bands. Those shifted bands were cut 
from the gel for mass spectrometric analysis. 
2.2.7.2 Sample preparation for mass spectrometric analysis 
Bands of interest were excised from gels. Gel pieces were cut into small pieces and 
destained by incubating in destaining solution (50% methanol, 50 mM ammonium 
carbonate) at room temperature with gentle shaking. Vortex and replacing the 
destaining solution with fresh ones can accelerate the destaining process. 
Then in-gel trypsin digestion was carried out. The gels were firstly dehydrated in 100 
\x\ acetonitrile (ACN) for 5 minutes for three times. Then the gels were dried by 
centrifugation under vacuum for 2 to 5 minutes until the gel appears "dust-like". Next, 
the gels were rehydrated in 10 |J1 trypsin enzyme (40 ng/ |j.l trypsin in 50 mM 
ammonium bicarbonate) and incubated on ice for 30 minutes. Custom amount of 
buffer (50 mM ammonium bicarbonate) was further added to cover the hydrated gel 
piece. The digestion was performed at 30°C overnight. The digested peptides were 
extracted by repeating the following steps for three times: Sonicated the gels in 20 i^l . 
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of 50% CAN/ 2.5% tetrafluoroacetic acid (TFA) for 10 minutes, removing the 
supernatant to new eppendorf tubes (or combine with previous supernatant). The 
supernatant poured together was dried by centrifugation under vacuum and the pellet 
was then resuspended in 10 |LI1 0.1% TFA buffer. 
Finally, the digested peptides were cleaned using ZipTip (Millipore). A ZipTip was 
aspirated by 10 50% ACN twice. Then ZipTip was equilibrated by aspirating 10 |il 
0.1% TFA twice. The peptides were allowed to bind to the ZipTip by slowly aspirating 
and dispensing the sample for 10 times. After that, ZipTip was washed in 10 |al 0.1% 
TFA for five times. Lastly，the peptides were eluted in 2 ml 50% ACN/ 0.1% TFA. 
Eluted peptides were spotted onto MALDI plates. 
A peptide mass fingerprint (PMF) for each spot was generated by the 4700 Proteomics 
Analyzer MALDI MS/MS tandem time of flight mass spectrometer (Applied 
Biosystems) ancfthe profile was matched against the NCBI nr database using the GSP 
ExplorerTM Workstation software with protein and peptide mass tolerance of 0.5 Da. 
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2.3 RSEULTS 
2.3.1 Construction of the Vector pMAL-c2P 
To facilitate the production of non-tagged N protein, protease cleavage site in 
pMAL-c2E was modified to that of PreSdssion Protease that can be purified in our 
laboratory. In order to replace the enterokinase (EK) recognition site with that of 
PreSdssion Protease (PP), the region between Ndel and EcoRI, which contains the 
^ a l E gene followed by the EK site，of pMAL-c2E was cut out and then inserted with 
a DNA fragment comprising the same region except a PP site was made after the 
^ a l E gene. This generated the difference in the linker region (in blue) as shown 
below: 
pMAL-c2E linker region: 
Aval 
5 ’ malE … … T C G A A C A A C A A C A A C A AT A A C A AT A A C A A C A A C C T C G G G •� 
Kpn\ EcoRI BamKl Xbal Sail 
G A T G A C G A T G A C A A G G T A C C G G A A T T C G G A T C C T C T A G A G T C G A C 
Asp Asp Asp Asp Lys t En te rok inase c l e a v a g e site 
PMAL-C2E l inker reg ion: 
Aval 
5 ’ malE … … T C G A A C A A C A A C A A C A AT A A C A AT A A C A A C A A C C T C G G G 
EcoRI BamHl Xbal Sail 
C T G G A A G T T C T G T T C C A G G G G C C C G A A T T C G G A T C C T C T A G A G T C G A C 
Leu Glu Val Leu Phe Gin TOly Pro 
cleavage site 
The DNA fragment was PCR amplified from pMAL-c2E using the primers mentioned 
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in section 2.2.2.1 (Figure 2.3.1.1). The PCR product and the pMAL-c2E vector was 
restriction digested by Ndel and EcoKL (Figure 2.3.1.2) and then ligated together. 
After transformation and DNA mini-preparation, sequences were verified by 












H H - 500 
Figure 2.3.1.1 PCR products (1196 bp) for the construction of pMAL-c2P vectors. 
Lanel - Negative control without template; Lane 2, 3, 4 - PCR products; Lane M -
GeneRuler Ikb DNA ladder. 
I l f l 10000 ^ ^ ^ M 10000 
• / 6 0 0 0 • • • / 6 0 0 0 
Pi , 
figure 2.3.1.2 Restriction digestion of pMAL-c2E vectors and the PCR products. Lane 
1 - pMAL-c2E digested by Ndel and EcoRl; Lane 2 - PCR products digested by Ndel and 
丑coRI; Lane M — GeneRuler Ikb DNA ladder. 
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2.3.2 Construction of Recombinant N protem-pAC28m, N-protein- pGEX-6P-l, 
N protein-pMAL-c2E and N proteiii-pMAL-c2P Plasmids 
The insert of N protein-pAC28m was generated by restriction digestion of the 
previously cloned N protein-pcDNA4/HisMax© by Ndel and EcoRl (Figure 2.3.2.1). 
The Ndel site was not found in the vector pcDNA4 but artificially added before the N 
gene during the construction of the N protein-pcDNA4 plasmids as mentioned in 
section 2.2.2.1. After ligation and transformation, positive clones were checked by 
restriction digestion (Figure 2.3.2.2). 
For the assembly of N protein-pMAL-c2E plasmids, another pair of primers with 
^amlil and Sail cutting sites in the forward and reverse positions respectively was 
designed to suit the MCS of the vector. The N protein gene of the size 1269 bp was 
amplified from N protein-pcDNA4 (Figure 2.3.2.3) using the profile described in 
section 2.2.2.2. The PGR product was restriction digested by BamHl and Sail (Figure 
2-3.2.4). After ligation to the digested plasmid and transformation, positive clones 
Were screened by restriction digestion (Figure 2.3.2.5). 
^ protein-pGEX-6P-1 and N protein-pMAL-c2P were constructed by sub-cloning 
from N protein-pMAL-c2E using the restriction sites BamHl and Sail (Figure 2.3.2.6 
and 2.3.2.8). Positive clones were screened by restriction digestion or PGR 
amplification (Figure 2.3.2.7 and 2.3.2.9). . 
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All of the N protein genes cloned was sequenced and matched against the National 
Centre for Biotechnology Information (NCBI) nr database through the BLAST 









P 二 m = 
2500 
^ ^ ^ ^ ^ ^ ^ ^ ^ 1500 
1000 
^ ^ H v 』 ： 
\ 250 
Figure 2.3.2.1 Restriction digestion of the N protein gene from the recombinant N 
protein-pcDNA4 plasmids and pAC28m vectors. Lane 1, 2 - N protein-pcDNA4 digested 
by Ndel and EcoK\\ Lane 3,4 - pAC28m digested by Nde\ and 五coRI; Lane 5 - Single cut 
control (pAC28m digested by EcoRl only); Lane 6 - Single cut control (pAC28m digested by 
Nde\ only); Lane M - GeneRuler 1 kb DNA ladder. 
f E I ^ 8 1 4 4 
• • • ^ 1 6 1 3 
figure 2.3.2.2 Screening of positive N protein-pAC28m clones by restriction digestion. 
” L a n e 1，2 — Positive clones with N protein gene inserts digested from the recombinant 
plasmids by Ndel and ^coRI; Lane M — Invitrogen Ikb DNA ladder. 
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Figure 2.3.2.3 PGR products of N protein gene (�1269 bp) for the construction of N 
protein-pMAL-c2E recombinant plasmids. Lane 1 to 7 - PGR products; Lane M — 






^ ~ 2500 
N protein gene 2000 
1269 bp 1500 
1000 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 750 
500 
\ 250 
figure 2.3.2.4 Restriction digestion of the Nprotein gene PCR products and pMAL-c2E 
Vectors. Lane 1, 2 - P C R products digested by BamHl and Sail.’ Lane 3 - pMAL-c2E vectors 
” digested by BamUl and Sail; Lane 4 - Single cut control (pMAL-c2E digested by BamUl 
only); Lane M — GeneRuler 1 kb DNA ladder. 
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Figure 2.3.2.5 Screening of positive N protein-pMAL-c2E clones by restriction digestion. 
Lane 1 to 6 - Positive clones with N protein gene inserts digested from the recombinant 
plasmids by Barnm and Sail, Lane M - Invitrogen Ikb DNA ladder. 
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B m 
10000 
pMAL-c2E m _ 10000 / / 二二 
6.7 kb ^ ••• — 5000 ^ 5000 
N protein gene • = | o o 5.4 kb 一 4000 
1269 bp _ • ； 擺 8 H = 
= 750 1500 
• 500 H ^ I O O O 
一 250 - 750 
500 
Figure 2.3.2.6 Restriction digestion of the N protein gene from the recombinant N 
protein-pMAL-c2E plasmids and pGEX-6P-l vectors. Lane 1, 2 -N protein-pMAL-c2E 
plasmids digested by BamWl and Sail•’ Lane 3 - pGEX-6P-l vectors digested by BamUl and 
Sail; Lane M - GeneRuler Ikb DNA ladder. 
m ^ m i • 10000 
• Aqooo 
N protein gene ^ ^ 2 0 0 0 
1269 bp • K \ i 5 0 0 
1 ^ 7 5 0 
H \ 500 
• \ 2 5 0 
• I 
” Figure 2.3.2.7 Screening of positive N protein-pGEX-6P-l clones by PGR 
amplification. Lane 1 to 3 — Positive clones with Nprotein gene inserts amplified by PCR; 
Lane M - GeneRuler Ikb DNA ladder. 
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^D I 
pMAL-c2P pMAL-c2E B H 一 10000 
6 7 k b kb 啤 一 5000 
— 3500 
N protein gene • • = 2000 
1269 bp 1000 • 
Figure 2.3.2.8 Restriction digestion of the N protein gene from the recombinant N 
protein-pMAL-c2E plasmids and pMAL-c2P vectors. Lane 1 to 7 - pMAL-c2P vectors 
digested by BamHl and Sail; Lane 8，9 - N protein-pMAL-c2E digested by BamUl and Sail. 
10000 
• / 6000 
• 欽 4000 
3500 
^ • ― 3000 
^ • ： ^ 2500 
2000 
\ 
Figure 2.3.2.9 Screening of positive N protein-pMAL-c2P clones by PCR amplification 
using the malE and M13 primers and restriction digestion. Lane 1, 2 - Positive clones 
_ with N protein gene inserts amplified from the recombinant plasmids; Lane 3，4 - Positive 
clones with N protein gene inserts restriction digested by BamYil and Sail; Lane M -
GeneRuler Ikb DNA ladder. 
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2.3.3 Optimization of Expression Conditions 
A number of small scale expressions had been performed to test for an optimal 
expression condition that can produce the highest proportion and amount of soluble 
proteins. Different E. coli strains were used for different tags of N protein. Strains like 
B834, B834+, BL21 pLysS and C41 (DE3) had been tried out. After transformation 
and further culturing at 37®C until the OD at 600mn reached 0.5，protein expression 
was induced by addition of 0.1 mM IPTG. The expression may perform at 25°C or 
2>TC and at each time point (3 hrs, 6 hrs and overnight); part of the culture was taken 
out to analyze the solubility of the fusion N proteins, as the duration and rate of 
protein production can affect the proper folding of the protein, which may be 
correlated with its solubility. The optimized expression conditions are listed in table 
2.3.3.1 and the solubility of the Hise-, MBP- and GST-tagged N proteins are about 
45%, 40% and 35% respectively (Figure 3.4.1, 3.4.2 and 3.4.3). 
Optimized Bacterial Solubility (% of 
Temperature Duration 
condition cell strain total expression) 
_His6-N protein B834 20°C 6 hours 45%-
J ^ P - N protein BL21 37�C 3 hours ^ 
^ 3 hours to 
GST-N protein BL21 37�C . , 35% 
overnight 
Table 2,3.3.1 Listed of optimized conditions for the expression of His6-，MBP-
and GST-tagged N proteins and their corresponding solubility. 
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J S P M kDa 
_ 98 
I mm 
’ “ 64 
His-N protein 遍 
-50 kDa ^ I t e ^ 50 
.AMA 4MMP ^^ 
m 3 6 
鞴 … I … 2 2 
lii I  ^ 
Figure 2.3.3.1 Solubility test on Hise-tagged N protein expressed in B834 E. coli cells at 
20"C for 6 hours. Lane T - Total bacterial cell lysate after IPTG induction; Lane S -
Supernatant, i.e. soluble, fraction of the bacterial cell lysate after induction; Lane P - Pellet, 
i.e. insoluble, fraction of the bacterial cell lysate after induction; Lane M — Invitrogen 
SeeBlue® Plus2 Pre-Stained Standard. 
N T S P M kDa 
— . 2 5 0 
148 
MBP-N protein 98 
-88 kDa 64 
Wmm 5 0 
'fl^HH ilMPl 
^^^W QC 
~ —• ob 
m m wBM\ - • _ 
Figure 2.3.3.2 Solubility test on MBP-tagged N protein expressed in BL21 E. coli cells 
at 37®C for 3 hours. Lane N - Total bacterial cell lysate before induction; Lane T — Total 
bacterial cell lysate after IPTG induction; Lane S - Supernatant, i.e. soluble, fraction of the 
bacterial cell lysate after induction; Lane P - Pellet, i.e. insoluble, fraction of the bacterial cell 
lysate after induction; Lane M - Invitrogen SeeBlue® Plus2 Pre-Stained Standard. 
Remarks: The molecular size of the MBP-N protein was not equal to the sum of the MBP tag 
and N protein because the molecular sizes state here were only estimations from both the 
niigration of the proteins with reference to the standards and the online molecular weight 
prediction. These estimations may contain errors. 
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—250 
_ 148 
r _ 98 
GST-N ^ m m ^ r n m , 64 〜71 kDa 、. 禱 
• 50 
ft ^mmrn 0 
» Ik 
• 36 
Figure 2.3.3.3 Solubility test on GST-tagged N protein expressed in BL21 E. coli cells at 
37"C for 3 hours Lane S - Supernatant, i.e. soluble, fraction of the bacterial cell lysate after 
IPTG induction; Lane P - Pellet, i.e. insoluble, fraction of the bacterial cell lysate after IPTG 
induction; Lane M - Invitrogen SeeBlue® Plus2 Pre-Stained Standard. 
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2.3.4 Screening of Purification Strategies 
In order to produce highly purified N proteins, a number of purification strategies had 
been attempted by different combinations of chromatographic separation methods and 
different buffering systems for the purification of the three tagged and untagged N 
proteins. Figure 2.2.4.8.1 shows the approaches of purifying the untagged N protein, 
which attained the highest purity among all the try-outs. 
2.3.4.1 Purification of His6-N protein 
Bacterial cells expressing His6-N protein was lysed. Soluble fraction was passed 
through nickel affinity chromatography. Most of the His6-N protein could bind to the 
resin, but a small amount of Hise-N protein was washed out in 20 mM imidazole. The 
majority of His6-N protein was eluted in 150 mM imidazole. The purity was low as 
shown in figure 2.3.4.1 and thus required further purification. 
The purity showed an improvement after passing through gel filtration column. The 
His6-N protein was always eluted together with some other protein species and the 
purity was still low. The His6-N protein was eluted in a spectrum from 32.5 to 47.5 ml, 
which is very close to the void volume (33 ml) of the gel filtration column. It is 
obvious that the protein is sticky and was binding to some other proteins to form 
complexes of different size and of different components which were co-eluted with 
the His6-N protein (Figure 2.3.4.2). , 
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W1 W2W3 E1 E2 E3 E4 M 
飞 > :— 2 5 0 
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His-N protein J 64 
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暴 
• * , 2 2 
Figure 2.3.4.1 Washing and elution fractions from nickel affinity chromatography of 
His6-N proteins. Lane W1 - Washing (buffer without imidazole); Lane W2 and W3 -
Washing (buffer with 20mM imidazole); Lane El to E4 - Elution of His6-N protein in 150 
mM imidazole; Lane M - Invitrogen SeeBlue® Plus2 Pre-Stained Standard. 
^ 1 2 3 4 5 6 7 8 9 10 M kDa 
A . — 250 
148 
- 9 8 
His-N protein • 64 
-50 kDa ‘ 5 0 
W S*. H ^ p 
* 36 
q ^ A 
"HO 
>jO 
- I ' . > I I > . I I . . . . . . > . / . . . . . ， ， 
11 I I I I I I _ L^ i—J I I I I I I I I I I I r I 
_ 、 •。 ^ T - p T T l I 4 I 3 I j p I 8 [ V I IB 12 I 13 I 14 I 15 I 16 I 17 I 18 I 19 I 20 J 21 I 22 I 23 I 24 I 15 I 26 I 27 [ 28 
Figure 2.3.4.2 [A� Eluted fractions of gel filtration chromatography of Hise-N proteins. 
Lane 1 to 10 - Corresponding to fraction number 17 to 26 of elution profile in [B]; Lane M -
Invitrogen SeeBlue® Plus2 Pre-Stained Standard. [B] His6-N proteins gel filtration elution 
profile showing changes in OD^o (blue) and the collected fractions (red). 
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2.3.4.2 Purification of MBP-N protein 
Bacterial cells expressing MBP-N protein was lysed. Soluble fraction was passed 
through amylose affinity chromatography. Some of the MBP-N protein can bind to the 
resin, but still a significant amount of MBP-N protein was present in the flow-through 
and also in the washing. This should not be due to a saturation of binding capacity as 
the amount of protein bound was considerably less than that claimed by the 
manufacturer. For those protein that are able to bind onto the amylose resin, they were 
eluted in 20 mM maltose with a much higher purity than that from a nickel column 
(Figure 2.3.4.3) though further purification is still needed. 
Purity of MBP-N protein did not show a great improvement after passing through gel 
filtration column. The purity was about 85% (Figure 2.3.4.4). The majority of the 
protein was eluted just after the void volume (37ml). 
FtW1&2R 1 2 3 4 5 6 7 M kDa 
H 250 
, I 148 
f i -
MBP-N protein l A - 黨 
m : 如 。 
Figure 2.3.4.3 Fractions from amylose affinity chromatography of MBP-N proteins. 
Lane Ft — Flow-through; Lane W1&2 - Fractions from washing; Lane R - Resin after 
Washing; Lane 1 to 7 — Elution of MBP-N protein in the presence of 20 mM maltose; Lane 
M - Invitrogen SeeBlue® Plus2 Pre-Stained Standard. 
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Figure 2.3.4.4 (A] Comparison of the purities of MBP-N proteins before and after 
passing through gel filtration column. Lane 1 - Sample applied to gel filtration column 
after amylose affinity chromatography; Lane 2 - MBP-N protein eluted from gel filtration, i.e. 
fractions 1 and 2 of elution profile in [B] poured together; Lane M - Invitrogen SeeBlue® 
Plus2 Pre-Stained Standard. [B] MBP-N proteins gel filtration elution profile showing 
changes in OD^o (blue) and the collected fractions (red). 
2.3.4.3 Purification of GST-N protein 
Bacterial cells expressing GST-N protein were lysed. The soluble fraction was passed 
through glutathione affinity chromatography. About 70% of the GST-N protein can 
bind to the resin. This showed a higher binding affinity than that of MBP-N protein. 
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The purity was about 80% after the affinity chromatography as shown in lane 1 of 
figure 2.3.4.5 [A]. The purity of GST-N protein did not show any great improvement 
and was about 85% pure after passing through gel filtration column. (Figure 2.3.4.5, 
lane 2) The GST-N protein was eluted at the void volume (40 ml). 
1 2 M kDa 
A 250 
^ 148 
GST-N protein ^ ^ 98 
-71 kDa 64 
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Figure 2.3.4.5 [A] 
Comparison of the purities of GST-N proteins before and after 
passing through gel filtration column. Lane 1 — Sample applied to gel filtration column 
after glutathione affinity chromatography; Lane 2 一 GST-N protein eluted from gel filtration, 
i.e. fractions 14 to 16 of elution profile in [B] poured together; Lane M - Invitrogen SeeBlue® 
Plus2 Pre-Stained Standard. [B] GST-N proteins gel filtration elution profile showing 
changes in OD280 (blue) and the collected fractions (red). 
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2.3.4.4 Purification of untagged N protein 
Bacterial cells expressing MBP-N protein were lysed and the soluble fraction 
containing the target protein was firstly passed through SP sepharose. All of the 
MBP-N protein did not bind onto the resin and was present in the flow-through 
(figure 2.3.4.6, lane 2). The Flow-through was then loaded onto a Q sepharose column. 
Still, the majority of the MBP-N protein was passed out the column directly in 
flow-through. For those protein bound to the resin, they were eluted at 81 ml of a 165 
ml gradient of increasing salt concentration, corresponding to 510 mM NaCl. The 
purity of MBP-N protein was 65 to 70 % (Figure 2.3.4.6). 
The buffer condition of the eluted fractions were adjusted and loaded into heparin 
HiTrap column. All the MBP-N protein can bind onto the column and was eluted at 
700 mM NaCl concentration and the purity was improved to 80% (Figure 2.3.4.7). 
The fractions containing MBP-N protein were incubated with GST-tagged PreScission 
protease. MBP-N protein was cleaved into MBP and N protein. The PreScission 
protease was removed by passing through a glutathione HiTrap column and the MBP 
Was separated from N protein through the heparin HiTrap column. The N protein was 
eluted in 600 mM NaCl buffer. This yielded a purity of 85-90% (figure 2.3.4.8). 
Finally, fractions after heparin column containing the N protein was concentrated and 
injected into Superdex 200 gel filtration column. The N protein was eluted with a . 
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purity of about 95% (figure 2.3.4.9). 
The molecular size of the N protein eluted was determined by passing through the gel 
filtration colume together with the protein standard (figure 2.3.4.9). From the equation 
obtained from the calibration curve, the molecular weight (MW) of the N protein 
should be 67 kDa. According to the predicted MW of N protein monomer, 46 kDa, the 
N proteins purified were not aggregated and most likely existed as monomers. 
From the purification strategy, it should be noted that the "untagged" N proteins refer 
to the N proteins originally expressed in MBP fusion and the MBP tags were cleaved 
afterwards leaving the N proteins without tags. This is different from the N proteins 
expressed in a non-fusion form, which closely resembled the His6-tagged N proteins 
and had not been expressed and purified in the present study. 
1 2 3 4 h W H M kDa 5 6 7 8 9 M kDa 
^ ， 250 250 
• 漂 = 148 
J l f W MBP-N protein 64 64 
ffi I ； -88 kDa 
i W ^ i - 50 50 
靈 ， d l _ 36 
Figure 2.3.4.6 Fractions from SP and Q sepharose ion exchange chromatography (SS 
^ and QS) of MBP-N proteins. Lane 1 - Sample applied to SS column; Lane 2 — Flow-through 
of SS column; Lane 3 - Sample applied to QS column; Lane 4 - Flow-through of QS column; 
Lane W — Washings of QS; Lane 5 to 9 - Elution of MBP-N protein in the presence of about 
510 mM NaCI; Lane M - Invitrogen SeeBlue® Plus2 Pre-Stained Standard. 
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Figure 2.3.4.7 Fractions of heparin affinity chromatography of MBP-N proteins. Lane 
1 一 Flow-through from heparin column; Lane 2 - Sample applied to heparin column; Lane 3 -
Washing of heparin in 250 mM NaCl buffer; Lane 4 and 5 - Fractions eluted from 500 mM 
NaCl buffer; Lane 6 and 7 -Fractions eluted from 700 mM NaCl buffer; Lane 8 - Fractions 
eluted from 800 mM NaCl buffer; Lane 9 - Fractions eluted from 900 mM NaCl buffer; Lane 
M - Invitrogen SeeBlue® Plus2 Pre-Stained Standard. 
S FtW 1 2 3 4 5 6 7 8 9 10 11 M kDa 
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1 w „, 
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Figure 2.3.4.8 Fractions of heparin affinity chromatography of tag-cleaved N proteins. 
Lane S - Sample applied to the two columns; Lane Ft -Flow-through from heparin column; 
Lane W - Washing of hepkin in 250 mM NaCl buffer; Lane 1 to 3 - Fractions eluted from 
500 mM NaCl buffer; Lane 4 to 9 - Fractions eluted from 600 mM NaCl buffer; Lane 10 and 
11 - Fractions eluted from 700 mM NaCl buffer; Lane M - Invitrogen SeeBlue® Plus2 
Pre-Stained Standard. 
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Figure 2.3.4.9 [AJ Eluted fractions of gel filtration chromatography of tag-cleaved N 
proteins. Lane S - Sample applied to gel filtration; Lane 1 to 8 - Fractions eluted from S200 
gel filtration; Lane M — Invitrogen SeeBlue® Plus2 Pre-Stained Standard.�B] Gel filtration 
elution profile of N protein with the two protein standards (Ferritin and ribonuclease A) 
showing changes in OD280 (blue). Tag-cleaved N protein (<0.1mg/ml), ferritin and 
ribonuclease A were injected together into S200 column and run in lOmM Tris, 500mM NaCl, 
pH 7.5 buffer at 2 ml/ min. Their corresponding molecular size (kDa) and elution volume (ml) 
Were indicated. [C] A plot of the elution volume against log of molecular weight of protein 
standards in [B]. 
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2.3.5 Limited Trypsinolysis for the Determination of Discrete Structural Unit 
As mentioned in section 1.4, the N protein possesses a majority of coils and loops in 
its secondary structure according to the PHD secondary structure prediction (Figure 
2.3.5.3) and the solved N-terminal structure (Huang et al, 4004). These coils and 
loops may be exposed and are more susceptible to proteolysis. And to facilitate 
structural determination processes like crystallization, limited proteolysis was used to 
identify distinct regions in the N protein that may fold into a more compact, discrete 
element of structure (Figure 2.3.5.1) for the cleavage sites inside these compact 
structure are expected to be less accessible to proteases. 
After trypsin digestion, a fragment of apparent molecular weight 26 kDa accumulated 
in reactions containing 100 ng and 250 ng trypsin enzyme as stable digest products. 
Mass spectroscopy analysis showed that the 26 kDa fragments consist of residue 
179-422 of N protein (Figure 2.3.5.2). This fragment was selected for two reasons: 1) 
it can be maintained even in the presence of 350 ng trypsin; 2) it was well separated 
from other bands such that the MS analysis could be performed with less error. 
A stretch of loops were predicted at residues 179 to 214 (Figure 2.3.5.3). To prevent 
” the N-terminal of the fragment to be loops, which may hinder the effective folding of 
the protein during peptide synthesis, the 214 to 422 residues were designed for further 
purification and analysis. ‘ 
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Figure 2.3.5.1 His6-N protein subjected to increasing extent of trypsin digestion. Lane 1 
to 5 - 8 |Lig His6-N protein subjected to digestion by Ong, 50ng, lOOng, 250ng and 350ng 
trypsin respectively, corresponding to reaction 1 to 5 described in section 2.2.5.; Lane M — 
Invitrogen SeeBlue® Plus2 Pre-Stained Standard. The digests was carried out at room 
temperature for 20 min. The limiting digest products were as indicated. 
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Figure 2.3.5.2 [A] Peptide mass fingerprint (PMF) of the limiting digest product 
showing peptide counts against the mass to charge ratio of the peptides. The amino acid 
residues of the matched N protein peptides were indicated. [B] A detailed list of the peptides 
matched. 
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8 . . . , 1 9 . " , 2 0 . " , 21. 22. , 23 2 
AA ISQA33RS3SRSRGN3RNSTPG3SRGN3PARHASGGGETALALLLLDRLNQLESKVSGKGQI 
PHD I HHHHHHHHHHHHHHHH | 
R e l I 9988999899999999998888999998899999327899999999994651698998861 
d e t a i l : 
prH-I 000000000000000000000000000010000035789999999998677400000012 
prE-IOOOOOOOODOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO10000000 
prL-I 98888888899989998888889999988899986411000000000032 2578899887 
s u b s e t： SUB | L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L . , H H H H H H H H H H H H . H H . L L L L L L L L | 
4 " . 2 5 . " , 2 6 . . . 21 2 8 . " , 29 … ， 3 
AA IQQQGQTVTKKSAAEASKKPRQKRTATKQYNVTQAFGRRGPEQTQGNFGDQDLIRQGTDYKI 
PHD IHHHHHHHHHHHHHHHH E E E E HHHHH I 
R e l I 12 44789999999997 6988899999994156423 47999888 6779977899 61999991 




s u b s e t : SUB | HHHHHHHHHHHHLLLLLLLLLLLL " E E L L L L L L L L L L L L L H H H H H . L L L L L | 
0. . . 31. . . 32.,_, 33 . . . , 34. . . , 3S. . . , 3 
AA I HWPQIAQFAPSASAFFGHSRIGHEVTPSGTTiTLTYHGAIKLDDKDPQFKDNVILLNKHIDAI 
PHD 1 E E E E E E E E E E E E E E E E E E E E E E E E E HHHEEEHHHHHHHH| 
R e l I 95317773 67772378712146750799739898554674799993111112114224451 
d e t a i l : 
prH-I Oil110000010000000000000000000Q00000000000000344344444655666 
prE-|0124777521113S7874346777410016889876678610000001345544210000 
p r L - l 8 65311137877531115543乏12488973010122321389998543210011133232 
su tose t： SUB 丨 L L • _ E E E • L L L L • • E E E E E E • L L L L • E E E E E E . E E • L L L L L H| 
6. . . 37 38 39 40 41 4 
AA IYKTFPPTEPKKDKKKKTDEAQPLPQRQKKQPTVTLLPAADHDDFSRQLQNSHSGASADSTI 
PHD I EEEE HHHHHHHHH i 
R e l I 178999899689898679999996679999926744357812788999973577432457| 
de ta i l : 
prH-1410000000210000110000Q02210000000000011145888888983211333221 
prE-IOOOOOOOOOOOOOOOQ00000000000000057863311000000000000000000000 
p rL - I 47899988978988877889999778999993112 6 667854111000015787 655 668 
s u t o s e t : SUB | . L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L . E E , • . L L L . .HHHHHHHH.LLL L L | 
2 4 3 . . . . . . . . 4 4 . . . . . . . . 4 5 . . . . . . . . 4 6 . . . . . . . . 4 7 . 4 
AA IQAI 
PHD丨 丨 
R e l I 99 




sutoset: SUB 1LL] 
Figure 2.3.5.3 Secondary structure prediction of the SARS-CoV N protein generated 
from the PHD secondary structure prediction method. In each block, the first line 
indicates the number of amino acid residue. The residue at 19 means it is the 190^ ^ amino acid 
residue and the next will be the 191®^  The second line is the amino acids in the N protein. The 
line PHD shows the regions that probably fold into a-helix (H) or P-coils (E). The line Rel 
” expresses the reliability of the prediction. The lines prH, prE and prL express the probability 
.. of the region to be a-helix, p-coils and loops respectively. The line SUB combines the 
predictions and shows the predicted secondary conformation (H: a-helix; E: p-coils; L: loop). 
The arrow indicates the starting site of the designed stable fragment. 
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2.3.6 Partial Purification of the N (214-422) Fragment 
Bacterial cells expressing MBP-N (214-422) fragment were lysed and the soluble 
fraction containing the target protein was firstly passed through a SP sepharose 
column. A large proportion of the protein was present in the flow-through, but still a 
significant amount can bind to the resin and was eluted at about 37 ml of a 150 ml 
gradient, equivalent to 284 mM salt concentration. The purity was 65 to 70 % (Figure 
2.3.6.1). 
To adjust the buffering condition for the next column, the sample containing the 
MBP-N (214-422) was dialyzed against the equilibration buffer of the heparin affinity 
chromatography. In order to get rid of the MBP tag, PreScission protease was also 
added during dialysis. After that the protein sample was incubated with glutathione 
resin to bind to the GST-tagged PreScission protease. The sample was then applied to 
heparin column to remove the MBP. All of the untagged N protein fragments can be 
adsorbed to the resin and eluted at about 864 mM NaCl with a purity of 80 to 85% 
(Figure 2.3.6.2). 
Finally, fractions after heparin column containing the N protein 214-422 fragment 
” were concentrated and injected into Superdex 200 gel filtration column. The N protein 
was eluted at 88.7 ml with a purity of 85 to 90% (figure 2.3.6.3). The raised basal 
level after 95 ml elution may due to a switch in a different batch of buffer in the run in , 
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this particular experiment. 
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Figure 2.3.6.1 Fractions of SP sepharose ion exchange chromatography (SS) of MBP-N 
(214-422). Lane S - Sample applied to SS column; Lane Ft - Flow-through of SS column; 
Lane W - Washings of SS; Lane 3 to 8 - Elution of MBP-N (214-422) in the presence of 284 
mM NaCI; Lane M - Invitrogen SeeBlue® Plus2 Pre-Stained Standard. 
Remarks: The molecular size of the MBP-N (214-422) was not equal to the sum of the MBP 
tag and N (214-422) because the molecular sizes state here were only estimations from both 
the migration of the proteins with reference to the standards and the online molecular weight 
prediction. These estimations may contain errors. 
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Figure 2.3.6.2 Fractions of heparin affinity chromatography of tag-cleaved N (214-422) 
fragments. Lane S - Sample applied to heparin column; Lane Ft -Flow-through from heparin 
column; Lane W - Washing of heparin in 250 mM NaCI buffer; Lane 3 to 8 - Elution of N 
(214-422) in the presence of 864 mM NaCI; Lane M - Invitrogen SeeBlue® Plus2 Pre-Stained 
Standard. 
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Figure 2.3.6.3, [A] Eluted fractions of gel filtration chromatography of N (214-422) 
fragments. Lane S - Sample applied to gel filtration; Lane 1 to 8 — Corresponding to fraction 
number 17 to 24 of elution profile in [B]; Lane M - Invitrogen SeeBlue® Plus2 Pre-Stained 
Standard. [B�Gel filtration elution profile of N (214-422) fragments showing changes in 
OD280 (blue) and the collected fractions (red). 
. ‘ 
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2.3.7 Sumoylation of the SARS-CoV N Protein 
2.3.7.1 Sumoylation site prediction 
Putative sumoylation sites of N protein were predicted by the program SUMOplot™ 
of ABGENT fhttp://www.abgent.coiTi/doc/sumoplot). The principle of the program is 
to predict the probability for the SUMO consensus sequence (平KXE) to be engaged 
in SUMO attachment based on two criteria: 1) direct amino acid match to the SUMO 
consensus sequence observed and shown to bind Ubc9，and 2) substitution of the 
consensus amino acid residues with amino acid residues exhibiting similar 
hydrophobicity, which denote the binding specificity of the target protein to the 
substrate motif of Ubc9. 
There are two putative sites for sumoylation in N protein as predicted by the 
SUMOplotTM program (Figure 2.3.7.1). They are located at the K62 and K339 
residues of the” N protein. The K62 sumoylation site had been proven by Li et al. 
(2005) using the in vivo overexpression strategy. According to their report, the fact 
that the overexpression of K62A nucleocapsid mutant ceased the extra band of 
sumoylated N protein apparently excluded the probability of K339 being sumoylated. 
Yet from the prediction of sumoylation sites, K62 has a lower score when compared 
with K339, although the value is still significantly high. Therefore, it would be 
interesting to investigate the situation in vitro and compare with the in vivo results. , 
97 • 
Chapter II Results 
SUMOplot™ Prediction 
Developed by Abgent, copyright 2003-2004 
Protein ID: N/A 
Defiiition: N/A 
Leiiuth: 422 aa 
1 HSDNGPQSHQ RSAPRITFGG PTDSTDMQN GGRNGARPKQ RRPQGLPNMT 
SI ASTJFTALTQH GKEELRFPRG QGVPIimiSG PDDQIGYYPR ATRRVRGGDG • Motifs with hiah Drobabilitv 
101 KHKELSPRWY FYYLGTGPEA SLPYGANKEG IVTJVATEGAL NTPKDHIGTR ^ ^ ^ 
151 HPHWWMTVL QLPQGTTLPK GFYAEGSRGG SQASSRSSSR SRGNSRNSTP • ^^ nhohiiiK. 
201 G3SRGHSPAR HASGGGETAL ALLLLDRLNQ LE3KV3GKGQ QQQGQTVTO? • MotlfS With lOW probability 
251 SAAEASKKPR QKRTATKQYN VTQAFGRRGP EQTQGNFGDQ DLIRQGTDYK 
301 HWPQIAQFAP SASAFFGHSR IGHEVTPSGT WLTYHGAIKL DDKDPQFKDN 
351 VILLNKHIDA YKTFPPTEPK KDKKKKTDEA QPLPQRQKKQ PTVTLLPAAD • Overlapping MotifS 




Ho. Pos. Group Score Ho. Pos. Grovp Score 
1 K339 TYHGA IIOJ) DKDPQ 0.94 5 K343 AIKLD Dia)P QFKDN 0.39 
2 K62 ALTQH GI^ LRFPR 0.67 6 K389 LPQRQ KWIP TVTLL 0.37 
K370 FPPTE PM® KKKKT 0.61 7 Ki70 QGTTL P ^ YAEGS 0.26 
‘ I •� 
4 K376 KKDKK KpO EAQPL 0.48 
1 
Figure 2.3.7.1 Result of the SUMOplot^^ prediction of putative sumoylation sites. Two 
sumoylation sites of the SARS-CoV N protein were predicted. They are located at K339 and 
K62 residues and have a score of 0.94 and 0.67 respectively. The higher the score indicates 
} 
“,. the higher the probability of the residue being subjected to sumoylation. The maximum score 
I \ is 1.00. ‘ 
f ‘ 
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2.3.7.2 In vitro Sumoylation Assay 
The in vitro sumoylation assay of the SARS-CoV N protein was set according to 
section 2.2.7.1 and the untagged full length N proteins (MBP-tagged N proteins with 
tag cleaved) were employed in the assay. Two controls were run in parallel to the 
reaction. One is the control with all the reaction constitutes but the sumoylation 
reaction was stopped as soon as they were mixed by the addition of loading buffer and 
incubation on ice. This reaction mixture without sumoylation being carried out helped 
to identify bands that are impurities of the proteins purified but not sumoylated 
proteins. Another one is the negative control with all the reaction constitutes except 
the purified N proteins. This control can figure out sumoylated El if present. After 
comparing with these two controls, there are two bands that at present only in N 
protein sumoylation reactions and they have molecular weights either around 15 or 30 
kDa larger than the N protein (Figure 2.3.7.2.1). Thus, they can be the sumoylated N 
proteins with one or two SUMO tagged to the N protein substrate. 
To better analyze the extra bands, the sumoylation reaction was scaled up and four 
prominent extra bands with molecular weights around 15 or 30 kDa larger than the N 
..protein can been observed (Figure 2.3.7.2.2). They were designed band A to D in 
descending molecular masses. Judging solely from the bands sizes, the following 
conclusion can be made. Band A and B are of the same sumoylation status that two , 
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SUMO-1 proteins were attached to a single N protein molecule, while band C and D 
are grouped for only one SUMO-1 protein was conjugated to a single N protein 
molecule. The N protein substrates were slightly degraded as seen from the 
overlapping bands of N protein in figure 2.3.7.2.1. This account for the two pairs of 
bands, in which bands B and D are in a slightly lower molecular size in comparison to 
bands A and C respectively. Therefore，bands B and D are degraded N proteins that 
were subjected to sumoylation. However, this is only a rational explanation to the 
pattern of extra bands, further proof is required for conformation and the four bands 
were proven to be sumoylated N proteins by mass spectrometric analysis in the next 
section. 
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Figure 2.3.7.2.1 In vitro sumoylation assay of the SARS-CoV N protein showing the 
presence of extra bands above the untagged full length N proteins with higher molecular 
weights. Lane 1 — Reaction 1 of the in vitro sumoylation assay incubated on ice with loading 
buffer to stop the sumoylation reaction; Lane 2 — Reaction 1 of the in vitro sumoylation assay; 
Lane 3 - Reaction 2 of the in vitro sumoylation assay; Lane Ml - Amersham full-range 
rainbowTM molecular weight marker; Lane M2 - Amersham high-range rainbowTM molecular 
weight marker:�The reactions were carried out at 30°C for 3 hours. The position of untagged 
full length N protein, El, E2 and SUMO-1 and the two extra bands (black arrows) present 
after sumoylation were indicated. 
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Figure 2.3.7.2.2 Scaled up reaction 1 of the in vitro sumoylation assay analyzed in 
10% SDS-PAGE showing prominent, well-resolved bands of the N protein with 
increased molecular weights. Lane 1 to 3 — Reaction 1 of the in vitro sumoylation assay, 40 
|Lil reaction mixture (10 |Lig N protein) per lane; Lane M - Amersham Biosciences high-range 
rainbowTM molecular weight marker. The original position of untagged N protein (hollow 
arrow,�50 kDa) and the four extra bands of shifted N protein (black arrows) were indicated. 
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2.3.7.3 Mass spectrometric identification of sumoylated SARS-CoV N protein 
The protein bands A, B, C and D were excised, destained and digested by trypsin. The 
digested peptides were extracted from the gel slices and cleaned using ZipTip as 
described in section 2.2.7.2. After subjected to MALDI-TOF MS/MS the peptides 
masses of each sample were recorded to generate the PMF spectrum, which was then 
matched against the NCBI nr database using the GPS Explorer software. 
The accuracy of a protein matched can be observed from two values that accompanied 
the search. They are the Protein Score and the Protein Score C.I. % (confidence 
interval). Indicated in the report of Mascot Search Results is the Probability Based 
Mowse Score of each sample. Proteins matched with a score higher than the Mowse 
score are considered significant. The Protein Score C.I. % calculated how closely the 
required data matches previous database searches under differing conditions. The 
closer the confidence interval percentage value is to 100%, the more likely the protein 
is correctly identified. 
For the bands A, B, C and D, their protein score of the SARS-CoV nucleocapsid 
protein matched are 208, 229, 291 and 394 respectively, which are remarkably higher 
than the Mowse core of 76 (Figure 2.3.7.3.1 to figure 2.3.7.3.4). Together with 100% 
C.I. percentage, all of the four bands can match the SARS-CoV nucleocapsid protein 
with a high accuracy. Yet, the protein score and C.I. % of the SUMO-1 protein (Homo . 
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sapiens) matched are only 68/ 99%，62/ 94%，59/ 84% and 51/ 28% for bands A, B, C 
and D respectively (Figure 2.3.7.3.1 to figure 2.3.7.3.4). The comparatively low 
accuracies are due to the dominant peptides masses from the N proteins. Nevertheless, 
the presence of the peptide fragments of both the SARS-CoV N proteins and SUMO-1 
protein {Homo sapiens) indicates that the extra protein bands with molecular masses 
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A ffil^i} Mascot Search Results 
Usei Eaiil Seaich title : Sa-pleSet!D: 1704, AnaljsisID: 4254, HaUiffelllD: 77424, SpectinalD: 413452, Path-Mei Database : ICBInr 20Q41Q16 (2082196 sequences； 699ftl03ft5 lesilmes) 
T i a e s t a a p : 7 J«1 2005 t l 12 :37 :35 OFT 
Top Scoie : 20ft for nmcleocapsid pioteia [SARS coioniTiivs HB) 
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Score is -10»Lo2(P), w J r f f T P k t h e probability that the observed match is a random event. 
Protein scores greater significant (pcO.OS). 
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\ Figure 2.3.7.3.1 The search result of band A in different layouts displaying the matched 
SARS-CoV N protein and SUMO-1 protein (Homo sapiens) with their protein scores and C.I. %. 
� [A] Mascot Search Result indicating the Mowse score of the sample (76) and a graph showing 
distribution of the protein score of the 20 top hits of proteins matched. [B] Result from the GPS 
� Explorer software showing the SARS-CoV N protein matched with its protein score (208) and C.I. % 
(100%). [C] Result from the GPS Explorer software showing the SUMO-1 protein {Homo sapiens) 
matched with its protein score (68) and C.I. % (99%). The Mowse score (green circle), protein score 
(red circle) and C.I. % (purple circle) were as indicated. 
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\ Figure 2.3.7.3.2 The search result of band B in different layouts displaying the matched 
SARS-CoV N protein and SUMO-1 protein {Homo sapiens) with their protein scores and C.I. %. 
” [A] Mascot Search Result indicating the Mowse score of the sample (76) and a graph showing 
distribution of the protein score of the 20 top hits of proteins matched. [B] Result from the GPS 
Explorer software showing the SARS-CoV N protein matched with its protein score (229) and C.I. % 
(100%). [C] Result from the GPS Explorer software showing the SUMO-1 protein {Homo sapiens) 
matched with its protein score (62) and C.I. % (94%). The Mowse score (green circle), protein score 
(red circle) and C.I. % (purple circle) were as indicated. 
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Figure 2.3.7.3.3 The search result of band C in different layouts displaying the matched 
SARS-CoV N protein and SUMO-1 protein {Homo sapiens) with their protein scores and C.I. %. 
[A] Mascot Search Result indicating the Mowse score of the sample (76) and a graph showing 
distribution of the protein score of the 20 top hits of proteins matched. [B] Result from the GPS 
Explorer software showing the SARS-CoV N protein matched with its protein score (291) and C.I. % 
(100%). [C] Result from the GPS Explorer software showing the SUMO-1 protein {Homo sapiens) 
matched with its protein score (59) and C.I. % (84%). The Mowse score (green circle), protein score 
(red circle) and C.I, % (purple circle) were as indicated. 
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Figure 2.3.7.3.4 The search result of band D in different layouts displaying the matched 
SARS-CoV N protein and SUMO-1 protein {Homo sapiens) with their protein scores and C.L %. 
” [A] Mascot Search Result indicating the Mowse score of the sample (76) and a graph showing 
distribution of the protein score of the 20 top hits of proteins matched. [B] Result from the GPS 
Explorer software showing the SARS-CoV N protein matched with its protein score (394) and C.L % 
(100%). [C] Result from the GPS Explorer software showing the SUMO-1 protein {Homo sapiens) 
matched with its protein score (51) and C.L % (28%). The Mowse score (green circle), protein score 
(red circle) and C.I. % (purple circle) were as indicated. 
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2.4 DISCUSSION 
Much effort has been devoted to purify the SARS-CoV nucleocapsid protein in order 
to produce soluble，properly folded N proteins for functional assays as well as 
structural determination by protein x-ray crystallography. Proteins for structural 
studies required a high purity of over 95% and devoid of aggregation while proteins 
for functional assays required correct folding and a comparatively lower purity. 
In order to improve the expression level as well as solubility of the protein, a number 
of plasmids that provide different fusion tags to the target protein were constructed. 
As can be observed from the results, the proteins from E. coli are generally high in 
expression level and they are quite soluble as well. However, two major problems 
aroused during purification. One is "aggregation" and the other is the low affinity to 
column resin. These made purification difficult and purified proteins were unsuitable 
for structural studies. 
Aggregation refers to the association of proteins in a nonspecific manner. This is 
usually a consequence of improper folding that the hydrophobic cores of proteins are 
exposed or due to the hydrophobic regions of membrane proteins such that 
transmembrane regions are forced to associate with other proteins. In most of the time, 
proteins are aggregated into extremely large macromolecules that are insoluble and , 
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exist as inclusion bodies during expression. Yet, there were publications mentioning 
the formation of "soluble aggregates" (Yurkova et a!., 2004; Bjomdal et al, 2003; 
Ristriani et al., 2002; Nomine et al” 2001). Soluble aggregates also exist as large 
macromolecules，but their sizes are smaller when compared with those form inclusion 
bodies and thus are present in the soluble phase. 
From the purifications of His6-, MBP- and GST-tagged N proteins, the purified 
proteins were soluble, but when they passed through the gel filtration column, they 
were usually eluted very close to the void volume. This showed that they were 
aggregated. The aggregation was not improved even after 10% glycerol or 0.1% 
nonionic detergent, like Nonidet P-40，was added. By comparing the situation for the 
MBP-N protein, with that of MBP-N (214-422) fragment, which were not aggregated, 
the presence of the N-terminal half of the N protein appeared to have a positive effect 
on the tendency of the N protein to associate with each other. 
Also, the affinity of the proteins to resin is relatively low, no matter whether the 
protein is purified by affinity chromatography or ion exchange. Although there may 
be a portion of proteins that are able to bind to the resin, in many cases the majority 
were present in the flow-through. And this fraction of protein generally had low 
affinities towards other resins as well. This made purification really difficult as 
proteins in flow-through would not have improved purity. Also, according to some 
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Stability studies, the N protein is unstable and can be subjected to degradation rather 
rapidly (Wang et al., 2004; Tang et al” 2005). This further increase the difficulty as 
complicated purification steps to obtain proteins of higher purity can pose higher 
chances of degradation at the same time. 
Nevertheless, the small portion of proteins that could bind onto the resin retained this 
property throughout the purification. So, this population of N proteins could be 
purified to a high purity of 95% and were found not aggregated as well, ever though 
the yield was low, only 0.15 mg/ L. These pure, dispersed N proteins were designated 
"untagged N proteins" and distinguished from the His6-, MBP- and GST-tagged N 
proteins aggregates. It should be noted that these untagged N proteins were originally 
expressed as MBP-tagged fusion proteins and the MBP tags were cleaved afterwards 
during purification. Proteins obtained from this strategy were used for setting up 
crystal screens for structural studies. 
Considering those aggregated N proteins, correct folding is the main concern. There 
are several reports on soluble aggregates (Yurkova et al., 2004; Bj0rndal et al., 2003; 
Ristriani et al, 2002; Nomine et al., 2001). Some proteins may be insoluble in nature. 
However, the proteins became soluble in the presence of tags. For these proteins, 
cleavage of the tags directly lead to precipitation of the proteins since the proteins 
were still misfolded even tagged (Nomine et al., 2001). Yet this phenomenon is . 
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different from the case in the present study as N proteins were not precipitated upon 
tag cleavages and N proteins were soluble even when tagged with polyhistidine. This 
implies that N proteins were not "forced" to become soluble but they just had the 
tendency to associate together. So this sticky property cannot represent the presence of 
misfolded proteins. According to Masters and Banerjee (1998 a and b), this kind of 
aggregate is not exclusive for SARS-CoV N protein. The nucleocapsid protein of 
vesicular stomatitis vims also existed as soluble aggregates as soon as they were 
expressed. The publications proved these N protein aggregates were properly folded 
and functional. In another report, Yurkova et al. (2004) had also demonstrated purified 
proteins forming soluble aggregates that could still retain the functional characteristic 
of the native counterpart. Therefore, together with the solubility of the untagged/ 
His6-tagged N proteins and the behavior of viral nucleocapsid proteins, the purified N 
proteins were not likely misfolded and the term "aggregate" referred only to the sticky 
nature to form molecules of high molecular weight. 
Except RNA binding, which will be discussed in the next chapter, there had been no 
specific assay for the SARS-CoV N protein. Thus, the quality of the purified proteins 
was analyzed by its ability to be recognized by the antibodies present in the patient 
serum (Figure 2.4.1). From the result of the western blotting, the N proteins purified 
can be successfully detected by the antibodies in the patient serum, suggesting the 
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purified His6-N proteins share same antigenicity as viral N protein. 
After lots of try-outs for the expression and purification strategies, different 
purification methods would be chosen for the production of different qualities of N 
proteins. If aggregation is not a key issue and comparatively low protein purity can be 
accepted, e.g. for the ELISA assays and animal immunization for the production of 
antibodies, GST-N proteins is preferred. It is because the proteins have a high affinity 
towards the glutathione resin and the proteins have the highest purity among all the 
three tagged ones. This outweighs its comparatively slightly lower solubility and thus 
provides a rapid mean to produce N proteins with high yield. However, if the aim of 
purifying N proteins required pure and non-aggregated proteins like crystallization, 
only the untagged N proteins can satisfy these criteria. 
Besides producing the polypeptide, one of the post-translational modifications, 
sumoylation' was also elucidated in the SARS-CoV N protein. From the in vitro 
sumoylation assay performed in this study, it was found that the SARS-CoV N protein 
is susceptible to sumoylation. The presence of two, instead of one, sumoylated N 
、.：：• 
\ proteins bands, regardless of the degradative ones, with different gain in molecular 
- 一 
masses opened the theoretical possibility that two SUMO proteins were tagged to a 
single N protein molecule. This is different from the findings from Li et al. (2005) 
that only the K62 was sumoylated. Although there are reports describing the 
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formation of poly-SUMO (analogous to the chain of polyubiquitin) (Pichler et al., 
2002; Li et al., 2003), considering usually only one SUMO is tagged to a conjugation 
site in the cellular activities as well as in vitro assays, the SUMO tags should be 
conjugated to two distinct sumoylation sites of N protein rather than two SUMO tags 
polymerize at one site in a chain. To get a brief idea on the sumoylation sites, we did 
try to use the 26 kDa N protein fragment for the sumoylation assay. However, due to 
the presence of the MBP tag, we cannot confirm the sumoylation occurred in the N 
fragment or the MBP part in our preliminary experiments. The exact positions of 
sumoylation sites remain to be elucidated as mentioned in section 4.2.2. 
Another character of the sumoylation of N protein is the low proportion of proteins 
being sumoylated. With reference to the in vitro sumoylation assay of other 
publications (Chung et al., 2004; Chen et al., 2004; Ahn et al.’ 2001), the proportion 
of proteins subjected to sumoylation of other protein species would not be as low as 
observed in the present study. However, this condition is not limited to this in vitro 
assay. Report from Li et al. (2005) also exhibited such a low efficiency of 
sumoylation upon SARS-CoV N protein in vivo. Thus, the in vitro assay showed that 
this inefficient modification should attribute to the intrinsic property of N protein 
rather than the regulation of sumoylation activity in cells. Although, in many cases, 
only minority of the substrate population were being modified would lead to a query , 
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in the significance of this alteration, Li et al (2005) had demonstrated its effect in 
terms of sub-cellular localization of N protein as well as host cell division. 
As a brief summary of this section, the SARS-CoV nucleocapsid protein has been 
successfully purified and it was also found to be susceptible to sumoylation. Except 
the analyses mentioned in the present report, the N proteins purified had also been 
used for the production of monoclonal antibodies (Figure 2.4.2 and 2.4.3), as 
substrates in ELISA for the study of N protein antigenicity, for the generation of 
phage display library as well as setting up crystal screens for future structural analysis. 
Thus, developing a routine purification strategy is beneficial to the studies of 
SARS-CoV nucleocapsid protein. 
»� 
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Pat ient 1 Pat ient 2 Pat ient 3 control 
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113 kDa —• —• — 
92 kDa —• —• —• 
52.9 kDa —• -fmm — | | | | | — — • 
35.4 k D a — • —• —• — 
29 k D a — — —• —• 
21.5 kDa —• — — — -
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Figure 2.4.1 Western blotting showing purified Hise-N proteins specifically detected 
by SARS patients' sera. Sera of a healthy subject and three convalescent S A R S patients were 
5OX fold diluted and probed separately against purified His6-N proteins (8.0 mg/ lane). Strong 
immimoreactive bands (-55 kDa) were detected. Lane 1 - Sera samples; Lane M - Protein 
standards. In collaboration with Prof. Cheung WT (Biochemistry, CUHK), the western 
blotting was performed by Mr. Cheng Man. 
kDa 
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Figure 2.4.2 Western blotting showing recognition of purified GST-N protein (8 jig) 
using monoclonal antibodies raised by purified MBP-N proteins. In collaboration with 
Prof. Chui YL (Clinical Immunology, CUHK), monoclonal antibodies were produced by Mr. 
Ben Chan. 
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A Nucleocapsid protein 
Amino add _ ,„„ residue 1 ^ 172 2 3 422 
N, I I I I I C, 
H H H H 
I N24 I N4 N6 N13 N18 N20 
|< H 
N15 
B Monoclonal Antigenicity Antigenicity against N fragment (aa position) 
Antibody Isotype Western “ “ V-105- 172- 214- Binding 
Clone 匕Lit>A blotting 213 213 213 422 region 
N24 IgM 2.55 + +++ + - - - 1-104 
N15 lgG1 2.51 + + + + + + + - 1-213 
N4 lgG1 2.61 +++ + + + - - - + 214-422 
N6 lgG1 2.61 + + + + + - . - + 214-422 
N13 lgG1 2.66 + + + + + _ - - + 214-422 
N18 lgG1 2.56 ++ ++ - + 214-422 
N20 ~ ~ 2 . 1 7 + + + + + - - - + 214-422 
C Anti-N clones G F P - N protein DAPI 
“ • • 
侧••• 
Figure 2.4.3 [A] Schematic diagram showing the regions on the SARS-CoV 
nucleocapsid"protein that the epitopes of the seven monoclonal antibody (mAb) clones 
raised by the MBP-N protein refined to. [B] Table elaborating the antigenicities of the 
seven mAb clones against the SARS-CoV N protein using ELISA, western blotting (WB) 
and immunofluorescence (IF), and the mapped binding regions of the antibodies. [C] 
Immunofluorescence showing the recognition of the GFP-N protein transfected into 
HeLa cells by the mAb raised by MBP-N protein. The GFP-N protein was stained by the 
mAb clones N24 and N20 (Anti-N clones). The signals were compared with the fluorescence 
from GFP-N proteins (GFP-N protein). The nuclei were counter stained by DAPI. 
^ In collaboration with Prof. Chui YL (Clinical Immunology, CUHK), monoclonal antibodies 
were produced by Mr. Ben Chan. The ELISA, WB and IF were performed by Mr. Ben Chan. 
The clones of N protein fragments were generated in our laboratory. 
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Chapter III 
Characterization of the Nucleic Acid Binding Ability 
of SARS-CoV N Protein 
3.1 INTRODUCTION 
It is well-documented that coronaviruses nucleocapsid proteins are RNA-binding 
proteins. This property has been demonstrated from their biological function for being 
structural proteins in the nucleocapsid cores of virions that closely interact with the 
viral genomic RNA (Lai and Cavanagh, 1997; Ksiazek et al.’ 2003; Marra et al., 2003; 
Holmes et al., 2003)，as well as experimentally by RNA binding band shift assays 
(Tang, 2005; Molenkamp and Spaan, 1997; Stohlman et al., 1988; Nelson et al.’ 2000). 
The later ones involve intentionally adding RNA for the N proteins to bind to and the 
RNA were not sequences in the viral genome in some cases. In other words, the 
bindings were not specific. Therefore, the N proteins should, in theory, have the 
chance to bind to the RNA they encountered as soon as they are expressed in the 
- bacterial cytoplasm. A simple way to investigate whether there is any nucleic acid 
binding activity is to detect the nucleic acids in the expressed proteins, presumably by 
calculating the ratio OD260/ OD280 of the at least partially purified N proteins. If . 
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nucleic acids do bind to the protein, a step forward would be finding out whether they 
are DNA or RNA. This was performed by two typical assays on DNA and RNA, the 
Dische and Orcinol assays that specifically determine their quantities in a solution 
irrespective to the proteins or other species of compounds present in it. 
Moreover, a brief treatment with RNase A can also analyze qualitatively the 
protection provided by the N protein to the RNA. Finally, the RNA can be extracted 
from the protein and analyzed in an agarose gel. Their sizes could provide us with 
some basic information of the RNA-protein interaction although further cloning and 
sequencing is required to look into what RNA sequences the proteins are bound to. 
In addition, electrophoretic mobility shift assay (EMSA) was employed to further 
investigate the RNA binding ability of N protein and the specificity was qualitatively 
studied by its tendency to bind to the total RNA ofVero E6 cells. 
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3.2 METHODOLOGIES 
Materials 
Mammalian cell line 
Vero E6 (ATCC) 
The Vero E6 cell line is derived from the African green monkey (Cercopithecus 
aethiops) kidney cells. They are normal cells with epithelial morphology. It was well 
documented for its susceptibility towards Zaire Ebola virus and SARS-CoV infection. 
The Vero E6 cells were maintained in DMEM (GIBCO) supplemented with 10% (v/v) 
fetal bovine serum and 1% (v/v) penicillin/streptomycin. 
Buffers and solution 
1% agarose gel 
0.5 g agarose (USB) was added to 50 ml IX TAE and dissolved by microwave oven 
heating. After the solution was slightly cool down, 1 \x\ EB solution (1 \xgl ^il) was 
added and mixed. „ 
- • . 
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6X agarose gel loading dye 
The 6X agarose gel loading buffer was prepared by adding 0.25 g bromophenol blue 
(Sigma), 0.25g xylene cyanol FF (Sigma) and 30 ml glycerol (Sigma) was added to 
deionized water and made up to 100 ml. 
Bovine serum albumin (BSA) solution (Img/ml) 
5 mg BSA (Sigma) was dissolved in 5 ml RNase digestion buffer and was stored at 
-20�C in 200 i^l aliquots. 
Coomassie brilliant blue staining solution 
0.3 g Coomassie Blue R 250 (Sigma) was dissolved in 200 ml de-staining solution 
containing 60 ml absolute ethanol，20 ml 98% acetic acid and 120 ml distilled water. 
De-staining solution 
60 ml absolute ethanol, 20 ml 98% acetic acid and 120 ml distilled water were added 
^ together and mixed thoroughly. 
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Dische reagent 
The reagent was freshly prepared by firstly dissolving 1 g of diphenylamine (Sigma) 
in 100 ml glacial acetic acid and then further addition of 2.75 ml concentrated 
sulphuric acid. 
Dulbecco ’s Modified Eagle ’s Medium (DMEM) (Sigma) 
1 bottle of DMEM powder (Sigma, Cat. no.: D-1152) and 1.5 g sodium bicarbonate 
were dissolved in 900 ml distilled water. pH was adjusted to 7.2 and volume was 
brought up to 1 L. The medium was filtered through 0.22 |j,m filters for sterilization. 
Orcinol reagent 
1 g of orcinol (BDH) was dissolved in 10 ml 95% ethanol. 0.2 g ferric chloride was 
dissolved in 100 ml concentrated hydrochloric acid. The two solutions were added 
together just before use as the combined reagent is very unstable. 
RNase digestion buffer (50 mMTris’ 10 mMEDTA, pH8.0) 
^ 0.606 g Tris and 0.372 g EDTA were dissolved in 90 ml distilled water. The pH was 
f • 
adjusted to 8.0 and the buffer was brought up to 100 ml. 
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Saline sodium citrate (SSC) 
A lOX SSC stock solution was prepared by dissolving 43.83 g sodium chloride and 
22.06 g sodium citrate-2 H2O in distilled water. The pH was adjusted to 7.0 and the 
volume was brought up to 500 ml. Working IX solution was prepared by ten fold 
dilution using distilled water. 
Standard DNA solution (500fj,g/ml) 
50 mg DNA sodium (Sigma) was completely dissolved in 100 ml IX SSC solution. 
Standard RNA solution (100jug/ml) 
10 mg RNA (Sigma) was dissolved completely in 100 ml distilled water by stirring 
continuously. 
TAE buffer 
SOX TAE buffer was prepared by dissolving 242 g Tris base (USB) in 600 ml distilled 
water. 57.1 ml acetic acid and 100 ml 0.5M EDTA were also added. The pH was 
. adjusted to 8.0 and the buffer was brought up to IL by distilled water. IX TAE 
working buffer (40mM Tris, 0.1% (v/v) acetic acid, ImM EDTA, pH 8.0) was made 
by dilution of the 5 OX buffer with distilled water. . 
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Methods 
3.2.1 Spectrophotometric Measurement of Ratio OD260/ ODiso 
To determine the nucleic acid content in the N protein, GST-N proteins and the 
untagged N proteins and fragments purified as described in Chapter II, the 
Methodology were taken for the measurement of OD260 and OD280 against their 
corresponding buffer. Their ratios of OD260 to OD280 were compared with that of 
bovine serum albumin (BSA) as a control. 
3.2.2 Native Gel Electrophoresis 
In order to support the hypothesis that the nucleic acid detected from 
spectrophotometer is related to the N protein but not sample contamination, the 
purified N protein underwent native gel electrophoresis and the presence of nucleic 
acid was visualized by ethidium bromide (EB) staining. 
2 to 5 lag purified MBP-N protein, GST-N protein, untagged N protein, MBP-N 
(214-422) and N (214-422) were run in 1% native agarose gel using TAE buffer and 
agarose gel loading dye. Nucleic acid was detected by UV trans-illumination on the 
EB pre-stained gel. The corresponding protein positions were also revealed by 
staining the gel with coomassie brilliant blue staining solution followed by 
de-staining. ‘ 
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3.2.3 Quantitative Determination of Nucleic Acids Content 
The Dische and Orcinol assays were employed to determine the amount of DNA and 
RNA in a solution sample (Mikkelsen, 2004; Munro and Fleck, 1966). Orcinol assay 
is specific to pentoses, while Dische assay is specific to 2-deoxypentoses only. Thus, 
presence of DNA can be detected in both assays, whereas RNA can only give positive 
results in the orcinol test. 
3.2.3.1 Dische assay - quantitative determination of DNA content 
In the experiment, 4 ml Dische reagent was added to 2 ml purified GST-N protein 
solution of various concentrations and heated in a boiling water bath for 10 minutes. 
The acidic condition of the reaction converted ring form deoxyriboses to straight 
chain form and then to the reactive hydroxylevulinaldehyde, which reacts with the 
diphenylamifte in the reagent to give a blue complex. The blue complex has a 
maximum absorbance at 600 nm. Therefore, ODeoo represents the relative content of 
DNA in the protein sample. 
The amount of DNA in the sample and the control was determined from a reference 
.. standard curve of DNA (Set up see table 3.2.3.1) and the amount of DNA detected in 
the GST-N protein was compared with that of the BSA control. 
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力 “ \ GST-N ‘ BSA IX SSC Dische 
Reaction ^ DNA s o l u t i o n , 呵 / ml) “ (1 mg/ ml) solution reagent 
“ : � ; ’ 丨 4 � , 推 5 k n g / _ / ” . ； 
Standard 1 - ： 遣 ml 
r 0.10 ml - - 1.90 ml 
r 0.20 ml - - 1.80 ml 
4 0.40 ml - - 1.60 ml 
厂 0.60 ml - - 1.40 ml 
6 0.80 ml - ： 1.20 ml 
� 1.00 ml — 1.00 ml 4.00 ml 
G S T - N r - 2.5 \il - 2.00 ml 
^ - 5.0 - 2.00 ml 
3 - — 10.0 - 2.00 ml 
BSA 1 - - 25 2.00 ml 
2 ^ - 50 i^l 1.95 ml 
V - — … 100 |il 1.90 ml I 
Table 3.2.3.1 Table showing components in the reactions of DNA standards, GST-N samples 
and BSA controls for the Dische assay. 
3.2.3.2 Orcinol assay - quantitative determination of RNA content 
The assay is modified from the Bial's test of pentoses. In the experiment, 1.5 ml 
orcinol reagent was added to 1.5 ml purified GST-N protein solution of various 
concentrations and heated in a boiling water bath for 45 minutes. During this period, 
pentose, in this case from both DNA and RNA in the protein sample, is converted to 
furfural when boiled with concentrated hydrochloric acid, and the furfural formed 
-
” reacted with orcinol in the presence of ferric chloride to yield a green iron complex. 
The complex has a specific absorbance at 670 nm. Thus, ODevo represents the relative 
content of nucleic acids in the protein sample. ‘ 
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The amount of nucleic acids was determined from a standard curve of RNA (ref. table 
3.2.3.1) and the amount of RNA detected in the GST-N protein was compared with 
that of the BSA control. 
” RZji^V l^taiiaatdRNA � P " ^ ~ ^ ^ 
‘ ‘ .. , . ' GST-N BSA Distilled Orcinol � R e a c t i o n r: “ � solution … ，，、" , , � 
. , r ( lOmg/ml) (1 mg/ml) water reagent 
Standard 1 - - - 1.50 ml 
2 0.20 ml - - 1.30 ml 
3 0.40 ml - - 1.10 ml 
4 0.60 ml - - 0.90 ml 
5 0.80 ml - - 0.70 ml 
6 1.00 ml - - 0.50 ml 
- 1 C A 
GST-N 1 ‘ • 2.5 III - 1.50 m T " . 
2 - ’ 5.0 - 1.50 ml 
3 - 10.0 - 1.50 ml 
BSA 1 - - 25 ]x\ 1.50 ml 
2 - - 50 1.45 ml 
3 - I - I 100 1.40 ml 
Table 3.2.3.2 Table showing components in the reactions of RNA standards, GST-N samples and 
BSA controls for the Orcinol assay. 
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3.2.4 RNase Digestion of the N Protein-bound RNA 
The GST-N protein was dialyzed against the RNase digestion buffer and reactions 
were set as follows and the reaction mixtures incubated at 30°C for 20 min. 
、释。-.1' Protein/ RNA RNase A RNase ^ , , 
^ Reaction 广（ Total volume 
： • p ! ‘ � s a m p i e ： (1 }ig/ ^li) digestion buffer 
GST-N 8 1^ 1 M 2^1 
protein 8 \i\ 1 I j ^ 
(0.5 \ig/ ^1) M ^ O^il 10 i^l 
Vero E6 total 3 jil OjU 1 
RNA 3 III — 1 i^l 6^1 
The reactions were then run in a 1% agarose gel and nucleic acids were detected by 
UV trans-illumination on the EB pre-stained gel. 
3.2.5 Isolation of RNA from Purified GST-N Proteins 
The„RNA bound in the GST-N protein was extracted. The total RNA of Vero E6 cells 
was also isolated at the same time used as a control. 1 ml TRIzol (Invitrogen) reagent 
was added to 80 GST-N proteins (3.1 |ig/ pi) and 20 mg Vero E6 cells each. The 
solution was mixed and the cell pellet was resuspended completely by pipetting. The 
mixture was then centrifuged at 12,000 rcf in a microcentrifuge at 4°C for 10 min. The 
supernatant was transferred to new eppendorf tubes. 300 ml chloroform was added 
and shaken vigorously for 20 seconds. After standing at room temperature for 2 
minutes, the mixture was again centrifuged at 11,400 rcf at 4°C for 15 min. The upper 
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aqueous layer was carefully pipetted a set to new eppendorf tubes and 750 \i\ 
isopropanol added to it. The solution was mixed by inversion and incubated at room 
temperature for 10 minutes. The mixture was centrifuged at 11,400 rcf for 10 min at 
4®C to bring down the precipitated RNA. The supernatant was removed. The RNA 
pellet was washed by 1.5 ml chilled 70% ethanol and then dried briefly. Finally, the 
RNA was dissolved in 10 and 60 \x\ DEPC-treated water for the N protein-bound 
RNA and Vero E6 total RNA respectively. 
6 \x\ and 3 |il of the extracted RNA from the N protein and Vero E6 cells were taken to 
run in a 1% agarose gel respectively. 
3.2.6 In vitro Transcription of SARS-CoV Genomic RNA Fragment 
A stretch of RNA of length 979 bp comprising the SARS-CoV genome nucleotide 
19571 to 20549 was cloned into the vector pSPTlS following the procedures 
described in section 2.2.2, using a cloned SARS-CoV CUHK-Wl genome fragment 
as template. The sequence was verified by sequencing but a C to T point mutation was 
found at the nucleotide 19926 (corresponding to the nucleotide of the fragment). 
So, site-directed mutagenesis was employed to reverse the mutation and the sequence 
was checked with 100% correctness. , 
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The resulted plasmid pSPT18-PS was restriction digested by HincRW at 37�C for 2 
hours. The linearized plasmids were cleaned with the PCR Purification Kit (QIAGEN) 
and acted as templates for in vitro transcription. 
The in vitro transcription was carried out at 37°C for 2 hours by setting up the 
following reaction mixture: 
. . ,鲁 1 二 . ^ ^ ^ ^ ^ Negative control 
pSPT18-PS plasmid template (0.12 mg/ ml) 8 i^l -
NTPs (20 mM) ^ ^ l \ i \ 
10 X transcription buffer 2 \i[ 2 |j,l 
T7 RNA polymerase (20 U/ pX) Ijd 1 [i\ 
RNase inhibitor 1 [xi 1 \i\ 
DEPC-treated distilled water 6^1 14 |il 
Total 20 20 i^l 
The RNA was cleaned from reaction mixture by phenol/ chloroform extraction. 100 [i\ 
phenol/ chloroform was added to the reaction mixtures and mixed thoroughly by 
vortex. The combined solution was centrifuged at 13000 rpm at 4°C for 2 minutes. 
�� 
The upper aqueous layer was collected and 40 \i\ absolute ethanol was added and 
mixed. RNA was precipitated by incubating at -20�C for 1 to 2 hours. The precipitate 
was spun down in a microcentrifuge at 13000 rpm at 4°C for 5 minutes. The pellet 
was further washed with 70% ethanol, briefly dried and eluted in 30 fil DEPC-treated 
*� distilled water. The RNA was frozen at -80°C for used. 
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3.2.7 Vero E6 Cell Line Maintenance and Total RNA Extraction 
Vero E6 cells were maintained in DMEM with 10 % FBS and 1% penicillin/ 
streptomycin in normal mitogenic condition. Cells were incubated at 37°C in a 5% 
CO2, 95% air humidified atmosphere. A T25 flask of Vero E6 cells of confluences 
reached 85% were trypsinized and cell pellet was washed with PBS twice. 1 ml 
TRIzol was added to the pellet. RNA extraction procedures were same as those 
described in section 3.2.5. 
3.2.8 Electrophoretic Mobility Shift Assay (EMSA) 
The SARS-CoV RNA genome fragment and the total RNA of Vero E6 cells were used 
as substrates to analyze the RNA affinity of the N protein. 
Reaction mixtures listed in Table 3.2.8.1 were set up and the RNA and proteins 
(Purified untagged N proteins and BSA) were allowed to interact with each other by 
incubating at room temperature for five minutes. The reactions were then run in 1% 
\ agarose gel to analyze for band shift by EB staining. 
» • 
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1 2 3 4 5 6 7 8 9 
,Reaction ‘ 
N N N N N N BSA 
mixture RNA BSA 
0.1 nM O.S^iM L O | A M 2 . 5 ^ M 5.0\M Ctl Ctl 
Reaction buffer 3 3 i^l 3 |il 3 3 3 |al 3 |il 3 3 
Ikb RNA 
1 |il 1 \i\ 1 nl 1 1 \i\ 1 ul 1 ul - -
fragment (3nM) ^ 
1^1 1 1 |il 1 i^l 1 1 … 
N protein - . 
( 1 _ (5^M) ( _ M (25nM) (50nM) (50| iM) 
BSA (10 _ • - _ - - 1 III _ 1 
DEPC-treated 
6 ul 5 III 5^1 5 ul 51^1 5 III 5 ^ 1 6 l^l 6 ul 
water 
Total 10 i^l 10 … 10 I0\i\ 10 10|xl 10 ^ il 10 “1 10^1 
Table 3.2.8.1 Table showing constitutes of the reaction mixtures set up in the EMSA of 
N protein and in vitro transcribed SARS-CoV RNA genome fragment. Reaction buffer 
contains 100 mM Tris, 1 M NaCl, pH 7.5 (DEPC-treated). Concentrations in brackets indicate 
the concentrations of chemicals in stocks. 
^ . 1 I 2 I 3 I 4 5 6 7 a 9 
Reaction 
nxTA N N N N N. N BSA mixture,, RNA BSA 
0 . _ 0 , 5 _ l . 0 _ 2.5txM 5 華 Ctl Ctl 
Reaction buffer 3 |il 3 i^ l 3 \i\ ' 3 3 3 fxl 3 3 3 
Vero E6 total 
RNA(lOnM) : ‘ ^ ^ : … _ _ ^ _ _ _ _ 
—N protein - ^ ^ ； ^ T 
( _ ) ( 5 _ ) (lO^iM (25^M) ( 5 0 _ ) (50nM) 
BSA (10 i^M) _ 一 _ _ • _ 1 - 1 
DEPC-treated 
6 ^ 1 5 ul 5 \x\ 5 5 III 5 |xl 5 ul 6 ul 6 ul 
water ^ 
-Total I 1 0 I 101^ 1 10^1 10^1 10 10 … 10 … 10 10^1 
Table 3.2.8.2 Table showing constitutes of the reaction mixtures set up in the EMSA of 
N protein and the total RNA of Vero E6 cells. Reaction buffer contains 100 mM Tris, 1 M 
NaCl, pH 7.5 (DEPC-treated). Concentrations in brackets indicate the concentrations of 
chemicals in stocks. 
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3.3 RESULTS 
3.3.1 Detection of Nucleic Acids in the Purified N Proteins by Spectrophoto-
metric Measurement of Ratio OD260/ ODiso 
The protein purified as described in Chapter II were taken to measure the OD260/ 
OD280 ratio to determine whether nucleic acids were bound to N proteins during 
synthesis of the proteins in the bacterial cells or cell lysis. 
The results show that the nucleic acid content in the GST-N proteins were 
significantly higher than that of the untagged N proteins, MBP-tagged fragments and 
untagged fragments as their OD260/ OD280 ratios are higher than 1 when compared 
with that of other proteins like the BSA, which are known not to possess any nucleic 
acid binding ability, with OD260/ OD280 ratios between 0.6 and 0.7 (Table 3.3.1). Also, 
according to the ratio of GST, which is 0.699, it showed that the negative control GST 
protein did not bind to nucleic acids. 
Purities of the proteins should not contribute to the differences in their RNA contents 
as proteins, except the untagged N proteins, were purified to similar extent of purities. 
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… « 會 二 气 • 巧 閱 秘 g ? 牲 ' ： 染 … R a t i o n 
Siiiiipkj M ^ i ； — : # O D � ‘ n n Ratio average 
^ . V ' . - ' " - r ' � : OD260/ QP28O 
0.426 0.324 1.315 
GST-N protein 0.341 0.323 1.056 1.193 士 0.137 
0.354 
0.086 — 0.134 0.641 
Untagged N o . 0 9 2 0.143 0.643 0.649 ±0.015 
protein .丨1 • � _ _ _ ' “ — — ^ 
0.085 0.128 0.664 
0.299 0.371 0.616 
MBP-N 
0.269 0.443 0.607 0.609 土 0.07 
(214-422) 
0.255 0.422 0.604 
0.055 0.082 0.671 
N (214-422) i 0.034 0.100 0.340 0.512 ±0.172 
0.066 ’ 0.126 0.524 
0.162 0.689 
BSA 0.165 0.242 0.682 0.688 ± 0.006 
0.022 — 0.031 0.710 
GST 0.089 — 0.131 0.679 0.699 土 0.020 
0.095 0.134 0.709 
Table 3.3.1 Raw data of the OD260 and OD280 measured from the protein samples and 
their calculated OD260 to OD280 ratios. 
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3.3.2 Native Gel Electrophoresis 
To further confirm the results in the last section, the purified proteins were run in an 
agarose gel (Figure 3.3.2) and obvious glowing bands can be seen for the MBP-N 
protein and GST-N protein but not others after EB stained. And these two bands 
co-localized with the position of the proteins as shown from the coomassie blue 
stained gel. This indicates that the presence of nucleic acids should not be due to 
sample contaminations but probably association with the proteins. Otherwise the 
nucleic acids should migrate towards the positive terminal according to their sizes. 
Terminal ^ B 
1 • • 
Figure 3.3.2 Native agarose gel electrophoresis of the purified protein samples. Lane 
1 一 MBP-N proteins; Lane 2 - GST-N proteins; Lane 3 - Untagged N proteins; Lane 4 -
MBP-N (214-422) fragments; Lane 5 - Untagged N (214-422) fragments; Lane 6 — BSA. The 
polarities of the electrophoresis were as indicated. [A] 1% agarose gel pre-stained with EB 
prior to electrophoresis. [B] The 1% agarose gel was stained with coomassie blue after 
electrophoresis and then destained. 
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3.3.3 Quantitative Determination of Nucleic Acids Content in Purified GST-N 
Proteins 
The DNA content in GST-N proteins and BSA were both rather low and had no 
significant difference between the two as evaluated from the Dische assay. However, 
the amount of RNA in GST-N protein was remarkably high (about 0.1 |ig per \xg of 
protein) when compared with that of BSA, which were undetectable. The results 
pointed out that the nucleic acids found associated with the GST-N protein were RNA. 
Although the mass of DNA bound to the proteins seemed higher than that of RNA, 
this is not meaningful as it should be noted that the sensitivities of the two assays are 
very different and focuses should be put on the comparison between GST-N proteins 
and BSA. 
3.3.3.1 Dische assay for the determination of DNA 
In each set of experiment, a standard DNA curve was generated by plotting the 
absorbance at 600 nm of the DNA standards against their masses ranging from 0 |ig to 
500 \xg. The DNA content in 25 ^ig, 50 fig and 100.|ig GST-N protein and BSA were 
determined from the standard curve and an averaged DNA amount (|ig) per jig protein 
were calculated . The assay has been performed for three times. Table 3.3.3.1 shows 
the data obtained. . 
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' I _ ： “ P r o t e i n 、：' L Protein 终） DNA content DNA content/ 
Sample s o l u t i o n:，a m o u n t � O D e o o calculated unit protein 
:、,:;);::：.：：： i :勘A t i ^滅;•’；懇“ ： _ ( . g / 幽 
2.5 25 0.008 20.0 0.787 
GST-N 5.0 50 0.008 20.0 0.393 
(10 -0.008 
10.0 100 - -
(rejected) 
25.0 25 0.005 ^ 0,500 
BSA 50.0 50 0.010 25.0 0.500 
(rejected) 
Table 3.3.3.1 Absorbance of purified GST-N proteins and BSA recorded from the 
Dische assay and the calculated DNA content per \ig of protein. The amounts of proteins 
used in the reactions were shown. The DNA content in each reaction was calculated from a 
standard curve of 0 )j,g to 500 i^g DNA. 
After averaging the valid data, the DNA content per }ig of protein in GST-N protein 
can be compared with that of the BSA: 
Amount of DNA present in each |ig of GST-N protein is 0.590 \ig 
Amount of DNA present in each jig of BSA is 0.500 ^g 
The p value .is 0.4253. Thus, there was no significant difference between the amounts 
of DNA detected from GST-N proteins and BSA. Referring to the absorbance 
obtained, the values were so low (compared with a range of 0.020 to 0.160 for the 
DNA standards) that the DNA content can be regarded as null. 
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3.3.3.2 Orcinol assay for the determination of RNA 
The assay has been performed for three times. In each set of experiment, a standard 
RNA curve was generated by plotting the absorbance at 670 nm of the RNA standards 
against their masses ranging from 0 [xg to 100 ^g. The RNA content in 25 |Lig, 50 |ig 
and 100 |Lig GST-N protein and BSA were determined from the standard curve and an 
averaged RNA amount (|Lig) per |Lig protein were calculated . 
According to the results shown in table 3.3.3.2, the amount of RNA detected in BSA 
is not significant and can be regarded as nil. On the contrary, the RNA found in 
GST-N protein is rather abundant, and it reached a level of approximately 0.1 |ig RNA 
per fig of GST-N protein. This remarkable difference between the GST-N proteins and 
BSA indicates the nucleic acids detected in the previous experiment are RNA. 
r 7 » 4 -" 'w . ——I— 
— � … P r o t e i n sU- Protein；；^ RNA content RNA content/ 
Sample solution, ^ o u n t ； OD670 calculated unit protein 
- ' ' v o l u m e (l^g) ’ (Hg) (lig/^ig) 
G s t n 2.5 25 0.144 7.06 0.278 
( l O ^ g / m ) ~ ^ _ 0 . 2 8 3 一 1 3 . 8 7 
10.0 100 0.443 21.72 0,214 
(rejected) 
(1 Mg/ 1^1) 50.0 ^ 0.050 2.45 一 0.049 
100.0 100 0.084 4.12 
Table 3.3.3.2 Absorbance of purified GST-N proteins and BSA recorded from the 
Orcinol assay and the calculated RNA content per ^g of protein. The amounts of proteins 
used in the reactions were shown. The RNA content in each reaction was calculated from a 
standard curve of 0 |ig to 100 jig RNA. 
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After averaging the valid data, the RNA content per pig of protein in GST-N protein 
can be compared with that of BSA: 
Amount of RNA present in each \ig of GST-N protein is 0.255 \ig 
Amount of RNA present in each [ig of BSA is 0.045 |ag 
The p value is 0.0205 (* p < 0.05). 
3.3.4 RNase Digestion Treatment 
The purified GST-N proteins had shown a high tendency of binding to RNA in the 
analysis mentioned above. The proteins were treated with RNase A in this study. As 
revealed from figure 3.3.4，the intensity of glowing bands did not show any 
significant difference with increasing amounts of RNase A added in the reactions 
(Lane 2 to 4 - 0 jiig, Ijiig and 2 jig RNase A in 10 |j.l reactions respectively). Therefore, 
the RNAs were only subjected to a limited amount of digestion when compared with 
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1 2 3 4 5 6 7 
• 
Figure 3.3.4 RNase treatment on purified GST-N proteins. Lane 1 - 4 of GST-N 
proteins control without any treatment; Lane 2 - 4 |ag GST-N proteins without addition of any 
RNase A in the treatment; Lane 3 - 4 |ig of GST-N proteins treated with 1 ^g RNase A; Lane 
4 - 4 |Lig of GST-N proteins treated with 2 jig RNase A; Lane 5 -Total RNA prepared from 
Vero E6 cells without any treatment; Lane 6 - Vero E6 total RNA without addition of any 
RNase A in the treatment; Lane 7 -Vero E6 total RNA treated with 1 |ig RNase A; Digestion 
reactions were performed at 30�C 20 min followed by native gel electrophoresis in 1% 
agarose gel. 
3.3.5 Extraction of RNA from GST-N Proteins 
TRIzol reagent was used to remove the protein component from the GST-N proteins 
sample and the RNA was prepared by phenol/ chloroform extraction and isopropanol 
precipitation. 
As shown in figure 3.3.5, the RNAs associated with the GST-N proteins are of 
relatively small size. Their mobility is even higher than that of the 5.8s rRNA which 
has only 160 nucleotides. So, the size of the RNA extracted from the GST-N protein is 
below 160 nucleotides, and can be smaller than 100 nucleotides according to the . 
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position observed from the gel electrophoresis. Another feature is that the RNA bound 
may not be of single species as the band is not very sharp. Our results suggest that the 
RNAs have a broad distribution of lengths with an average size of 100 nucleotides. 
From the total RNA extracted from the Vero E6 cells, RNA were not subjected to 
extensive degradation throughout the process. The RNA integrity was still high as 
reflected from the intensity ratio of 28s to 18s that was at least 1.8. 
• 
28s (4.72)— 一 
18s (1.87) — H H ^ ^ H 一 
一 
5.8s (0.16)一 ^ H P ^ H 一 
Figure 3.3.5 RNA extracted from, the purified GST-N protein and Vero E6 cells. Lane 
1 - Total RNA extracted from Vero E6 cells; Lane 2 - RNA extracted from purified GST-N 
proteins; Lane M 一 Invitrogen 0.24 kb to 9.49 kb RNA ladder. The position of 28s, 18s and 
5.8s rRNA and their corresponding sizes (bracketed) were as indicated. 
141 • 
Chapter III Results 
3.3.6 In vitro Transcription of SARS-CoV Genomic RNA Fragment 
The template for in vitro transcription was synthesized by cloning the fragment into 
pSPTlS. As point mutation was found in the original DNA template for cloning, site 
directed mutagenesis was employed to reverse the mutation. Thus, the 979 bp 
fragment was firstly amplified as two portions using primers spanning the mutation 
site (Figure 3.3.6.1). PCR of the full length fragment was then made from these two 
portions which annealed at the mutated site for elongation (Figure 3.3.6.1). The full 
length fragment and pSPTlS were restriction digested by EcoRl and Hindlll. The 
constructed plasmids were screened for inserts and sequence was verified with 100% 
correctness (Figure 3.3.6.2). 
1000 2000 
Figure 3.3.6.1 [A] PCR products of the first round amplification: The genome fragment 
was amplified in two portions with 19 bp overlapped for the second round PCR of the 
full length fragment. Lane 1, 2 - P C R products of the 5 365 bp of the fragment; Lane 3，4 -
PCR products of the 3 632 bp of the fragment; Lane M - GeneRuler 1 kb DNA ladder. [B] 
PCR products of SARS-CoV genome fragment (-979 bp) from the second round 
amplification for the construction of pSPT-PS recombinant plasmids. Lane 1 to 5 - PCR 
products; Lane M - GeneRuler 1 kb DNA ladder. 
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^ ^ ^ ^ ^ 17�5��� 
500 
250 
Figure 3.3.6.2 Screening of positive pSPT18-PS clones by PCR amplification. 
Lane 1 to 3 - Positive clones with N protein inserts amplified by PCR; Lane 4 - Negative 
control of PCR without template; Lane M - GeneRuler Ikb DNA ladder. 
The plasmids constructed were linearized by HindUl digestion and the DNA was 
cleaned. In vitro transcription was carried out and the transcript synthesized was 
analyzed by running in a 1% agarose gel (Figure 3.3.6.3) 
kb 
一 
transcribed 2 34 
SARS-CoV RNA 1:35 
genome fragment 0.24 • 
Figure 3.3.6.3 Single stranded RNA transcript of the SARS-CoV genome 19571 to 
20549 nt synthesized by in vitro transcription. Lane 1 - Negative control of the in vitro 
transcription reaction without template; Lane 2 - RNA (~980 nt) synthesized from in vitro 
transcription; Lane M - Invitrogen 0.24 - 9.5 kb RNA ladder. 
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3.3.7 Electrophoretic Mobility Shift Assay (EMSA) 
The N protein/ RNA interaction was studied by EMSA. The purified untagged N 
protein was incubated with in vitro transcribed RNA fragment of the SARS-CoV W1 
genome 199571 一 20549 nt or with the total RNA extracted from Vero E6 cells at 
room temperature for five minutes. The mobility of RNA was observed in a 1% 
agarose gel. If the protein can associate with the RNA, the glowing band of RNA will 
be shifted due to a change of mass to charge ratio as well as the conformation of the 
macromolecules after binding. According to figure 3.3.7.1, a band shift can be 
observed in lanes 3 to 6 with an increasing amount of N proteins. This indicated that 
N proteins can bind to the in vitro transcribed RNA. This is in contrast to lane 7 that 
the RNA band stayed at its original position as BSA is known not possess any RNA 
binding character. 
Figure 3.3.7.1 1% agarose gel of EMSA showing the 1 kb in vitro transcribed RNA 
band shifted after incubation with N proteins at room temperature for 5 minutes. Lane 
1 - Reaction mixture containing RNA only; Lane 2 - Reaction mixture containing 0.1 |j.M N 
protein and RNA; Lane 3 - Reaction mixture containing 0.5 jaM N protein and RNA; Lane 
4 一 Reaction mixture containing 1.0 |aM N protein and RNA; Lane 5 - Reaction mixture 
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containing 2.5 |j,M N protein and RNA; Lane 6 - Reaction mixture containing 5.0 }iM N 
protein and RNA; Lane 7 - Reaction mixture containing 5.0 fiM BSA and RNA; Lane 8 -
Reaction mixture containing 5.0 |i,M N protein only; Lane 9 - Reaction mixture containing 
5.0 jiM BSA only. The final concentration of RNA was 0.3 nM. The native (Black arrow) and 
shifted (Hollow arrows) 1 kb RNA fragment were as indicated. 
Similar results were obtained for the EMS A of N proteins with total Vero E6 RNA. In 
figure 3.3.7.2, with an increasing amount of N protein, the lane distributed with 
different sizes of RNA became clear at the high mobility position. In return, large, 
bright band can be seen at the higher position (Lane 4 to 6). The smaller sizes RNA 
were shifted and there was a preference of N protein to bind to 28s and 18s rather than 
the 5.8s as observed from the band intensities. Again, the RNA position showed no 
observable change when incubated with BSA (Lane 7). 
n Q Q I ^ R j j ^ m ^ Q 
Figure 3.3.7.2 1% agarose gel of EMSA showing the Vero E6 total RNA shifted after 
incubation with increasing amount of N proteins at room temperature for 5 minutes. 
Lane 1 - Reaction mixture containing RNA only; Lane 2 — Reaction mixture containing 0.1 
I^ M N protein and RNA; Lane 3 - Reaction mixture containing 0.5 |iM N protein and RNA; 
Lane 4 一 Reaction mixture containing 1.0 i^M N protein and RNA; Lane 5 - Reaction mixture 
containing 2.5 jiM N protein and RNA; Lane 6 - Reaction mixture containing 5.0 }iM N 
protein and RNA; Lane 7 - Reaction mixture containing 5.0 pM BSA and RNA; Lane 8 -
Reaction mixture containing 5.0 |iM N protein only; Lane 9 - Reaction mixture containing 
5.0 [iM BSA only. The final concentration of RNA was 1 nM. The native bands of 28s, 18s 
and 5.8s (Black arrows) and shifted RNAs (Hollow arrows) were as indicated. ‘ 
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To access briefly the in vitro binding of RNA with N proteins, the RNA/ N proteins 
complexes formed by Vero E6 total RNA with 5 |LIM N protein (Figure 3.3.7.2，lane 6) 
was subjected to RNase A digestion at 30°C for 10 min. It was shown in figure 3.3.7.3 
that the N proteins posed very little protection to the RNA as all of the RNAs were 
digested (Lane 2). 
Figure 3.3.7.3 RNase treatment on RNA/ N proteins complexes formed by in vitro 
binding assay. Lane 1 - Binding assay reaction mixture of RNA with 5 |iM N proteins 
without any treatment; Lane 2 -Binding assay reaction mixture of RNA with 5 |xMN proteins 
treated with 1 jag RNase A; Lane 3 - Binding assay reaction mixture of RNA only without 
any treatment; Lane 4 - Binding assay reaction mixture of RNA only without addition of 
RNase A in the treatment but incubated 30�C for 20 min; Lane 5 -Binding assay reaction 
mixture of RNA only treated with 1 |ig RNase A; Digestion reactions were performed at 30�C 
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3.4 DISCUSSION 
From the OD260/ OD280 ratio recorded and the EB staining of native agarose gel 
electrophoresis, the MBP-N protein and GST-N protein were found immediately 
bound to nucleic acids as the proteins are synthesized. And from the Dische and 
Orcinol assays, the nucleic acids were found to be RNA. The innate RNA binding 
ability of N protein was well demonstrated as soon as the proteins were expressed 
because addition of RNase A during bacterial cell lysis did not help remove RNA 
from the N proteins. So, the N proteins had already bound to endogenous RNA when 
cells were growing but not due to artifacts in cell lysis. The interactions between RNA 
and N proteins were also found to be extremely strong as revealed from the RNase A 
digestion. The endogenous RNA was extracted and their sizes were estimated from 
the agarose gel to be between 70 to 130 nt. 
With respect only to the sizes of the N protein-bound RNA, there is not enough 
information to determine the RNA species. Further conversion to cDNA and cloning 
of the extracted RNA is needed to provide concrete evidence. The sizes oifRNAs only 
... denoted the lengths of the nucleic acids that are buried in the N proteins and protected 
from digestion. The original RNA may be much longer but the exposed parts were 
degraded through the different treatments during purification. It is also not likely that , 
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the N protein is specific to tRNA，the most abundant single RNA species free in the 
cytoplasm, as bacterial mature tRNAs are about 77 nucleotides long only. 
The specificity and affinity of N protein towards RNA can also be observed 
qualitatively from the electrophoretic mobility shift assay (EMSA). The EMSA 
concerning in vitro transcribed SARS-CoV RNA genome fragment clearly showed 
that N protein possesses strong affinity to that portion of the genome. However, 
whether it is because that region is a putative packaging signal (Qin et al., 2003) is not 
of importance as the protein expressed a similar binding ability towards the total RNA 
of the Vero E6 cells. It is obvious that the situation should not be the same in the real 
viral infection and replication. The viruses should acquire certain mechanisms to 
ensure specific packaging of the RNA genome but not other RNA species in the Vero 
E6 or other host cells. This phenomenon was also shown in Tang et al. (2005) and Yu 
et al. (2005). And the N-terminal structure of N protein solved had also been shown to 
bind to a piece of intentionally added ssRNA. Taken together the strong affinity of N 
proteins towards endogenous E. coli RNA suggested the binding of N protein to RNA 
is not specific. ^ 
•� It has been proposed that N protein of coronavirus should bind to leader sequences or 
packaging signals that promote the encapsidation and replication of the virus 
(Molenkamp and Spaan, 1997; Stohlman et al.’ 1988; Nelson et al., 2000). According 
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to Gott et al. (1993), the RNA-bound nucleocapsid proteins of Hantaviruses they 
purified are not sequence-specific as well. Thus, the presence of N protein alone may 
not be enough for sequence-specific RNA binding. Example like vesicular stomatitis 
virus had shown other proteins that form a complex with viral nucleocapsid proteins 
were responsible for specific RNA interactions but not the nucleocapsid protein itself 
(Masters and Banerjee, 1988 a and b; Das and Banerjee, 1992). Furthermore, even 
nucleocapsid proteins from the same virus family can exhibit a disparity in RNA 
binding specificities (Uitenweerde et al.’ 1995). Therefore, the mechanism of 
SARS-CoV N protein/ RNA interaction may be a novel one and is distinct from other 
coronavirus N proteins. 
The purification strategies of polyhistidine and GST had been described by a number 
of publications but none of them addressed co-purification of RNA together with N 
protein (Wang et a!” 2004) and the OD260 to OD280 ratio was reported to be 0.47 in Yu 
et al. (2005). The reason behind is still unclear but the proteins are able to bind RNA 
may imply the folding of the proteins is reasonably correct. There are reports that the 
nucleocapsid proteins of some other viruses were already associated to RNA after 
-�• purification but in their case these interactions does not affect purification steps and 
• • 
qualities of the purified proteins (Gott et al.’ 1993). Yet, in their cases, the association 
between proteins and RNAs were also very tight and denaturation and renaturation is . 
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needed to remove the RNA bound, which are processes that we tried to avoid in the 
analysis as SARS-CoV N proteins contain lots of coils and loops. Renaturation cannot 
guarantee proper folding also. 
Concerning the N protein/ RNA complex formed, there is an obvious difference 
between the MBP-N proteins and GST-N proteins that are bound to the endogenous 
RNA and those formed during the in vitro binding assay because the former one 
associated very tight to protect the RNA bound but the later one failed to confer such 
a protection. The possible reasons for only the MBP-N protein and GST-N protein 
purified were found binding to RNA may correlate with their nature in 
self-association as mentioned in section 4.1. Also, there is a disparity between the 
mobility of the N protein/ RNA complexes. 
With reference to the EMSA performed by Tang et al (2005) and Yu et al. (2005)， 
there are generally two sorts of patterns of the band shift produced from the 
interaction between the SARS-CoV N proteins and RNA. Those observed from the 
publication of Tang et al (2005) and Gott et al (1993) exhibited a typical pattern of 
gel shift assay that the bands either had their mobilities of naked RNA or they moved 
. in a single unique velocity of protein associated RNA. And those RNA/ N protein 
complexes formed in their EMSA were so large that the complexes could totally 
retard the mobility of RNA and get stuck in the wells. This can be a feature of . 
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cooperative binding. This situation is comparable to the MBP-N proteins and GST-N 
proteins purified in this project. Yet, the EMSA performed in the present study did not 
exhibit such an condition. Rather, very small amount of N proteins were able to bind 
to lots of RNA. Further increasing the N protein content can produce greater shift but 
the complexes formed were not necessarily stucked in the well. There are a number of 
intermediate positions between those of the naked RNA and the wells. This is similar 
to those mentioned in Yu et al. (2005). 
Even though information is inadequate to justify the kinetics, as well as the manner of 
interaction purely from the present study, certain speculations can be posed to explain 
the band pattern. Firstly, the RNA fragment used in Tang et al (2005) is very short 
(<20 nt), far less than the 70-130 nt proposed in the present study, that one RNA 
molecule can only be bound by one N protein. However, the EMSA here utilized 1000 
nt RNA. More than one N protein molecule can bind to one RNA fragment, so 
different positions of bands may be the outcomes of RNA molecules bound with 
different number or N protein molecules as the interactions were non-specific (Lane D 
et a l , 1992). Moreover, one N protein molecules may also be able to bind to more 
. than one RNA fragment. This turned out to be a clump of N proteins and RNA that 
• • 
migrate all together. This can explain the observation of merging of the 28s, 18s and 
5.8s to a single glowing band. It is not likely that the intermediate positions were the . 
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consequences of the dissociation and association of complexes because the caging 
effect in the gel matrix generally prevents this (Lane D et al., 1992). 
Although research studies on the MHV nucleocapsid suggested a specific interaction 
between coronavirus N protein and the viral RNA (Molenkamp and Spaan, 1997; 
Stohlman et al” 1988; Nelson et al.，2000), this may not be a stringent rule as some 
other viruses may make use of viral proteins other than the N protein to provide this 
sequence specific RNA interaction for encapsidation, replication and transcription. 
According to Master and Banerjee (1988), failing to demonstrate the highly specific 
packaging process in the encapsidation of the vesicular stomatitis virus by the N 
protein and RNA in vitro binding assays was because the the non-specific RNA 
binding of N protein was actually prevented by the formation of the complex between 
the nucleocapsid protein and an viral phosphoprotein in vivo. Therefore, pre-complex 
of the nucleocapsid protein and the phosphoprotein of the vesicular stomatitis virus 
can produce a specific RNA binding in vivo instead of the non-specific one when 
involving the nucleocapsid protein alone. Also, from Nishio et al. (2005), specific 
viral RNA binding was found in the P and V protein of the human parainfluenza virus 
type 2 while no such RNA binding ability was reported from the nucleocapsid protein. 
These two examples suggested that the mechanism of viral replication and packaging 
may vary from virus to virus and these may be a potential explanation for the low . 
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Specificity of RNA binding of the SARS-CoV nucleocapsid protein for N protein 
alone may not be enough for providing the high specificity of RNA binding. 
Results from the nucleic acids analysis display the innate RNA binding and protecting 
property of N protein when it is exposed and purified from E. coli. However, this 
protecting property could not be demonstrated from the RNA/ N protein complexes 





4.1 Purity, Aggregation and RNA Binding Property of the SARS-CoV 
Nucleocapsid Protein 
Success in purifying the soluble dispersed N proteins was not due to the ability to 
separate the aggregated N proteins apart but to select those that were not aggregated. 
Both the aggregated and dispersed N proteins purified were taken for the analysis on 
f 
RNA binding and it was found that the aggregated ones (MBP-N protein and GST-N 
protein) and the non-aggregated ones (untagged N protein) behave differently in many 
aspects. The disparities are summarized in table 4.1. The reasons that give rise to the 
differences in the tightness of RNA binding and hence the protection exerted are 
unclear, but It was speculated these can be the outcome of the fundamental differences 
between aggregated and dispersed proteins or it is because the conditions during 
complex formation is so different between in vitro and in vivo. Despite these 
discrepancies, it is evident that the SARS^CoV N protein possesses a 
’ non-sequence-specific RNA binding property. 
•» 
In conclusion, this project developed a strategy for the purification of dispersed 
untagged SARS-CoV nucleocapsid protein to near homogeneity. The N protein . 
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fragment containing amino acid residue 214 to 422 was also purified. From both the 
EMSA and endogenous RNA-bound N protein, it was demonstrated that the 
SARS-CoV N protein has a high tendency but low sequence specificity towards RNA 
binding. Moreover, the protein was found susceptible to sumo-1 modification 
although the sumoylation sites are yet to be mapped. The N protein purified in this 
report laid the fundamental for the studies on SARS-CoV N protein. 
_ protein- | 
,Characters/ properties , & G S I ^ r o — Untagged N protein 
Aspects in purification 
Soluble ^ Yes 
Tags cleavage No Yes 
Affinity to resin before i 
, Low High 
tags cleavage 
Purity Low (Below 85% pure) High (95% pure) 
Aggregation Yes No 
Associated with RNA 
广 . 产 . Yes No 
after purification 
Preparation yield High Low 
Aspects in RNA binding 
Positive Positive 
RNA interaction ,, , (To the endogenous RNA (To any RNA species 
present in E. coli) encountered in vitro) 
-yi^ i^ ^^ i^ i^ilijai^ i^ iii^ i^ li^ ilwy^ tjj^ ijli^ iljfi^ jlinMW乡jj.ijjjji -
' ' Nil Nif 
Sequence specificity (Bind to the endogenous (Bind to the total RNA 
/ RNA in coli) . extracted form Vero E6) 
.. Positive Negative 
RNA protection (RNA bound resistant to (RNA bound completely 
. : ;、： . :,.:、:、：.::. ： RNase A digestion) digested by RNase A) 
Table 4.1 Comparison of the two populations of the N protein purified in their 
behaviors during purification and in RNA binding. 
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4.2 Future Perspectives 
4.2.1 Structural study of the SARS-CoV N protein through x-ray 
crystallography 
Due to the multi-functional role of the nucleocapsid protein speculated, how this 46 
kDa protein can acquire all those functions like RNA binding and protein interactions 
with the membrane protein and the replication complex at the same time remained an 
interesting issue to be addressed. A simple and direct way is to solve the structure of 
the protein that can reveal the domains of the protein and the spatial arrangement 
between them. It is certain that x-ray crystallography would be an informative 
approach for all these questions. 
4.2.2 Mapping the sumoylation sites in the SARS-CoV N protein 
Site-directed mutagenesis can be employed to mutate the lysine residues at the two 
putative sumoylation sites, K62 and K339. One or both of the sites could be mutated 
to see if these two sites are both responsible for the sumoylation and to compare their 
susceptibilities towards SUMO-1 modification. 
4.2.3 Determination of aggregation state by lateral turbidimetry analysis 
. The aggregation reported in the present study was derived from the gel filtration study 
as well as the native gel electrophoresis. Further conformation on the aggregation 
state can be done by experiments on lateral turbidimetry. Spectrofluorometer was used , 
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to scan the absorption spectrum of 280iim-500nm by using 280nm as excitation. An 
"aggregation ratio" can be calculated from OD280 to OD340. OD340 is the fluorescence 
signal of the aromatic amino acid side chains of proteins, which is relatively high in 
monodispersed soluble protein. Thus, soluble aggregates generally display a higher 
ratio of OD280 over OD340. 
4.2.4 Exploring protein interacting partners that enhance RNA binding 
specificity 
It is well understood that nucleocapsid proteins of RNA viruses can interact 
specifically to the viral genomic RNA for encapsidation. Many studies in attempts to 
define that stretch of genomic RNA failed because the nucleocapsid proteins generally 
bind to all kinds of RNAs just like the findings in the present study. Yet, a report from 
Master and Banerjee (1988) explored new possibilities to explain the disparity 
between low sequence specificity of nucleocapsid proteins observed in the in vivo and 
in vitro assays and the highly specific packaging process in the encapsidation during 
viral replication. The report found out complex formation of the nucleocapsid protein 
of the vesicular stomatitis virus with another viral phosphoprotein that can prevent the 
. non-specific RNA binding of N protein. In the case of SARS-CoV, a number of 
proteins had been suggested interacting with the N protein recently. Thus, before 
interacting with RNA, pre-incubation with proteins like the viral membrane protein, , 
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human cellular heterogeneous nuclear ribonucleoprotein Al , SARS-CoV protein XI， 
X4 as well as the nsps produced from the ORF lab can be attempted to investigate 







I. Sequence of the SARS-CoV N protein (CUHK-Wl, NP_828858) 
ATGTCTGATMT_CCCCAATCAAACCAACGTAGTGCCCCCCGamCATITGGTGGACCCACAGAT 
M S D N G P Q S N Q R S A P R I T F G G P T D 
TCMCTGACMTMCCAGMTGGAGGACGCMTGGGGCAAGGCCAAAACAGCGCCGACCCCAAGGTTTA 
S T D N N Q N G G R N G A R P K Q R R P Q G L 
CCCAATAATACTGCGTaTGGTrCACAGCTCTCACTCAGCATGGCAAGGAGGMCmGATTCCCTCGA 
P N N T A S W F T A L T Q H G K E E L R F P R 
GGCCAGGGCGTTCCMTCMCACCAATAGTGGTCCAGATGACCAAArrGGCTACTACCGAAGAGCTACC 
G Q G V P I N T N S G P D D Q I G Y Y R R A T 
CGACGAGTTCGTGGTGGTGACGGCAAAATGAAAGAGCTCAGCCCCAGATGGTACTTCTAmCCTAGGA 
R R V R G G D G K M K E L S P R W Y F Y Y L G 
ACTGGCCCAGAAGCTTCACfTCCCTACGbCGCTAACAAAGAAGGCATCGTATGGGTTGCMCTGAGGGA 
T G P E A S L P Y G A N K E G I V W V A T E G 
GCCTTGMTACACCCAAAGACCACATTGGCACCCGCAATCCTAATAACAATGCTGCCACCGTGCTACAA 
A L N T P K D H I G T R N P N N N A A T V L Q 
aTCCTCAAGGAACAACATTGCCAAAAGGCTTCTACGCAGAGGGAAGCAGAGGCGGCAGTCAAGCCTCT 
L P Q G T T L P K G F Y A E G S R G G S Q A S 
TCTCGCTCCTCATCACGTAGTCGCGGTAATrCMGAAArrCAACTCCTGGCAGCAGTAGGGGAAATTCT 
S R S S S R S R G . . N S R N S T P G S S R G N S 
CCrGCTCGAATGGCTAGCGGAGGTGGTGAAACTGCCCTCGCGCTArrGCTGCTAGACAGATrGAACCAG 
P A R M A S G G G E T A L A L L L L D R L N Q 
aTGAGAGCAAAGTrTCrGGTAAAGGCCMCAACMCAAGGCCAAACTGTCACTMGAAATCTGCTGCT 
L E S K V S G K G Q Q Q Q G Q T V T K K S A A 
GAGGCAAAGCCTCGCCAAAAACGTACTGCCACAAAACAGTACAACGTCACTCMGCATITGGGAGACGT 
E A S K K P R Q K R T A T K Q Y N V T Q A F G 
GGTCCATCTAAAGAACAAACCCAAGGMATTTCGGGGACCAAGACGTAATCAGACAAGGAACTGAmC 
R R G P E Q T Q G N F G D Q D L I R Q G T D Y 
AAACATtGGCCGCAAATTGCACMTTTGCTCCAAGTGCCTCTGCATTCnTGGAATGTCACGaTTGGC 
'、 K H W P Q I . A Q F A P S A S A F F G M S R I G 
• ATGGAAGTCACACCTTCGGGAACATGGCTGACTTATCATGGAGCCAmAATTGGATGACAAAGATCCA 




Q F K D N V I L L N K H I D A Y K T F P P T E 
CCTAAAMGGACAAAAAGAMAAGACTGATGMGCTCAGCCnTGCCGCAGAGACAMAGMGCAGCCC 
P K K D K K K K T D E A Q P L P Q R Q K K Q P 
ACTGTGACTCTTCTTCCTGCGGCTGACATGGATGATTTCTCCAGACAACTTCAAAATTCCATGAGTGGA 
T V T L L P A A D M D D F S R Q L Q N S M S G 
GOTCTGCTGATTCAACTCAGGCATAA 




11. Sequence of the SARS-CoV genome fragment used for RNA binding assay 
in section 3.3.7.1. (CUHK-Wl, AY278554) 
aggacacttt gatggacacg ccggcgaagc acctgtttcc atcattaata atgctgttta 
cacaaaggta gatggtattg atgtggagat ctttgaaaat aagacaacac ttcctgttaa 
tgttgcattt gagctttggg ctaagcgtaa cattaaacca gtgccagaga ttaagatact 
caataatttg ggtgttgata tcgctgctaa tactgtaatc tgggactaca aaagagaagc 
cccagcacat gtatctacaa taggtgtctg cacaatgact gacattgcca agaaacctac 
tgagagtgct tgttcttcac ttactgtctt gtttgatggt agagtggaag gacaggtaga 
cctttttaga aacgcccgta atggtgtttt aataacagaa ggttcagtca aaggtctaac 
accttcaaag ggaccagcac aagctagcgt caatggagtc acattaattg gagaatcagt 
aaaaacacag tttaactact ttaagaaagt agacggcatt attcaacagt tgcctgaaac 
ctactttact cagagcagag acttagagga ttttaagccc agatcacaaa tggaaactga 
ctttctcgag ctcgctatgg atgaattcat acagcgatat aagctcgagg gctatgcctt 
cgaacacatc gtttatggag atttcagtca tggacaactt ggcggtcttc atttaatgat 
aggcttagcc aagcgctcac aagattcacc acttaaatta gaggatttta tccctatgga 
cagcacagtg aaaaattact tcataacaga tgcgcaaaca ggttcatcaa aatgtgtgtg 
ttctgtgatt gatcttttac ttgatgactt tgtcgagata ataaagtcac aagatttgtc 




III. Vector maps 
a) Vector map of pACYC177 
Feature Coordlnatss Source 
bla(Afi 3699^1 B(cw) Tn3 
8ph(3')-tim 1923-2738 Tn903 
origin 783-1328 p15A 
ort=origin of replication 
BgiHKA I 3899 Ap = ampicillio, Kn = kanamycin BSIHKAI daaa (cw)=clockwise 
Acll 3883 
Xmn I 3882 \ 
ApaL I - Bme1580 I - BsiHKA I 3814 \ \ HInc II 1 
Aat II - Zra I - BsaH I 3563 \ \ \ \ \ J l J L I / / , A c l l 315 
EC00109I 3505 \ Fsp I 320 
i r H j ^ ^ ， ； 4SS 
Bme1580 l 3429；：：：：^^ ^^ ^ . - X ^ ^ B s a l 473 
Drd I 3397 Bmr I 495 
- B s t B I 852 
- B s e R I 902 
- B s e R I 961 
� A l w N I 987 J、Nspl 103 
Age I 1178 
sac II 1339 




m i 1577 
1588 
591 
— - - , , , , , 
BfrBI -Nsi l 2200 / / \ Traill 1818 
Earl 2161 / ) PaeR7 丨.TH 丨 .Xho卜Ava 卜 BsoB I 1952 
Cla I - BspD I 2044 Ban H 2005 




b) Vector map and MCS of pET28a 
pET-MaW gquence landmarict 
T7 promoter 370-386 
T7 transcription start 369 
Hls'Tag coding sequence 270-287 
T7*Tag coding sequence 207-239 
Multiple cloning sites 
{BanMl-XboV) 158-203 
His'Tag coding sequence 140-157 
T7 terminator 26-72 Not l(ifis) 
J^c/codlngsequence 773-1852 HhSdVC/M 
pBR322 origin 3286 sal I(i79) 
Kan coding sequence 3995-4807 I J ^ I ^ M 
fl origin 4903-5358 BLIIH k m ) 
Bpu11021(80)y Mhe 1(231) Nde l(23B) 
Dra 111(5127), l J ^ " ^ NCO I(29B) 
1(335} 
；着 ‘ \ \ 
Sma 1(4300) • 糞 \ ^ M I U 1(1123) 
I ^ f U K B d 1(1137) 
Cla 1(4117) ^ \ Nm_3). ^ |BstE 11(1304) 
V p E ( 識 ⑷ ！ 卜 
\ 叫 /BSSH 11(1534) 
EC057 1(3772) \ / /EC0RV(1573) 
\ / AHpa 1(1828) 
AlWN 1(3(I40> ' A . / / 
- BssS 1 ( 3 3 0 7 ) P s h A Kioes) 
BspLUII ka^iT^N^ ^x^Bgi l(2iS7) 
Sap 1(3100) \\FSP 1(2205) 
Bsti 107 1(2095} / — \ P s p 5 11(2230) 
Tthlll l(2Bsg) f 
T7 promoter Pfinwr #88348^  
P 口 卿似 T7p««noter • ‘ tac�p«i»tor xbaX fb. 
AGATCTCCMCCCOCSWATTAA7ACaACTCACTA7/iaCGCAMT01GmcaMAACAAT7CCCCTCTAGmTU7TT7GTTimTTTWGAAGGMA 
Wwl Hi5»Tau Ndm\ Nt»l T7.T�g 
TMACCATGECCAGCAeCCATCATCATCATCATCACA&CWCaCCClGaTeCCCCGCCGCMCCATMCCnAGCATCWTCCTCCfcCilCCkA KftG I y$»r$»rK l»Hi»Kl»Hil»Kl*Kl «S*r»»rG I vL»uValProArQGlY$>i'H I »K»tAlaS«rK«tTKrC lyClyClrtGIrt 
£叫 t thfombin BwnnHIEeeRI Sac I SaM Hind ill Notl Xho\ 彻T场 
ATCGGTCCCCGATCCWATTCGACCTCCCTCaACAAaCTTliCCCCCCCWTCGACCACCACCACCWCACCACTCACATCCCCCTCCTAJkCfcAAGCCC j»ET-2Ba(«t K*t61 /Ar^G I y$»rC I uPh*G I wL會uArgAj^gG I nk IciCy»li lyArgTlirArgfc loProProProProProL参ufcrgS»rG I yCytEftd 
.. .CGTCCGGATCCIlAfcTTCGAGCTCCCTCGACAAGCTTGC6GCCCCACTCC/ieCACCACCACC«CWCACTGAaATCCGGC7CC7A,AC**AGCCCpET-2Bb(M ...CI yArgMpPro/^ *nS«r$er$ftrVa I A.*pLy»L«uA I aAloAloLsuG I uHM I »K I I »Hn •HI *End 
..GGTCGGA.TCCGAATTCGAGCTCCGTC6ACAAGCTTGC&GCCCCACTCGAGCACCACCikCCACC/lCCACTCAGATCCGGCTGCTmmGCCC pET-2Bc(•! •‘ I.. .Gly*.rql Ufcrq] l»ArqAlaPro&orThrSTL*uArqProHl>S>rS>rThrTKrThrThrThrThrClul l»ftrqfuL»MThrLy»Pro... 
E ^ I O Z I T7tfnilna*or 
CAAAGSAAGCTC4CTTGGCTCCTCCCACCaC7GACCtJlTA«TAGCMAACCCCT7GGGeCCTCTmCGGliTCT-raAGGGGTlTT7TC 
77 ienrinatur primer #80337-3 
pET-28a-c(+) cioning/expression region 
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c) Vector map and MCS of pAC28 
His tag 
•Xhor(158) 
Not 1 (166) 
Eag 1661 
Sal 丨 
/ Sac I (1 鄉 
/ BamH 1(190 
/ n^he I (231) 
/ Nde [ aZB) 
/ Nco 1(296) 
0 / His tag 
1 / T7 promoter (370«388) 
PAC28 1 \ \ 
_乂 i j 
物 e J 
d) Vector map and MCS of pGEX-6P-l 
PreSdssion"* Protease 
lieu Glu Vai Leu Phe Gln-^Gly Prol Leu Gly Ser Pro Glu Phe Pro Gly Arg Leu Glu Arg Pro His 
" CTG QAA GTT CTG TTC CAG GGG CCC CTG.GGATCC.CCG.GAAnC CCG GGTCGA CTC G/\G CGG CCG 
BamH I EcoRI sma l Sail xhol Not! 
m m I 
^ f ^ / pSjiOiBamTStop? \ 
[ / \ \ V ' -
丨 pGEX O 
‘ A ^ 4•如 丫 





e) Vector map of pMAL-c2X and MCS of pMAL-c2E 
Featurs Coordinates Source 
lad， 61-1163 [coli 
P社 1406-1433 -
expression ORF 1528-2991 -




M13 origin 4396-4908 M13 
origin 5019-5607 pMB1 
mp 6228^037 pMB1 
ori=origin of replication M M I m m 
Ap=_p_n Btsi 鄉 1 
EooOl09|.PpuMI I EoaOlOOl-PpuMI 6690 
BpulOl 6557 \ \ 
二丨二、 \ \ \ PflMI 7 
Afal 6411 \ \ \ \ \ , BstAPI 108 
BsmFI 6378 \ \ \ \ \ \ / Mlul-AIIIII 431 
B e m B I 6 0 1 6 \ \ M \ / / . B e l l 4 4 5 
PflFI-Tthun 6818 \ i X . B«tEII 612 
BBtZl7l<Accl 5894 \ \ Apal-PspOMI 638 
Poil-Afllll 5883 ^ y - 4 H Hpal 035 
^ ^ “ N^^：- BsmBI 1040 
/ ^ ^ K a i l - N a r l - S f o l 1070 
/ 麟 \ \ BsaXI 1086 
AlwNI S249 赫 \ 
/ ® L Ndsl 1525 
I 汇 
BopHI 4943 _ _ • — — 坤 E l 1722 
Nael-NgoMIV 4778. '{f ____^ B«iWI 1893 
D - 教 榜 
B s a X I 4621 -：：^：^^ 备 / C ^ B s s H II 2 0 3 8 
Psil 4547 象 B m g B I - B t r l 2143 
Dra I 44S0 T S ^ ^ .^m I 2217 
. Swi 444oZ 入 二 
� A H - , - / / N ^ ^ 
B^l 4156 ^w；；^^^ \ \ BIpl 2388 
J -1 — \ \ Afel 2511 
/ / 1 \ Bel l 2645 
Seal 3797 / / 1 
Dral 3700 / _ 3 0 7 9 / 愁 W : ， 
BspHI 3440 Bgll 2951 K 辉 签 發 . , 
MCS 妒;： 
p|ylAL-p2E and pMAL-p2G are identical to pMAL-p2X except they > 
replace the Factor Xa protean cleavage site with Ei^rokinase and , 
Genenase 1" cleavage sites, respectively. • a o a , i 
pMAL-c2-series vectors are Identical to the pMALi32-serles vectors 
above except lor a deletion of the mrffslgnal sequence (nt 1531-
腿） 
Kpnl EcoRI BamHl X b a l S a i l P s t I H i n d l l l 
” p M A L - p 2 E M C 8 6ATGACGAT6ACAAG GTACCeSAATTCGGATCCTCTAGAGTCSACCTGCAGGCAASCTTGSCACTSGCCGTCGTT... 
I W i l W M A V P E F G S S R V D L Q A S L A ... 7acZa 
EntaroMnae* —^  
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IV. Electrophoresis markers 
SeeBlus Plus Pre-Stained Standard 
Invitrogen (Cat. #LC5925) 
Apparent molecular weights of SeeBlue • 
Plus2 Pre-Stained Standard on a NuPAGE" 
Novex 4-12% Bis-Tiis Gel w/MES 
kOi Protein: 
t88 Myfwin 
98 Phosphoiylase B 
62 BSA 
广，Cluumlc dehydrogenase 
妨 I* � * Akvhui dvlivdiuKeiu»e 
28 Carbonic Jiihydrase 
17 i m m MyngloNn-RtHl 
M ^mtm Lysu^yine 
•i 
(i N w Aprotinin 
^ …Insulin B chain 
High-range Rainbow Molecular Weight Markers 
Amersham Biosciences (Cat. #RPN756) 
"‘ Myosin 220 K 
Phosphorvlasc b ^ ^ 97 K 
Bovine serum albumin R ^ B 66 K 
Ovalbumin 舞 45 K 
Carbonic anhvdrase 30 K 
Trypsin inhibitor 20.1 K 
�.. Lysozyme 14 J K 
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Full-range Rainbow Molecular Weight Markers 
Amersham Biosciences (Cat. #RPIV800) 
250 
�W 








GeneRulerTM ikb DNA Ladder 
Fermentas (Cat. #SM0311/2/3) 
t b p ng/0.5iig % 
8000 24.0 4.8 
6000 30.0 6.0 
B S t ^ 5000 30.0 6.0 
E S I / 4000 40.0 8.0 
B s I f ' 8 
2000 92.0 18.4 
^ S - 1500 24.0 4.8 
^ H - 1000 10.0 
^ ^ ^ 750 
I ^ H - - 500 14.5 2.9 






1 kb DNA Extension Ladder 
Invitrogen (Cat. #10511-012) 
bp 
切，咖 
10,000-E55H 8,144 -——lli'iil!'!'.!!!.!!!!'. 





517/506 - ^ ^ 9 
1 Kb DNA 
‘ Extension Ladder 
0.3 (ig/lane; 1% agarove inlXlAEiUinedwUb 
c th id i um bro tn id* . Cat. no. 10511-012 
0 . 2 4 - 9 . 5 kb RNA Ladder 
Invitrogen (Cat. #15620-016) 
_ mm 
W ^ m ^ ^ 35 1 
H f 為 、 1 
M l ‘‘為 
24 i 
_ J 
0.24-9.5 Kb RNA Ladder 
3 |ig/laiie (formaldehyde-treated) 
1.2% agarose gel 
stained with ethidium bromide 
168 • 
Appendix 
V. SDS-PAGE gel preparation protocol 
Constitutes of 5 ml running acrylamide gel solution 
15% 120/0 lOo/o 8% — 6% _ 
Distilled Water 1.1 ml 1.6 ml 1.9 ml 2.3 ml 2.6 ml 
30% Acrylamide/bis mix 2.5 ml 2 ml 1.7 ml 1.3 ml 1ml 
Tris (1.5 M，pH 8.8) 1.3 ml 1.3 m l 1.3 m l 1.3 m l 1.3 ml 
IQo/o SDS 50 III 50 l^l 50 |il 50 50 \i\ 
10% Ammonium persulfate 50 i^l 50 [i\ 50 i^l 50 [i\ 50 
TEMED 2 |il 2 nl 2 2\ i \ | 2 
Constitutes of 5 ml 5% stacking acrylamide gel solution 
Distilled Water 3.4 ml 
30% Acrylamide/bis mix 830 \x\ 
Tris (1 M，pH 6.8) 630 \i\ 
10% SDS 50 
10% Ammonium persulfate 50 |il 
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